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1
GENERAL INTRODUCTION
The normal knee
The	knee	joint	is	one	of	the	complex	and	heavily	loaded	joints	of	the	human	body.	
It	is	a	bicondylar	synovial	joint	which	is	formed	by	articulations	between	the	tibia,	
femur	and	patella.	The	knee	joint	allows	flexion,	extension	and	some	degrees	of	
internal	and	external	rotations.	Tendons	connect	the	bones	to	the	muscles	and	
together	with	the	ligaments	create	stability	to	the	joint.	The	articulating	ends	of	
the	bones	are	covered	by	articular	cartilage	and	the	fibrocartilaginous	menisci	lie	
between	the	tibia	and	the	femur.
Femur
Tibia
Cartilage
Meniscus Infrapatellar 
fat pad
Patella
Synovial ﬂuid
Synovial ﬁbroblast
Blood vessel
Adipocyte
Macrophage
Collagen ﬁber
Figure 1 The	normal	knee
The	knee	joint	is	formed	by	articulations	between	the	tibia,	femur	and	patella.	The	infrapatellar	fat	pad	is	locat-
ed	inside	the	joint	capsule	but	outside	the	synovial	membrane.	The	synovial	membrane	is	richly	vascularized.	
It	consists	of	a	layer	of	fibroblasts	and	macrophages	followed	by	a	layer	of	connective	tissue.	The	infrapatellar	
fat	pad	consists	mainly	of	adipocytes.
Articular	 cartilage	 allows	 smooth	 gliding	 movements	 and	 acts	 as	 a	 shock	 ab-
sorber.	It	is	a	specialized	tissue	that	is	avascular	and	aneural	and	only	harbors	a	
small	number	of	cells.	These	cells	are	called	chondrocytes	and	they	produce	and	
maintain	the	articular	cartilage	extracellular	matrix	(ECM).	The	articular	cartilage	
ECM	consists	mainly	of	collagen	type	2	fibers	and	proteoglycans.	The	negatively	
charged	glycosaminoglycans	(GAG)	side	chains	on	the	proteoglycans	attract	wa-
ter.	These	GAGs	attract	water	in	such	extent	that	65%-80%	of	the	cartilage	consists	
of	water.	Due	to	its	avascular	nature,	the	articular	cartilage	receives	its	nutrients	
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from	the	synovial	fluid	or	 from	the	subchondral	bone	underneath	 the	cartilage	
through diffusion1.	
The	synovium	fluid	is	encapsulated	by	the	synovial	membrane,	which	is	also	an	
integral	part	of	the	joint.	The	synovial	membrane	is	a	richly	vascularized	connec-
tive	tissue	that	is	responsible	for	the	production	of	synovial	fluid	and	for	filtering	
of	debris	out	of	the	synovial	fluid.	The	membrane	is	mainly	composed	of	two	cell	
types:	macrophages	and	synovial	fibroblasts2.	
Macrophages	are	a	type	of	cells	that	can	phagocytize	for	example	cellular	debris,	
foreign	material	and	microbes.	Macrophages	play	an	important	role	in	inflamma-
tion	and	wound	healing.	In	reaction	to	stimuli	from	their	microenvironment	these	
macrophages	can	become	activated	into	a	spectrum	of	different	types.	Roughly,	
macrophages	can	be	categorized	into	pro-inflammatory	(often	referred	to	as	M1)	
macrophages	 and	 anti-inflammatory/wound	 healing	 (often	 referred	 to	 as	 M2)	
macrophages3.	
Synovial	fibroblasts	are	cells	that	can	synthesize	ECM	such	as	collagen	type	1,	but	
also	hyaluronic	acid	and	lubricin	for	the	synovial	fluid.	During	inflammation,	these	
synovial	fibroblasts	can	also	be	triggered	to	secrete	inflammatory	and	catabolic	
factors.	Outside	the	synovial	membrane	but	inside	the	joint	capsule	several	fat	de-
pots	are	localized	of	which	the	infrapatellar	fat	pad	(IPFP)	is	the	largest.	The	IPFP	
is	also	called	Hoffa’s	fat	pad,	named	after	dr.	Albert	Hoffa	who	first	described	it	
in	19044.	The	IPFP	fills	the	anterior	knee	compartment	and	its	posterior	surface	is	
covered	with	synovial	membrane.	The	IPFP	provides	mechanical	cushioning	and	
facilitates	the	distribution	of	synovial	fluids.	The	IPFP	is	richly	vascularized	and	
innervated.	 Furthermore,	 it	 contains	many	 immune	 cells	 such	 as	macrophages	
and	stem	cells5;6.	These	 immune	cells	could	play	an	role	 in	 the	pathogenesis	of	
knee	osteoarthritis	(OA)	and	the	stem	cells	could	be	used	for	tissue	engineering	
purposes.		
The diseased knee
The	knee	joint	is	vulnerable	to	trauma	and	the	development	of	OA.	According	to	
the	United	States	Bone	and	 Joint	 Initiative,	 the	socio	economic	burden	of	 joint	
diseases	in	2014	was	very	high	with	more	than	50%	of	people	aged	18	years	and	
older	in	the	US	reporting	a	musculoskeletal	condition	and	all	costs	associated	with	
musculoskeletal	condition	was	about	5.7%	of	the	gross	domestic	product7.	OA	is	
the	most	common	degenerative	joint	disorder	and	affects	1.1	million	in	the	Neth-
erlands8.	Knee	OA	is	a	disease	of	the	whole	joint	and	is	more	than	‘wear	and	tear’	
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of	the	cartilage	alone.	The	symptoms	of	knee	OA	are	pain,	reduced	movement	and	
disability.	There	are	several	risk	factors	for	the	development	of	knee	OA,	which	
include	age,	sex,	obesity	and	previous	joint	injury.	Structurally,	there	is	cartilage	
damage,	subchondral	bone	sclerosis,	osteophytes	formation	and	synovial	inflam-
mation	and	fibrosis9.	Some	of	the	structural	changes	in	OA	are	associated	with	the	
degree	of	symptoms.	It	has	been	shown	that	inflammation	of	the	IPFP	is	associated	
to	knee	pain	and	that	synovial	fibrosis	with	reduced	joint	movement.	Currently,	
there	is	no	cure	for	OA.	There	are	only	treatments	against	the	symptoms	of	knee	
OA,	including	replacement	by	arthroplasty	in	end-stage	knee	OA9.	
It	is	generally	assumed	that	articular	cartilage	damage	if	left	untreated,	eventually	
could	lead	to	OA.	Articular	cartilage	normally	does	not	heal	spontaneously	or	only	
partially	due	to	its	avascular	and	aneural	nature.	Furthermore,	it	harbors	only	a	
relatively	small	number	of	chondrocytes	that	could	potentially	produce	matrix.	In	
the	case	of	cartilage	damage,	these	chondrocytes	react	by	producing	proteolytic	
enzymes	at	 the	 site	of	 injury	 that	destroy	 the	ECM	and	 thereby	worsening	 the	
damage10.	
Cartilage repair
Treatment strategies
Successful	 treatment	 of	 these	 cartilage	 defects	 remains	 a	 challenging	 clinical	
problem	because	none	of	the	current	regeneration	options	are	able	to	completely	
restore	 the	original	structural	and	biomechanical	properties	of	 the	cartilage.	 In	
the	knee,	surgical	treatment	options	are	marrow	stimulation	techniques,	such	as	
microfracture,	for	small	symptomatic	cartilage	lesions	and	autologous	chondro-
cyte	implantation	(ACI)	and	mosaicplasty	for	larger	lesions10.	
The	 microfracture	 procedure,	 first	 introduced	 by	 Steadman11,	 is	 a	 simple	 and	
low	 cost	 method	 to	 stimulate	 the	 body’s	 own	 repair	 response.	 In	 the	 original	
technique,	 during	 knee	 arthroscopy,	 the	 cartilage	 defect	 is	 debrided	 down	 till	
the	subchondral	bone	layer	and	small	holes	are	‘fractured’	into	the	subchondral	
bone11;12.	This	in	turn	creates	a	‘bleeding’	from	the	underlying	bone	marrow	and	
thus	stimulation	of	a	repair	response	by	bioactive	factors	and	mesenchymal	stem	
cells	(MSC)	from	the	underlying	bone	marrow13.	This	procedure	can	potentially	be	
enhanced	by	adding	growth	factors	or	scaffolds,	or	by	changing	the	technique	of	
creating	the	holes	or	the	size,	number	and	depth	of	the	holes14-16.	The	microfrac-
ture	treatment	is	generally	used	for	single	defects	smaller	than	2.5	cm2 and leads 
to	clinical	improvement	in	function	and	pain16-18,	but	not	to	hyaline	cartilage	repair.	
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Instead,	a	fibrocartilaginous	tissue	fills	the	defect,	which	is	of	inferior	biomechani-
cal properties13;19;20.	
The	ACI	procedure	uses	laboratory	expanded	autologous	articular	chondrocytes	
harvested	from	healthy	part	of	 the	 joint	to	fill	up	the	defect21.	These	 implanted	
articular chondrocytes can potentially repair the defect by laying down a new 
hyaline	cartilage	ECM.	It	is	also	possible	to	enhance	the	repair	process	by	adding	a	
(bio)scaffold22;23.	The	ACI	procedure	is	generally	used	for	cartilage	defects	greater	
than	4	cm2	or	multiple	defects	and	the	long	term	results	are	good24.	Compared	to	
microfracture,	 the	ACI	procedure	 is	 expensive	 and	 requires	 two	 surgeries.	 Fur-
thermore,	there	is	much	discussion	on	the	superiority	of	this	technique	compared	
to	the	cheaper	marrow	stimulation	techniques	such	as	microfracture17;	25;	26 
Besides	microfracture	and	ACI	procedure,	an	osteochondral	transplantation	can	
be	performed.		In	this	procedure,	also	called	mosaicplasty,	autologous	osteochon-
dral	grafts	 from	healthy,	 less	demanding	parts	of	 the	 joint	are	 transplanted.	Al-
logenous	graft	can	also	be	used.	No	evidence	is	yet	available	about	the	superiority	
of	this	procedure	versus	microfracture	and	patients	are	left	with	a	new	defect	at	
the	donor	site	that	causes	donor	site	morbidity25;27.	
Next	to	these	interventions,	current	research	is	also	focused	on	transplantation	
of	specific	engineered	MSC-based	constructs.	In	these	strategies,	a	novel	graft	is	
engineered	in-vitro	using	MSCs,	scaffolds	and	growth	factors10.	These	strategies	
could	potentially	reduce	donor	site	morbidity	and	lead	to	implantation	of	a	hya-
line	cartilage	implant28.	However,	these	are	only	experimental	treatments	and	cur-
rently	no	randomized	controlled	trial	has	been	published	yet	on	these	strategies.
Effect of inflammation 
Cartilage	repair	results	can	be	influenced	by	several	factors.	Twenty	four	hours	
after	joint	trauma,	there	is	a	peak	in	pro-inflammatory	cytokines	in	the	knee,	in-
cluding	tumor	necrosis	factor	alpha	(TNF-α),	interleuking-1	beta	(IL-1β),	as	well	as	
matrix	metalloproteinase(MMP)-1	and	MMP-1329-32.	 It	has	been	shown	that	these	
pro-inflammatory	cytokines	can	inhibit	chondrogenesis	and	therefore	potentially	
inhibit successful hyaline cartilage repair33-35.	
Although	the	level	of	these	pro-inflammatory	cytokines	drops	over	time,	the	level	
of	inflammatory	cytokines	in	injured	knees	is	still	higher	than	in	non-injured	knees	
one	year	after	injury36.	Any	cartilage	repair	procedure	in	the	knee	therefore	takes	
place	in	an	environment	with	some	degree	of	 inflammation.	 Inflammation	is	not	
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always	detrimental	to	successful	wound	healing,	because	some	degree	of	inflam-
mation	is	necessary	to	 initiate	and	maintain	any	healing	response37.	Controlling	
the	amount	of	 inflammation	and	reducing	the	amount	of	pro-inflammatory	anti-
chondrogenic	cytokines	in	the	knee	is	therefore	important.	
Obesity and adipose tissue inflammation
Obesity	is	another	factor	that	could	influence	cartilage	repair	results	in	the	knee.	
Obesity	is	defined	by	a	body	mass	index	(BMI)	above	30.	Studies	have	suggested	
that	a	higher	BMI	could	adversely	affect	the	clinical	outcome	of	microfracture18;	38 
and	ACI39	in	the	knee	and	patients	with	a	BMI	above	30	are	now	generally	excluded	
from	treatment40.	
Obesity	is	a	well-known	risk	factor	for	the	development	of	OA41.	A	typical	struc-
tural	change	 in	obesity	 is	 the	 increase	 in	adipose	tissue	size.	Excessive	dietary	
intake	of	lipids	and	carbohydrates	leads	to	adipocyte	hypertrophy,	death	and	sub-
sequently	influx	of	inflammatory	cells	into	the	adipose	tissue.	This	in	turn	leads	
to	increased	inflammatory	cytokine	secretion	by	the	adipose	tissue	and	systemic	
inflammation.	These	inflammatory	changes	leads	to	systemic	metabolic	changes	
such	 as	 hyperglycemia,	 hyperinsulinemia	 and	 dyslipidemia42-44.	 Combined	 with	
obesity,	these	changes	are	called	metabolic	syndrome	and	are	all	risk	factors	for	
the	development	of	OA41.	Besides	increasing	the	risk	of	developing	OA,	obesity	also	
could	exaggerates	post-traumatic	arthritis45;46	and	decrease	skin	wound	repair46.	
Most	of	the	adipose	tissue	in	the	body	is	located	subcutaneously.	There	are	also	
adipose	tissue	located	intra-articularly.	In	the	knee	joint,	the	IPFP	is	the	biggest.	
The	IPFP	is	however	not	the	same	as	subcutaneous	adipose	tissue.	On	MRI,	total	
IPFP	volume	is	not	associated	to	BMI47;48	and	 IPFP	adipocyte	size	 in	mice	 is	not	
influenced by high fat feeding49.	The	IPFP	does	play	an	role	in	joint	homeostasis.	
MRI	studies	have	shown	that	a	larger	IPFP	is	even	associated	with	less	OA47;50-52.	
Previously	we	have	shown	that	the	secretion	of	pro-inflammatory	cytokines	by	the	
IPFP	can	be	increased	by	an	inflammatory	stimulus53	and	that	the	IPFP	secretes	
factors	 that	 could	 influence	 the	 cartilage	 in	 degenerative	 joint	 disease54.	Other	
authors	 report	 that	 the	 IPFP	 contains	many	 inflammatory	 cells	 and	 that	 it	 is	 a	
source	of	inflammatory	factors55;	56.	
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AIMS AND OUTLINE OF THE THESIS
Adipose	tissue	becomes	inflamed	in	obesity	and	secretes	factors	that	affect	the	
knee	joint.	These	factors	originate	from	adipose	tissue	located	outside	the	knee	
joint	 and	 thus	 influence	 the	 knee	 through	 systemically	 secreted	 factors.	 There	
is	however	also	the	intra-articularly	 located	IPFP	that	can	directly	 locally	affect	
the	knee	joint.	Therefore,	the	main	aim	of	this	thesis	is	to	investigate	the	effect	of	
inflammation	in	adipose	tissue	on	degenerative	joint	disease	and	cartilage	repair.	
More	specifically,	we	investigate:
1.	 whether	adipose	tissue	in	and	outside	the	knee	influences	degenerative	joint	
disease	and	cartilage	repair	in	the	knee
2.	 what	the	role	is	of	adipose	tissue	resident	macrophages	in	degenerative	joint	
disease	and	cartilage	in	the	knee
3.	 whether	we	can	modulate	adipose	tissue	and	macrophages	with	medication	to	
reduce	degenerative	joint	disease	and	to	improve	cartilage	repair.
Adipocyte	size	in	subcutaneous	and	visceral	adipose	tissue	is	increased	in	obesity.	
This	 increase	 in	adipocyte	 size	 is	 associated	with	adipose	 tissue	 inflammation.	
However,	there	is	no	information	yet	available	about	whether	obesity	influences	
the	adipocytes	 in	the	 IPFP	 in	humans.	 In	Chapter 2	we	 investigate	whether	the	
adipocytes	 in	the	 IPFP	are	 increased	 in	obese	patients.	The	posterior	aspect	of	
the	IPFP	is	covered	by	synovial	membrane	and	the	synovial	membrane	is	heavily	
influenced	by	factors	secreted	by	the	 IPFP.	Synovial	fibrosis	 is	common	in	knee	
OA	and	causes	joint	stiffness.	In	Chapter 3	we	determine	whether	IPFP	secretes	
factors	 that	 influence	 fibrotic	 processes	 in	 synovial	 fibroblasts.	 Previously,	 we	
have	shown	that	the	IPFP	secretes	factors	that	influence	cartilage.	In	Chapter 4 we 
examine	whether	the	IPFP	secretes	factors	that	also	influence	MSC-based	cartilage	
repair.	Furthermore,	in	Chapter 4	we	describe	the	role	of	macrophages	residing	
in	the	IPFP	on	MSC-based	cartilage	repair.	To	improve	the	joint	environment	for	
cartilage	repair,	in	Chapter 5	we	focus	on	the	effect	of	different	anti-inflammatory	
medication	on	the	IPFP	and	macrophages	in	the	IPFP.	
The	IPFP	is	an	intra-articular	adipose	depot	and	most	adipose	tissue	are	located	
extra-articular.	Subcutaneous	and	visceral	adipose	tissue	depots	are	located	out-
side	the	joint	and	obesity	leads	to	changes	in	these	depots.	This	results	in	systemic	
metabolic	and	inflammatory	changes	that	could	influence	degenerative	joint	dis-
ease	and	cartilage	repair.	These	systemic	effects	are	complex	and	therefore	in-vivo	
studies	 are	more	 suitable.	 In	Chapter 6	 we	 test	whether	 commonly	 used	 lipid	
modifying	medications	can	prevent	degenerative	joint	disease	and	cartilage	dam-
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age	in	a	mouse	model	of	spontaneous	cartilage	damage	with	metabolic	syndrome.	
However,	when	cartilage	damage	does	occur	in	obese	patients	a	cartilage	repair	
treatment	might	be	needed.	Currently,	there	are	no	studies	available	examining	the	
structural	cartilage	repair	outcome	in	obese	patients	or	explaining	how	obesity	
influences	cartilage	repair.	In	Chapter 7	we	investigate	whether	a	high	fat	diet	can	
influence	cartilage	repair	in	a	mouse	model	of	cartilage	repair.		In	this	way,	I	hope	
to	find	new	treatments	to	improve	the	joint	environment	to	reduce	cartilage	dam-
age	and	improve	cartilage	repair.	Finally,	in	Chapter 8	I	will	summarize	and	discuss	
our	most	important	findings.	I	will	end	with	my	perspective	on	future	research.	
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ABSTRACT
Adipocyte	hypertrophy	and	the	resulting	adipose	tissue	inflammation	are	key	fea-
tures	of	obesity.	However,	it	is	still	unclear	whether	obesity	causes	the	adipocytes	
in	the	infrapatellar	fat	pad	(IPFP)	to	contribute	to	joint	inflammation.	The	aim	of	
this	study	was	to	determine	the	effect	of	obesity	on	the	size	of	IPFP	adipocytes.	
IPFP	was	obtained	from	end-stage	osteoarthritis	patients	with	a	mean	body	mass	
index	(BMI)	of	29.7	kg/m2	(range	21.5-48.47	kg/m2).	Subcutaneous	fat	was	obtained	
from	12	 end-stage	osteoarthritis	donors	with	 a	mean	BMI	of	 33.0	 kg/m2	 (range	
24.2-48.5	kg/m2).	Fat	 tissues	were	cryosectioned	and	stained	with	haematoxylin	
and	 eosin.	The	 cross-sectional	 area	of	 adipocytes	was	determined	using	 image	
analysis	software.	No	relationship	between	adipocyte	size	and	BMI	was	observed	in	
IPFP	adipocytes	(r=-0.06,	p=0.82),	whereas	subcutaneous	adipocyte	size	positively	
correlates	with	donor	BMI	(r=0.63,	p=0.028).	For	non-obese	donors,	size	of	 IPFP	
adipocytes	was	not	 significantly	different	 to	subcutaneous	adipocytes	 (p>0.99).	
Subcutaneous	 adipocytes	 from	obese	donors	were	 significantly	 larger	 than	 the	
IPFP	adipocytes	from	other	obese	donors	(p=0.03).	Our	results	demonstrate	that	
obesity	 does	 not	 affect	 the	 size	 of	 adipocytes	 in	 the	 IPFP,	which	 suggests	 that	
inflammation	of	the	IPFP	is	not	influenced	by	obesity	associated	adipocyte	hyper-
trophy.
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INTRODUCTION
A	high	body	mass	index	as	a	result	of	expansion	of	adipose	tissue	is	a	well-known	
risk	 factor	 in	 the	 development	 of	 knee	 osteoarthritis	 (OA)1.	 During	 expansion,	
adipocytes	in	adipose	tissue	become	hypertrophic.	Large	adipocytes	have	been	
shown	to	produce	substantially	more	pro-inflammatory	cytokines	and	adipokines	
than	smaller	adipocytes2	This	increased	secretion	of	pro-inflammatory	molecules	
such	 IL-6	and	tumor	necrosis	 factor	alpha	(TNF-α)	promotes	the	recruitment	of	
macrophages	and	 their	differentiation	 into	a	pro-inflammatory	phenotype.	This	
leads	to	low-grade	systemic	inflammation	and	metabolic	changes,	both	of	which	
have	been	associated	with	OA1.	Besides	mechanical	overloading,	obesity	related	
inflammation	and	metabolic	changes	have	also	been	associated	with	OA1.
The	 infrapatellar	 fat	 pad	 (IPFP)	 is	 an	 adipose	 tissue	 located	 intracapsular	 yet	
extra-synovial.	IPFP	is	a	potential	source	of	inflammatory	factors	in	the	knee	joint3.	
Due	to	its	intra-articular	location	and	because	adipose	tissues	generally	becomes	
inflamed	in	obesity,	it	has	been	long	thought	that	the	IPFP	could	play	a	major	role	
in	 obesity	 related	 joint	 inflammation.	Unlike	 subcutaneous	 adipose	 tissue,	MRI	
studies	 have	 suggested	 that	 total	 IPFP	 volume	 is	 not	 associated	 to	 body	mass	
index	(BMI)4.	However,	these	MRI	studies	did	not	investigate	the	susceptibility	of	
the	IPFP	to	obesity	related	events	that	lead	to	inflammation,	such	as	adipocyte	hy-
pertrophy.	The	aim	of	this	study	was	to	investigate	whether	increased	adipocyte	
size,	which	contributes	to	adipose	tissue	inflammation,	is	associated	with	BMI	in	
the	IPFP.	
METHODS
Tissue sample preparation
Eighteen	 IPFPs	 were	 obtained	 from	 end	 stage	 OA	 patients	 with	 a	 mean	 body	
mass	 index	 (BMI)	 of	 29.7	 kg/m2	 (range	 21.5-48.47	 kg/m2)	 undergoing	 total	 knee	
arthroplasty.	Subcutaneous	adipose	 tissue	was	obtained	 from	twelve	end	stage	
OA	donors	with	a	mean	BMI	of	33.0	kg/m2	(range	24.2-48.5	kg/m2)	undergoing	total	
hip	or	knee	 replacement.	Consent	was	given	 in	accordance	with	 the	guidelines	
of	the	Federation	of	Biomedical	Scientific	Societies	(http://www.federa.	org)	after	
approval	by	the	 local	ethical	committee	(MEC	2008-181	and	MEC	2012-267).	Do-
nors	were	subdivided	into	obese	(BMI	≥30)	and	non-obese	(BMI<	30)	for	each	of	
the	adipose	tissues	(a	total	of	4	groups).	Tissue	samples	were	cryosectioned	and	
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stained	with	haematoxylin	and	eosin	(H&E)	and	imaged	using	an	Olympus	SC30	
camera	(Olympus,	Zoeterwoude,	Netherlands).
Measurement of adipocyte size
The	cross-sectional	area	of	the	imaged	adipocytes	was	calculated	using	Fiji	Is	Just	
ImageJ	 software	with	 the	 additional	Adiposoft	 plugin.	 Three	 separate	 sections,	
with	a	minimum	of	25	adipocytes	in	each	section	were	measured	per	donor.	The	
Adiposoft	 application	was	 calibrated	 to	 identify	 cells	with	 a	 diameter	 between	
30-130	µm.	A	measuring	scale	of	0.33µm/pixel	was	also	used	by	the	application	
to	determine	 the	 cross-sectional	 area	 (size)	of	 each	adipocyte	 identifi	ed	 in	 the	
images.	A	manual	inspection	of	output	data	was	performed	to	confi	rm	the	consis-
tency	of	the	measurements	(Figure	1).
Figure 1 Identifi	cation	of	adipocytes	using	the	Adiposoft	plugin	for	FIJI.	
A)	Haematoxylin	 and	 eosin	 staining	of	 adipose	 tissue	 imaged	 at	 100x	magnifi	cation.	B)	 Image	processed	 in	
Adiposoft,	C)	Corrected	image	after	manual	inspection	of	processed	imaged.	The	yellow	contours	(B	and	C)	
represent	the	cross-sectional	area	of	an	adipocyte.	Scale	bar	=	100µm.	
Statistical analysis
The	Shapiro-Wilk	test	was	conducted	to	assess	the	distribution	of	the	adipocyte	
sizes	for	each	donor.	The	size	of	adipocytes	from	individual	donors	was	not	nor-
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mally	distributed.	Spearman’s	rho	was	determined	to	relate	BMI	to	adipocyte	size	
in	 IPFP	and	subcutaneous	adipose	 tissue.	The	Kruskal-Wallis	 test	with	multiple	
comparisons	was	used	to	compare	the	median	size	of	adipocytes	from	IPFP	and	
subcutaneous	fat	from	both	non-obese	and	obese	donors.	Statistical	signifi	cance	
was	considered	for	p-values	<0.05.
RESULTS
A	microscopic	observation	of	the	adipose	tissues	showed	no	distinct	difference	
between	adipocytes	in	terms	of	general	morphology	and	distribution	across	donor	
groups,	however	relatively	larger	adipocytes	were	noticeable	in	subcutaneous	fat	
of	obese	donors	compared	to	other	donor	groups	(Figure	2).	The	size	of	adipocytes	
in	 subcutaneous	 adipose	 tissue	was	 correlated	 to	donor	BMI	 (r=0.63,	p=0.028),	
which	was	not	the	case	in	the	IPFP	(r=	-0.06,	p=0.82)	(Figure	3A,	B).	For	non-obese	
donors	(BMI	<	30),	 IPFP	adipocyte	size	(1765	μm2	±	163.5)	was	not	signifi	cantly	
different	to	subcutaneous	adipocyte	size	(2157	μm2	±	835.6,	p	>0.99).	However	the	
size	of	adipocytes	from	the	IPFP	of	obese	(1732	μm2	±	292.4)	and	non-obese	donors	
(1765	μm2		±	163.5)	were	signifi	cantly	smaller	than	subcutaneous	adipocytes	from	
obese	donors	(3195	μm2	±	833.9,	p=0.03	and	p=0.04	respectively)	(Figure	3C).
Figure 2 Representative	images	of	H&E	stained	cryosections	of	adipose	tissue	from	the	IPFP	and	
subcutaneous	fat	(SCF)	of	non-obese	and	obese	donors.	
IPFP:	infrapatellar	fat	pad,	SCF:	subcutaneous	fat.	Scale	bar	=	100µm.	
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Figure 3 Obesity	does	not	affect	IPFP	adipocyte	size.	
Spearman’s	test	 for	correlation	between	donor	BMI	and	adipocyte	size	 in	the	A)	 infrapatellar	 fat	pad	(IPFP)	
and	B)	subcutaneous	fat	(SCF).	Each	dot	represents	an	individual	donor.	C)	Comparison	of	size	of	adipocytes	
between	IPFP	and	SCF	in	obese	and	non-obese	donor.	Values	are	mean±SD
DISCUSSION
The	obesity-related	alterations	that	occur	 in	adipose	tissues,	such	as	 increased	
adipocyte size5,	are	not	well	characterised	in	the	IPFP.		 In	the	current	study,	we	
have	shown	that	unlike	subcutaneous	adipose	tissue	adipocytes,	the	size	of	IPFP	
adipocytes	was	not	associated	with	BMI.
Our	observations	in	human	tissues	provide	evidence	that	the	IPFP	adipocytes	do	
not	undergo	the	metabolic	alterations	that	often	engenders	cellular	hypertrophy6,	
and	confirms	a	previous	investigation	that	showed	the	absence	of	hypertrophic	
adipocytes	in	the	IPFP	of	obese	mice.7 Subcutaneous adipose tissue is considered 
as	both	an	energy	storage	and	an	endocrine	organ	that	is	susceptible	to	inflam-
matory	macrophage	infiltration	during	obesity.	The	IPFP	is	a	potential	contributor	
to	local	joint	inflammation	via	the	production	of	adipokines	and	cytokines3 that 
exacerbate	joint	degeneration.	It	has	been	shown	that	inflammation	of	the	IPFP	is	
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associated	with	knee	pain	and	disability	in	obese	OA	patients.8 Since the adipo-
cytes	of	the	IPFP	itself	are	not	altered,	at	least	not	in	size	as	a	result	of	obesity,	it	
could	be	inferred	that	the	IPFP	derived	adipocytes	do	not	possess	the	same	pro-
inflammatory	phenotype	as	subcutaneous	adipocytes.	Hence,	our	findings	could	
highlight	novel	functional	differences	between	the	IPFP	and	subcutaneous	adipose	
tissue	in	obesity.	Perhaps	the	inflammatory	role	of	the	IPFP	in	the	pathogenesis	
of	obesity	related	OA	is	separate	to	that	of	subcutaneous	fat.	The	cellular,	genetic	
or	molecular	mechanisms	that	causes	this	difference	in	sensitivity	to	obesity	in	
the	IPFP	and	other	adipose	tissues	is	not	fully	understood	and	warrants	further	
investigation.
It	 is	 noteworthy	however,	 that	 recent	MRI	based	 studies	have	 associated	 large	
IPFP	with	a	reduced	number	of	a	bone	marrow	lesions,	low	walking	pain	and	higher	
total	cartilage	volume	in	OA	patients.	 9	Furthermore,	conditioned	media	of	 IPFP	
adipocytes	from	obese	OA	patients	was	found	to	have	no	effect	on	the	secretion	
of	TNF-α	in	lipopolysaccharide	stimulated	macrophages	in vitro,	but	interestingly	
inhibited	the	production	of	IL-12p40	in	these	stimulated	macrophages.10	We	have	
also	shown	that	there	were	no	differences	between	the	amount	of	secreted	factors	
in	 conditioned	media	of	 IPFP	 from	obese	and	non-obese	OA	donors11,	 and	 that	
conditioned	media	 from	 OA	 IPFP	 explants	 have	 a	 chondroprotective	 effect	 on	
cartilage.12	In	a	rat	model	for	ageing,	only	synovial	thickness	as	one	of	the	many	
OA	 features	 was	 correlated	 with	 IPFP	 adipocyte	 size	 and	 this	 correlation	 was	
independent	of	age.	The	secretion	of	the	pro-inflammatory	cytokine	TNF-α	 from	
IPFP	was	associated	with	age,	but	no	association	between	IPFP	adipocyte	size	and	
cytokines	release	was	reported13.	The	progressive	age-dependant	downregulation	
of	genes	related	 to	anti-inflammatory	macrophages	 in	 IPFP	explants	 from	these	
rats	suggests	 that	a	shift	 towards	a	pro-inflammatory	phenotype	 is	 likely	 to	be	
mediated	by	immune	cells	rather	than	adipocytes.	Taking	this	together,	it	is	clear	
that	further	investigations	are	required	to	clarify	whether	and	how	obesity	influ-
ences	the	IPFP,	and	if	so,	what	the	implications	are	for	OA.
The	 use	 of	 unmatched	 IPFP	 and	 subcutaneous	 fat	 is	 a	 limitation	 to	 this	 study.	
Assessing	a	bigger	sample	size	with	matched	 IPFP	and	subcutaneous	 fat	would	
further	 confirm	 the	 differences	 in	 adipocyte	 size	 in	 the	 two	 tissues	 within	 a	
particular	 donor.	 A	 recent	 study	 reported	 considerably	 larger	 adipocyte	 sizes	
for	both	IPFP	(3708	±	976	µm2)	and	subcutaneous	fat	(6082	±	628	µm2)	compared	
to our results14.	 This	 could	be	 attributed	 to	 the	difference	 in	methods	used	 to	
measure	cell	size.	Analysis	of	the	secretory	profiles	of	individual	adipocytes	would	
also	provide	valuable	 insight	concerning	the	 inflammatory	status	of	 the	 IPFP	 in	
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obese	and	non-obese	patients.	 Interestingly,	our	previous	experiments	revealed	
that	the	secretory	profile	of	IPFP	explants	and	the	presence	of	macrophages	in	the	
IPFP	are	not	influenced	by	donor	BMI.3,11	This	provides	supporting	evidence	for	
our	hypothesis	that	perhaps	an	increased	BMI	does	not	have	significant	influence	
on	the	adipocytes	in	the	IPFP.	Furthermore,	we	did	not	have	samples	from	non-OA	
IPFP	donors.	We	 therefore	cannot	exclude	 the	possibility	 that	 the	OA	could	al-
ready	have	influenced	the	adipocyte	size	in	our	donors.	The	IPFP	can	also	become	
fibrotic	which	could	possibly	limit	the	enlargement	of	adipocytes.	
In	conclusion,	to	our	knowledge,	this	is	the	first	evidence	that	IPFP	adipocytes	do	
not	become	hypertrophic	with	obesity.	A	difference	in	the	physiological	roles	of	
the	IPFP	and	subcutaneous	fat	could	possibly	account	for	the	difference	in	suscep-
tibility	of	their	adipocytes	to	hypertrophy.	The	data	presented	here	adds	to	the	
growing	body	of	literature	investigating	the	physiological	function	of	the	IPFP	and	
its	role	in	the	development	OA.
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ABSTRACT
Objective
Stiffening	of	the	joint	is	a	feature	of	knee	osteoarthritis	(OA)	that	can	be	caused	
by		fibrosis	of	the	synovium.	The	infrapatellar	fat	pad	(IPFP)	present	in	the	knee	
joint	produces	immune-modulatory	and	angiogenic	factors.	The	goal	of	the	pres-
ent	study	was	to	investigate	whether	the	IPFP	can	influence	fibrotic	processes	in	
synovial	fibroblasts,	 and	 to	determine	 the	 role	of	 transforming	growth	 factor	β 
(TGFβ)	and	prostaglandin	F2α		(PGF2α)	in	these	processes.
Methods
Batches	of	fat-conditioned	medium	(FCM)	were	made	by	culturing	pieces	of	IPFP	
obtained	from	the	knees	of	13	patients	with	OA.	Human	OA	fibroblast-like	synovio-
cytes	(FLS)	(from	passage	3)	were	cultured	in	FCM	with	or	without	inhibitors	of	
TGFβ	/	activin	receptor–like	kinase	5	or	PGF2α	for	4	days.	The	FLS	were	analyzed	
for	 production	 of	 collagen	 and	 expression	 of	 the	 gene	 for	 procollagen-lysine,2-
oxoglutarate	5-dioxygenase	2	(PLOD2;	encoding	lysyl	hydroxylase	2b,	an	enzyme	
involved	in	collagen	crosslinking)	as	well	as	the	genes	encoding	α-smooth	muscle-
actin and type I collagen α1	chain.	In	parallel,	proliferation	and	migration	of	the	
synoviocytes	were	analyzed.	
Results
Collagen	production	and	PLOD2	gene	expression	by	the	FLS	were	increased	1.8-
fold	(p<0.05)	and	6.0-fold	(p<0.01),	respectively,	in	the	presence	of	FCM,	relative	
to	control	cultures	without	FCM.	Moreover,	the	migration	and	proliferation	of	syn-
oviocytes	were	stimulated	by	FCM.	Collagen	production	was	positively	associated	
with	PGF2α	levels	in	the	FCM	(r=0.89,	p<0.05),	and	inhibition	of	PGF2α	levels	reduced	
the	extent	of	FCM-induced	collagen	production	and	PLOD2	expression.	Inhibition	
of	TGFβ	signaling	had	no	effect	on	the	pro-fibrotic	changes.	
Conclusion
These	results	indicate	that	the	IPFP	can	contribute	to	the	development	of	synovial	
fibrosis	 in	 the	knee	 joint	by	 increasing	collagen	production,	PLOD2	expression,	
cell	 proliferation,	 and	 cell	migration.	 In	 addition,	whereas	 the	 findings	 showed	
that	TGFβ	is	not	involved,	the	more	recently	discovered	pro-fibrotic	factor	PGF2α 
appears	to	be	partially	involved	in	the	regulation	of	pro-fibrotic	changes. 
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INTRODUCTION
Osteoarthritis	(OA)	is	a	multifactorial	disease	of	the	articular	joints,	with	an	inci-
dence	that	is	higher	in	women,	obese	subjects,	and	older	individuals1;2.	The	role	
of	the	synovium	in	OA	pathology	is	becoming	more	evident.	In	conjunction	with	
cartilage	damage	and	bone	alterations,	the	pathologic	 features	of	 inflammation,	
hyperplasia,	and	extensive	fibrosis	are	also	often	observed	in	the	synovium	of	OA	
joints3-5.
Fibrosis	 can	 be	 seen	 as	 an	 abnormal	 healing	 process	 that	 is	 characterized	
by	excessive	deposition	of	 extracellular	matrix	proteins,	 in	particular	 collagen,	
which,	in	turn,	results	in	alteration	of	the	structure	of	the	tissue	and,	finally,	even	
loss	of	 function	of	 this	 tissue.	Fibrotic	processes	are	a	response	 to	a	variety	of	
insults,	such	as	infection,	trauma,	autoimmunity,	or	inflammation,	resulting	in	an	
inflammatory	reaction	with	rapid	recruitment	of	monocytes	from	the	circulation	
or	macrophages	 resident	 in	 the	 tissue.	These	cells	 are	 important	 sources	of	 fi-
brotic	cytokines,	such	as	transforming	growth	factor	β	(TGFβ)	and	platelet-derived	
growth	factor,	that,	in	turn,	recruit	fibroblasts	to	the	site	of	injury	and	stimulate	
them	to	proliferate6.
Fibroblasts	can	also	differentiate	 toward	myofibroblasts.	Myofibroblasts,	which	
are characterized by the presence of α-smooth	muscle	actin,	are	present	during	
normal	tissue	repair,	but	when	the	wound	is	closed,	they	disappear	from	the	site.	In	
the	case	of	fibrosis,	myofibroblasts	persist	in	the	damaged	tissue7-9.	An	additional	
hallmark	of	fibrosis	is	the	increased	level	of	hydroxyallysine	collagen	crosslinks,	
which	 is	 regulated	by	 lysyl	hydroxylase	2b	 (LH2b),	 an	enzyme	encoded	by	 the	
gene	 for	 procollagen-lysine,	 2-oxoglutarate	 5-dioxygenase	 2	 (PLOD2)10.	 These	
hydroxyallysine	collagen	crosslinks	are	 found	 in	fibrotic	 tissues	and	are	associ-
ated	with	irreversible	accumulation	of	collagen11.	Recently,	it	was	demonstrated	
that	PLOD2	expression	and	the	presence	of	LH2b	are	up-regulated	in	the	fibrotic	
synovium	of	mice	with	OA12.
TGFβ	is	a	potent	inducer	of	PLOD2	expression	and	LH2b	activity12;13,	making	TGFβ 
a	very	potent	fibrotic	growth	factor	involved	in	all	of	the	processes	seen	in	fibro-
sis.	 In	addition	 to	TGFβ,	prostaglandin	F2α	 (PGF2α)	was	recently	discovered	as	a	
cytokine	that	facilitates	pulmonary	fibrosis	independent	of	TGFβ.	Mice	lacking	the	
PGF2α	receptor	did	not	develop	pulmonary	fibrosis	in	response	to	bleomycin,	and	
cells	stimulated	with	PGF2α	produced	more	collagen14;15.
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In	addition	to	cartilage,	menisci,	ligaments,	and	synovium,	the	knee	joint	contains	
fat	pads.	One	of	the	largest	of	the	fat	pads	is	the	infrapatellar	fat	pad	(IPFP).	The	
main	role	of	the	 IPFP	is	to	 facilitate	distribution	of	synovial	fluid	and	distribute	
mechanical	forces	through	the	knee	joint.	Several	adipokines	and	cytokines,	such	
as	tumor	necrosis	factor	α,	interleukin-6	(IL-6),	IL-10,	leptin,	and	vascular	endothe-
lial	growth	factor,	are	known	to	be	produced	by	the	IPFP16-20.	The	IPFP	is	located	
in	close	proximity	to	the	synovial	layers	and	cartilage	surfaces,	making	the	IPFP	
able	to	influence	inflammatory	processes	in	the	knee21.	Many	secreted	proteins	are	
derived	from	the	non-adipocyte	fraction	of	adipose	tissue	(macrophages,	T	cells,	
and	B	cells)18;22,	and	it	 is	suggested	that	most	of	the	cytokines	produced	by	the	
adipose	tissue	are	macrophage-derived23;24.	
Since	synovial	fibrosis	is	often	seen	in	end-stage	OA,	the	goal	of	the	present	study	
was	 to	 investigate	 whether	 the	 IPFP	 and	 its	 secreted	 factors	 influence	 fibrotic	
processes	in	synovial	fibroblasts,	and	to	determine	the	role	of	2	potent	fibrotic	in-
ducers,	TGFβ	and	PGF2α,	in	the	relationship	between	the	IPFP	and	synovial	fibrosis.
MATERIALS AND METHODS
Preparation and analysis of fat-conditioned medium
Samples	 of	 IPFP	 were	 derived	 from	 anonymized	 leftover	 knee	 tissue	 material	
obtained	from	patients	with	OA	who	had	undergone	total	knee	arthroplasty.	The	
IPFP	 samples	were	used	 to	produce	 FCM.	The	patients	 implicitly	 consented	 to	
the	use	of	these	tissues	for	scientific	research,	in	accordance	with	the	guidelines	
of	the	Federation	of	Biomedical	Scientific	Societies	(http://www.federa.org),	with	
approval	 from	 the	 local	 ethics	 committee	 in	 Rotterdam,	 The	 Netherlands	 (ap-
proval	no.	MEC	2008-181).	The	mean	age	of	the	donors	was	67.9	years	(range	54–81	
years)	and	the	mean	body	mass	index	(BMI)	of	the	donors	was	30.52	kg/m2	(range	
19.6–44.5	kg/m2).	The	inner	parts	of	the	fat	pads,	where	no	synovium	is	present,	
were	cut	into	small	pieces	of	±10	mg	and	cultured	in	suspension	for	24	hours	in	a	
concentration	of	50	mg	tissue/ml	in	Dulbecco’s	modified	Eagle’s	medium	(DMEM)	
with	Glutamax	(Gibco	BRL),	containing	insulin,	transferrin,	selenic	acid,	and	albu-
min	(ITS+)	(dilution	1:100;	BD	Biosciences)	as	well	as	50	µg/ml	gentamicin	and	1.5	
µg/ml	Fungizone	(both	from	Gibco	BRL).	As	a	control	medium,	we	used	identically	
composed	culture	medium	that	did	not	contain	pieces	of	IPFP,	cultured	in	parallel.	
After	24	hours,	the	medium	was	harvested,	centrifuged	at	300g	for	8	minutes	to	
remove	(immune)	cells,	and	frozen	at	 -80°C	in	aliquots	of	1.5	ml,	resulting	in	29	
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different	batches	of	FCM.	This	incubation	time	was	chosen	arbitrarily,	since	each	
mediator	has	its	own	optimum	regarding	release	kinetics22;25-27.
Isolation and culture of fibroblast like synoviocytes (FLS)
Samples	 of	 human	 synovium	were	 also	 obtained	 as	 anonymized	 leftover	mate-
rial	from	patients	with	OA	who	had	undergone	total	knee	arthroplasty	(approval	
no.	MEC	2004-322).	On	the	basis	of	its	specific	structure,	the	synovium	could	be	
distinguished	and	removed	from	the	adjacent	tissue.	The	synovium	samples	were	
then	digested	in	Pronase	(2	mg/ml;	Sigma)	for	2	hours	and	in	collagenase	B	(1.5	
mg/ml;	Roche	Diagnostics)	overnight.	Digested	cells	were	plated	out	as	3,500	cells	
per	 cm2	 and	 expanded	 in	 Iscove’s	modified	Dulbecco’s	medium	with	 10%	 fetal	
calf	serum	(FCS),	50	µg/ml	gentamicin,	and	1.5	µg/ml	Fungizone	(all	 from	Gibco	
BRL).	Cells	 from	passage	 3	were	 allowed	 to	 adhere	 at	 a	density	of	 50,000	 cells	
per	cm2	in	DMEM	with	Glutamax,	10%	FCS,	and	antibiotics	(all	from	Gibco	BRL).	
After	overnight	attachment,	the	culture	medium	was	removed	and	the	cells	were	
washed	carefully	3	times	with	saline.	FCM	was	mixed	1:1	with	fresh	DMEM	with	
Glutamax,	supplemented	with	50	µg/ml	gentamicin,	1.5	µg/ml	Fungizone,	and	ITS+	
(dilution	1:100),	and	applied	to	the	attached	FLS.	Thereafter,	the	FLS	were	cultured	
for	4	days.	The	mean	age	of	the	FLS	donors	was	67	years	(range	60–81	years)	and	
the	mean	BMI	was	32.4	kg/m2	(range	24.2–42.5	kg/m2).	
To	investigate	the	involvement	of	TGFβ1	or	PGF2α,	1	µM	SB505124	(Sigma),	an	
inhibitor	of	TGFβ1	signaling,	or	10	µM	AL8810	(Cayman	Chemical),	an	inhibitor	of	
PGF2α	signaling,	was	added	1	hour	prior	to	adding	the	FCM;	as	positive	control	for	
the	inhibition,	1	ng/ml	TGFβ1	or	1	µM	PGF2α	was	added.	Concentrations	and	timing	
were	based	on	those	previously	described	in	a	study	by	Oga	et	al14.
Analysis of collagen deposition 
Collagen	was	determined	using	the	Quickzyme	soluble	collagen	assay	according	to	
the	manufacturer’s	guidelines	(QuickZyme	Biosciences,	Leiden,	the	Netherlands).	
Briefly,	culture	medium	was	removed	and	the	cell/matrix	fraction	was	solubilized	
by	overnight	incubation	in	0.5M	acetic	acid	at	4°C.	The	assay	is	based	on	binding	
of	collagen	with	Sirius	Red.
Analysis of gene expression
After	 culture,	monolayers	 of	 synoviocytes	were	 suspended	 in	 350µl	 RLT	 buffer	
(Qiagen,	Venlo,	the	Netherlands)	supplemented	with	1%	β-mercaptoethanol.	RNA	
was	extracted	and	complementary	DNA	was	analyzed	for	gene	expression	using	
previously	 described	 methods28.	 The	 primer	 sequences	 for	 the	 genes	 were	 as	
follows:	 for	 the	 GAPDH	 reference	 gene,	 forward	 GTCAACGGATTTGGTCGTATT-
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GGG,	 reverse	 TGCCATGGGTGGAATCATATTGG,	 and	 probe	 FAM-CGCCCAATAC-
GACCAAATCCGTTGAC-TAMRA;	for	the	type	I	collagen	α	1	chain	gene	(COL1A1),	
forward	 CAGCCGCTTCACCTACAGC,	 reverse	 TTTTGTATTCAATCACTGTCTTGCC,	
and	 probe	 FAM-CCGGTGTGACTCGTGCAGCCATC-TAMRA;	 for	 PLOD2,	 forward	
CCCTCCGATCAGAGATGATT	and	reverse	AATGTTTCCGGAGTAGGGGAGTCTTTTT;	
and for the gene encoding α-smooth	muscle	actin	(ASMA),	forward	CGTTGCCCCT-
GAAGAGCAT	and	reverse	CCGCCTGGATAGCCACATACA.	Primers	for	the	type	III	col-
lagen	gene	(COL3)	were	purchased	from	Qiagen	Assays-on-Demand	(QT00058233).	
For	 analysis	 of	 GAPDH	 and	 COL1A1,	 TaqMan	 2x	 Universal	 Polymerase	 Chain	
Reaction	(PCR)	Master	Mix	(Applied	Biosystems)	was	used	 in	 the	reaction.	For	
analysis	 of	 PLOD2	 and	 ASMA,	 quantitative	 PCR	Master	Mix	 Plus	 SYBR	Green	 I	
(Eurogentec)	was	used	in	the	reaction.	In	determining	the	optimal	housekeeping	
gene,	we	compared	GAPDH,	18S	RNA,	2-microglobulin,	and	hypoxanthine	guanine	
phosphoribosyltransferase,	and	observed	that	GAPDH	was	the	most	stable	house-
keeping	gene	in	our	experiments.
Migration assay
To	investigate	the	migration	of	the	synoviocytes	in	response	to	soluble	factors,	a	
scratch	wound	assay	was	performed.	Synoviocytes	from	passage	3	were	seeded	at	
100,000	cells	per	cm2	in	12-well	plates	and	allowed	to	adhere	overnight	in	DMEM	
containing	10%	FCS.	A	10-µl	pipette	tip	was	used	to	make	a	scratch	in	the	confluent	
monolayer	of	the	synoviocytes,	after	marking	the	scratch	location	on	the	bottom	
of	 the	 well.	 When	 applicable,	 SB505124	 or	 AL8810	 was	 added	 1	 hour	 prior	 to	
making	the	scratch.	Cell	debris	was	removed	by	washing	with	saline,	and	the	cell	
culture	was	continued	 in	DMEM–1%	ITS+	mixed	with	FCM	(1:1)	with	or	without	
SB505124	or	AL8810.
Photographic	 images	were	obtained	directly	after	scratching	and	at	14,	16,	and	
19	hours	after	 scratching.	These	 time	points	were	chosen	on	 the	basis	of	pilot	
experiments	showing	that,	from	14	hours	onward,	migration	of	the	synoviocytes	
is	best	visualized	(results	not	shown)	without	 interference	from	proliferation	of	
the	cells.	Closure	was	measured	using	TScratch	software	(Computational	Science	
&	Engineering	Laboratory).	The	extent	of	migration	is	presented	as	the	percentage	
of	closure	after	wounding.
Proliferation assay
To	analyze	proliferation,	synoviocytes	from	passage	3	were	seeded	at	a	density	of	
10,000	cells	per	cm2	in	12-well	plates	and	allowed	to	adhere	overnight	in	DMEM	
containing	10%	FCS.	To	arrest	cells	in	the	S1	phase	(which	was	necessary	in	order	
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to	reduce	variation),	cells	were	cultured	in	DMEM	containing	0.1%	FCS	for	24	hours	
after	adherence.	Following	24	hours	of	starvation,	 the	culture	was	continued	 in	
DMEM–1%	ITS+	mixed	with	FCM	(1:1)	with	or	without	the	addition	of	SB505124	or	
AL8810.	When	applicable,	SB505124	or	AL8810	was	added	1	hour	prior	to	adding	
the	FCM.	Samples	for	DNA	measurement	were	obtained	after	1,	2,	3,	and	4	days	
by	suspending	the	monolayer	in	phosphate	buffered	saline	with	0.1%	Triton.	The	
amount	of	DNA	in	each	sample	was	determined	using	ethidium	bromide,	with	calf	
thymus	DNA	(Sigma)	as	standard.
Enzyme-linked immunosorbent assay (ELISA) for TGFβ1
To	determine	the	activity	of	TGFβ1	in	the	FCM,	a	human	TGFβ1	Quantikine	ELISA	
kit	(R&D	Systems)	was	used	according	to	the	manufacturer’s	guidelines.	To	acti-
vate	latent	TGFβ1	to	the	immunoreactive	form,	acid	activation	with	1N	HCl	and	
neutralization	with	1.2N	NaOH/0.5M	HEPES	was	performed.
PGF2α measurements using mass spectrometry
To	determine	the	levels	of	PGF2α	in	the	FCM	samples	that	remained	(n=7),	samples	
were	analyzed	with	 liquid	chromatography	tandem	mass	spectrometry	(LC-MS/
MS)	as	described	previously29.	Briefly,	to	prepare	the	samples	for	measurement,	
FCM	 samples,	with	 deuterated	PGF2α	 -d4	 (Cayman	Chemical)	 added	 as	 internal	
standard,	 were	 extracted	 with	 LC-MS–grade	 methanol	 (Riedel-de-Ha¨en).	 The	
methanol	 extract	 was	 loaded	 on	 an	 HLB	 SPE	 column	 (Oasis),	 after	 which	 the	
samples	were	reconstituted	in	100	µl	ethanol	containing	CUDA	(Cayman	Chemi-
cal)	as	a	second	internal	standard,	and	immediately	used	for	LC-MS/MS	analysis	
on	an	Acquity	C18	BEH	Ultra	Performance	liquid	chromatography	column	coupled	
to	a	Xevo	TQ-S	mass	spectrometer	 (Waters).	Cone	voltage	and	collision	energy	
were	optimized	for	each	compound	individually.	Parent	and	product	mass/charge	
(m/z)	 values	 of	 PGF2α	 were	 353.1	 and	 193.0.	 Parent	 and	 product	m/z	 values	 of	
PGF2α-d4	were	357.1	and	313.4.	Parent	and	product	m/z	values	of	CUDA	were	339.1	
and	214.1.	Identification	and	quantification	of	peak	values	were	performed	using	
MassLynx	software	version	4.1.
Statistical analysis
Experiments	examining	 the	effect	of	 FCM	were	performed	with	 samples	 from	3	
different	FLS	donors	and	13	different	FCM	batches	representing	13	different	IPFP	
donors.	Experiments	examining	the	effect	of	inhibition	of	TGFβ1	or	PGF2α together 
with	FCM	stimulation	were	performed	with	samples	from	2	different	FLS	donors	
and	8	different	FCM	batches	representing	8	different	IPFP	donors.	All	experiments	
were	performed	with	triplicate	samples	per	condition,	which	was	taken	into	ac-
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count	in	the	statistical	analysis.	A	mixed	linear	model,	followed	by	a	Bonferroni	
post	hoc	test,	was	used	to	analyze	gene	expression,	collagen	deposition,	and	cell	
migration.	A	univariate	general	linear	model	was	used	to	analyze	the	results	from	
the	proliferation	assays.	Since	not	every	FCM	batch	was	tested	on	FLS	from	every	
donor,	we	allowed	for	this	in	the	statistical	analysis	by	adding	a	subject	variable	
indicating	the	FLS	donor.	Spearman’s	rho	correlations	were	determined	to	exam-
ine	associations	between	TGFβ1	or	PGF2α	levels	and	other	parameters.	Data	were	
analyzed	with	IBM	SPSS	statistical	software	(version	20.0).
RESULTS
Induction of fibrotic processes with medium conditioned
by IPFP 
In	culture	conditions	with	8	of	the	13	FCM	batches	(derived	from	13	different	OA	
IPFP	donors),	collagen	production	by	FLS	was	 increased	1.8-fold	after	4	days	of	
culture,	 from	a	mean	1.9	µg/monolayer	 in	 control	 conditions	without	 FCM	 to	a	
mean	3.4	µg/monolayer	 in	cultures	with	FCM	(Figure	1A	 [all	 13	 included	 in	 the	
figure]).	In	addition,	gene	expression	of	the	enzyme	involved	in	the	formation	of	
pyridinolinebased	collagen	crosslinks,	PLOD2,	was	increased	6.0-fold	in	the	pres-
ence	of	FCM.	Surprisingly,	COL1A1	expression	on	day	4	was	2.5-fold	 lower	than	
Figure 1 The	 effect	 of	 fat	 conditioned	medium	 (FCM)	on	A)	 total	 collagen	prodution	by	 FLSs	
in	monolayer	after	4	days	of	culture	and	B)	gene	expression	after	4	days	of	culture	relative	to	
the	control	without	FCM	(set	at	1)	of	genes	describing	a	fibrotic	process:	Col1	(coll1,	α1	chain),	
procollagen-lysine,	2-	oxoglutarate	5-dioxygenase	2	(Plod2)	and	α	smooth	muscle	actin	(Asma).	A	
total	of	13	different	FCM	batches	was	tested	on	FLS	of	three	different	donors.	Bars	represent	the	
mean	±	standard	deviation.	Box-whisker	plots	indicate	the	75th	and	25th	percentile	with	the	median	
(boxes)	and	the	maximum	and	the	minimum	(whiskers).	*indicates	p<0.05,	**indicates	p<0.01.
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that	in	control	conditions	without	FCM,	and	ASMA	expression	was	1.7-fold	lower	
(Figure	1B).	COL3	expression	was	unaltered	by	the	addition	of	FCM	(results	not	
shown).	The	observed	increase	 in	collagen	production	but	decrease	 in	COL1A1	
expression	might	be	explained	by	the	hypothesis	that	altered	processing	of	the	
collagen	would	lead	to	more	efficient	translation,	but	would	not	alter	expression	
of	COL3.	Also,	the	collagen	deposition	represents	accumulation	in	the	total	culture	
for	4	days,	whereas	the	collagen	gene	expression	is	the	specific	expression	at	the	
moment	of	harvest.	
Since	 TGFβ1	 is	 known	 to	 be	 a	 potent	 inducer	 of	 collagen	 deposition	 and	 of	
COL1A1,	PLOD2,	and	ASMA	expression,	we	also	included,	as	a	positive	control	a	
culture	condition	in	which	TGFβ1	was	added	in	all	of	the	experiments.	Indeed,	irre-
spective	of	which	FLS	donor	was	used,	TGFβ1	induced	the	same	fibrotic	processes	
as	seen	in	FLS	cultures	with	FCM	(results	not	shown).
To	 investigate	whether	 the	BMI	of	 the	 IPFP	donor	 influenced	 the	effect	of	 FCM	
on	FLSs,	we	performed	a	post hoc	subgroup	analysis	comparing	the	FCM	batches	
made	from	IPFPs	of	donors	who	had	a	BMI	lower	than	30	kg/m2	(n=5)	with	FCM	
batches	made	from	IPFPs	of	donors	who	had	a	BMI	equal	to	or	higher	than	30	kg/
m2	(n=8).	No	differences	in	collagen	deposition	or	expression	of	COL1A1,	PLOD2,	
or	ASMA	were	observed	between	the	2	BMI	subgroups.	Both	groups	still	showed	
significant	differences	in	gene	expression	when	compared	with	the	control	condi-
tion	without	FCM	(Figure	2).
To	determine	the	effects	on	FLS	migration,	we	performed	a	scratch	wound	assay	
(typical	examples	right	after	scratching	and	19	hours	after	scratching	are	shown	
in Figures	3A	and	B).	Migration	of	FLS	(p=0.005)	and	proliferation	of	FLS	(p=0.002)	
were	stimulated	in	the	presence	of	FCM	(Figures	3C	and	D).
Association of FCM effects with the presence of TGFβ1 or PGF2α.
TGFβ1	and	PGF2α	are	both	known	as	potent	pro-fibrotic	mediators	and	candidates	
to	be	 involved	 in	 the	processes	seen	 in	 the	FLS	 in	response	 to	FCM.	The	mean	
TGFβ1	content	of	the	FCM	was	37.3	pg/ml,	ranging	from	0.1	pg/ml	to	74.9	pg/ml.	
The	mean	PGF2α	content	in	the	FCM	was	6,204	pg/ml,	ranging	from	560	pg/ml	to	
29,718	pg/ml.	The	level	of	PGF2α	was	positively	correlated	with	the	extent	of	col-
lagen	deposition	by	the	FLS	(Figure	4A)	and	negatively	associated	with	COL1A1	
expression	(Figure	4B).
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Figure 2 The	effect	of	FCM	subdived	 in	non	obese	(BMI	<	30,	n	=	5,	1	male	and	4	 female)	and	
obese	(n	≥	30,	n	8,	1	male	and	7	female)	donors	on	A)	collagen	deposition	B)	collagen	type	1	gene	
expression,	C)	Plod2	gene	expression,	and	D)	Asma	gene	expression	by	synoviocytes.	The	dotted	
line	indicates	the	levels	in	the	control	condition	without	FCM.	**indicates	significantly	different	
from	 control	 condition	with	p<0.01,	 ***indicates	 significantly	 different	 from	 control	 condition	
with p<0.005.	Bars	represent	the	mean	±	standard	deviation.
The	level	of	TGFβ1	was	positively	associated	with	COL1A1	expression	(Figure	
4C).	No	other	associations	were	seen.
To	 evaluate	 the	 effect	 of	 TGFβ1	 and	 PGF2α	 on	 FLS	 in	 our	 culture	 system,	we	
added	these	compounds	to	FLS	cultures	without	the	presence	of	FCM.	The	addi-
tion	of	1ng/ml	TGFβ1	increased	total	collagen	deposition,	COL1A1	expression,	and	
ASMA	expression.	The	addition	of	1	µM	PGF2α	 increased	PLOD2	expression	and	
total	collagen	deposition	(Figures	5A	and	D-F).	TGFβ1	and	PGF2α both increased 
the	migration	of	 the	FLS,	but	had	no	effect	on	proliferation	of	 the	FLS	 (Figures	
5B	and	C).	The	effects	of	PGF2α	best	simulated	the	effects	of	FCM	as	seen	in	our	
experiments	(as	described	in	Figures	1	and	2).
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Counteraction of the pro-fibrotic effect of FCM via inhibition of PGF2α 
signaling. 
To	examine	the	involvement	of	TGFβ1	and	PGF2α	in	the	pro-fibrotic	effect	of	FCM,	
the	FLS	were	cultured	with	FCM	with	or	without	a	TGFβ1	receptor	type	I	kinase	
inhibitor,	 SB505124,	 or	 a	 selective	 PGF	 receptor	 antagonist,	 AL8810.	 First,	 we	
verified	whether	SB505124	could	indeed	inhibit	the	effect	of	1	ng/ml	TGFβ1,	and	
whether	AL8810	could	indeed	inhibit	the	effect	of	1	µM	PGF2α.	SB505124	blocked	
Figure 3 The	effect	of	FCM	on	migration	and	proliferation	of	FLS	determined	by	a	scratch-wound	
assay.	
(A)	Pictures	of	the	scratch	were	taken	directly	after	making	the	scratch	and	(B)	after	migration	for	19	hours.	
The	lines	at	the	top	of	A	and	B	mark	the	bottom	of	the	well	as	reference	point	for	taking	pictures	during	migra-
tion.	The	effect	of	FCM	on	(C)	migration	as	percentage	open	and	(D)	proliferation	as	µg	DNA	per	monolayer	was	
tested.	A	total	of	9	different	FCM	batches	was	tested	on	FLS	of	three	different	donors.	*indicates	p	<	0.05	regard-
ing	the	total	migration	and	proliferation	curves.	Data	are	shown	as	mean	migration	or	proliferation	±	standard	
deviation	of	9	FCM	batches.
Figure 4 Associations	between	concentration	of	TGFβ1	and	PGF2α	in	the	FCM	and	the	effect	of	FCM	
on	the	FLS	in	culture.	
A)	a	positive	association	between	the	level	of	PGF2α	in	the	FCM	and	collagen	deposition	by	the	FLS	(R	=	0.89,	p	=	
0.028)	B)	a	negative	association	between	PGF2α	in	the	FCM	and	Col1	gene	expression	(R=	-0.82,	p	=	0.023),	and	C)	
a	positive	association	between	TGFβ1	in	the	FCM	and	Col1	gene	expression	(R	=	0.77	,	p	=	0.012).	The	p-values	
were	corrected	for	multiple	testing.
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the	effect	of	TGFβ1	on	collagen	production,	COL1A1	expression,	and	ASMA	expres-
sion,	confirming	the	efficacy	of	the	inhibitor.	AL8810	inhibited	the	effect	of	PGF2α 
on	collagen	production	and	there	was	a	trend	toward	normalization	of	PLOD2
expression	(p=0.08)	(Figures	5A	and	D–F).	The	presence	of	1	µM	SB505124	or	10	
µM	AL8810	alone	seemed	to	have	no	influence	on	collagen	deposition	or	COL1A1,	
PLOD2,	and	ASMA	expression	(Supplementary	figure	1).
Inhibition	 of	 TGFβ/activin	 receptor–like	 kinase	 5	 signaling	with	 SB505124	 did	
not	alter	 the	FCM-induced	effects	on	FLS,	 indicating	 that	 the	effect	of	FCM	was	
not	caused	by	TGFβ.	Blocking	the	PGF	receptor	with	AL8810,	on	the	other	hand,	
inhibited	the	increase	in	collagen	deposition	that	had	been	induced	by	FCM,	bring-
ing	the	collagen	deposition	back	to	the	levels	seen	in	control	conditions	without	
FCM	(Figure	6A).	The	increase	in	PLOD2	expression	induced	by	FCM	was	similarly	
abrogated,	with	 a	 return	 to	 the	 levels	 seen	 in	 control	 conditions	without	 FCM,	
when	the	FLS	were	co-incubated	with	FCM	and	AL8810	(Figure	6E).
Figure 5 The	effect	of	1	ng/ml	TGFβ1	and	1	µM	PGF2α	and	their	inhibitors	SB505124	and	AL8810	
in	the	absence	of	FCM	on	A)	collagen	production,	B)	migration,	and		C)	proliferation	and	gene	
expression	of	C)	Col1α1,	D)	Plod2	and	E)	Asma	by	FLSs	relative	to	the	control	without	these	ad-
ditions	(set	at	1).	All	analyses	were	done	in	triplicate	with	three	FLS	donors.	*indicates	p<0.05,	
**indicates	p<0.01.	Bars	or	dots	represent	the	mean	±	standard	deviation.
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The	effects	of	FCM	on	the	migration	and	proliferation	of	synoviocytes	and	on	
the	level	of	ASMA	expression	were	not	counteracted	by	the	addition	of	the	PGF	
receptor	inhibitor	AL8810	(Figures	6B,	C,	and	F).	COL1A1	expression,	which	had	
been	decreased	in	FLS	cultures	with	FCM,	was	decreased	even	more	in	cultures	
with	AL8810	(Figure	6D).	This	is	consistent	with	the	minimal	decrease	in	COL1A1	
expression	that	was	observed	when	only	AL8810	was	added	to	the	FLS	cultures	
(Figure	5D).
DISCUSSION
OA	is	a	disease	of	the	articular	joints	in	which	synovial	fibrosis	is	often	seen3,4,12.	
Accumulating	data	have	been	presented	 to	suggest	 that	OA	 is	an	 inflammatory	
Figure 6 The	effect	of	the	TGFβ/ALK5	(SB505124)	or	PGF2α	signalling	(AL8810)	inhibition	on	the	
effect	of	FCM	in	FLS	cultures	on	A)	collagen	production,	B)	migration	and		C)	proliferation	and	D)	
Col1α1	gene	expression,	E)	Plod2	gene	expression	and	F)	Asma	gene	expression		by	synoviocytes.	
A	total	of	8	different	FCM	batches	was	tested	using	FLS	of	two	different	donors.	The	control	with-
out	FCM	was	set	at	1	and	indicated	with	a	dotted	line	for	the	gene	expression	analyses.	*indicates	
p<0.05,	***indicates	p<0.005.	Bars	or	dots	represent	the	mean	±	standard	deviation	of	8	different	
FCM	batches.
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disease	 in	which	cytokines	and	 immune	cells	play	a	 role30.	Adipose	 tissue	can,	
in	general,	be	considered	to	be	an	endocrine	organ	that	secretes	cytokines	and	
growth	factors	and	that	exhibits	significant	infiltration	of	immune	cells,	including	
macrophages31-33.	In	earlier	studies	conducted	by	our	group	and	other	investiga-
tors,	 it	was	 shown	 that	 the	 IPFP	 is	 able	 to	produce	 cytokines,	 adipokines,	 and	
growth	factors,	and	thereby	contributes	to	their	levels	in	the	synovial	fluid18-20;34.	
In	 the	 current	 study,	 we	 demonstrate	 that	medium	 conditioned	 by	 samples	 of	
IPFP	obtained	 from	 the	 joints	 of	 patients	with	 end-stage	OA	 stimulates	 fibrotic	
processes	in	FLS.
Culturing	 the	FLS	with	FCM	 increased	collagen	production,	 the	expression	of	
PLOD2	encoding	 for	 the	 enzyme	LH2b	 (involved	 in	pyridinoline-based	collagen	
crosslinks),	and	the	migration	and	proliferation	of	FLS,	which	are	hallmarks	of	a	
fibrotic process11;13;35.	These	effects	were	independent	of	the	BMI	of	the	IPFP	donor	
(BMI<30	kg/m2	versus	BMI>30	kg/m2).
TGFβ1,	and	more	recently,	PGF2α14,	have	been	suggested	 to	act	as	pro-fibrotic	
factors	in	the	joints.	We	found	that	both	TGFβ1	and	PGF2α	were	present	in	the	FCM	
batches	used	for	culture	with	the	FLS;	this	finding	is	in	addition	to	the	previously	
described	presence	of	many	other	 cytokines,	 adipokines,	 and	 growth	 factors17.	
When	we	compared	the	levels	of	TGFβ1	and	PGF2α	in	the	FCM	with	our	functional	
parameters,	we	 found	a	positive	association	between	PGF2α	 levels	and	collagen	
deposition,	a	negative	association	between	PGF2α	levels	and	COL1A1	expression,	
and	a	positive	association	between	TGFβ1	levels	and	COL1A1	expression.	These	
associations	 indicate	 that	 PGF2α	was	 responsible	 for	 some	of	 the	 effects	 of	 the	
FCM.	The	 absence	of	 associations	between	PGF2α	 levels	 and	PLOD2	expression	
and	between	TGFβ1	levels	and	ASMA	expression	might	be	explained	by	the	fact	
that	the	FCM	contains,	in	addition	to	PGF2α	and	TGFβ1,	many	other	unknown	fac-
tors	that	could	also	have	influenced	the	fibrotic	processes	in	FLS.
Furthermore,	our	experiments	indicate	that	the	effects	of	FCM	on	FLS	are	com-
parable	to	the	effects	of	adding	PGF2α	to	FLS	cultures	without	FCM,	again	indicat-
ing	that	the	presence	of	PGF2α	contributes	to	the	FCM	effect.	The	profibrotic	effect	
of	FCM	may	be	attributable	not	only	to	the	PGF2α	present	in	the	FCM,	but	also	to	
the	PGF2α	that	is	produced	by	FLS	in	response	to	FCM.	Fibroblasts,	in	general,	are	
known	to	produce	PGF2α36;37.	This	may	explain	the	discrepancy	between	our	find-
ings	of	PGF2α	increasing	PLOD2	expression	and	AL8810	bringing	PLOD2	expression	
back	to	control	 levels	and	our	findings	of	the	absence	of	a	correlation	between	
PGF2α	levels	in	the	FCM	and	PLOD2	expression.	
Messenger	RNA	(mRNA)	and	protein	levels	are,	in	general,	associated	with	each	
other.	This	was	true	for	the	COL1A1	mRNA	and	protein	levels	in	this	study,	when	
we	 cultured	 the	 FLS	with	 TGFβ1.	However,	 collagen	 deposition	 is	 regulated	 on	
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many	levels,	and	its	regulation	through	variation	in	the	amount	of	mRNA	is	only	
the	beginning.	For	example,	after	synthesis	of	the	different	collagen	chains,	post-
translational	modification	through	enzymes	such	as	the	lysyl	and	prolyl	hydroxy-
lases	and	lysyl	oxidases	can	occur,	while	correct	folding	of	the	collagen	molecules	
requires	the	involvement	of	chaperones	such	as	Hsp47.	These	changes	not	only	
are	directly	involved	in	collagen	synthesis	but	also	can	indirectly	regulate	collagen	
content.	The	level	of	collagen	crosslinking,	for	example,	can	have	an	effect	on	the	
sensitivity	of	collagen	to	degradation	by	matrix	metalloproteinases38.	Of	course,	
degradation	of	collagen	can	have	a	major	role	in	determining	to	what	extent	col-
lagen	content	increases	over	time.	In	this	respect,	 it	 is	very	exciting	to	see	that	
despite	a	reduction	in	type	I	collagen	mRNA,	the	presence	of	FCM	or	PGF2α does 
result	 in	 increased	collagen	deposition,	 and	 that	 there	are	differences	between	
stimulation	with	PGF2α	 and	stimulation	with	TGFβ1.	Unfortunately,	we	were	not	
able	to	quantify	deposition	of	specific	types	of	collagen.
To	further	examine	the	involvement	of	TGFβ1	and	PGF2α	present	in	the	FCM	in	
the	different	fibrotic	processes,	we	used	a	TGFβ1	receptor	type	I	kinase	inhibitor,	
SB505124,	 and	a	 selective	PGF2α	 receptor	antagonist,	AL8810,	 together	with	 the	
FCM	incubation.	Blockade	of	PGF2α	with	AL8810	brought	collagen	deposition	and	
PLOD2	expression	back	to	the	levels	in	control	conditions	without	FCM,	whereas	
the	presence	of	the	TGFβ1	inhibitor	SB505124	did	not	alter	the	FCM	effect	on	FLS.	
Since	 the	addition	of	AL8810	decreased	PLOD2	expression,	our	 results	 indicate	
indirectly	 that	 PGF2α	 levels	 are	 associated	 with	 PLOD2	 expression,	 in	 addition	
to	 the	 already-shown	 association	 between	 PGF2α	 and	 collagen	 production.	 The	
latter	is	confirmed	by	the	fact	that	inhibition	of	the	PGF2α	receptor	with	AL8810	
normalized	collagen	deposition	in	FCM-treated	FLS.	Inhibition	of	TGFβ1	signaling	
with	SB505124	in	combination	with	FCM	did	not	normalize	collagen	deposition	or	
PLOD2	expression.	From	these	results,	we	conclude	that	PGF2α	might	be	a	more	
important	factor	than	TGFβ1	in	the	FCM-induced	fibrotic	processes	in	FLS.
No	effect	of	the	inhibitors	was	seen	on	the	FCM-induced	migration	and	prolifera-
tion	of	synoviocytes,	and	co-incubation	of	FCM	with	AL8810	decreased	COL1A1	
expression	even	more	than	that	with	FCM	alone.	Thus,	next	to	PGF2α,	other	factors	
also	influenced	the	parameters	of	fibrosis,	since	not	all	processes	induced	by	FCM	
were	counteracted	by	AL8810.	In	addition,	the	extra	inhibition	of	COL1A1	expres-
sion	that	occurred	when	the	FLS	were	cultured	with	FCM	and	AL8810	could	be	
explained	by	the	fact	that,	in	our	culture	system,	there	is	no	direct	effect	of	PGF2α 
on	COL1A1	expression	and	that	other	factors	are	involved	in	this	relationship.
Like	other	organs,	adipose	tissue	contains	a	resident	population	of	cells	of	the	
innate	 immune	 system,	 in	 particular	 macrophages	 and	 T	 lymphocytes.	 In	 our	
earlier	study,	we	demonstrated	that	macrophages	were	present	in	the	IPFP,	many	
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of	which	have	an	M2	phenotype39.	Alternatively	activated	M2	macrophages	have	
an	anti-inflammatory	or	repair	phenotype	and	produce,	predominantly,	IL-10	but	
also growth
factors	such	as	TGFβ1	and	insulin-like	growth	factor	1,	and	almost	no	IL-12	or	
IL-2340.	The	presence	of	M2	macrophages	 in	 the	 IPFP	of	patients	with	end-stage	
OA	might	contribute	to	the	profibrotic	effect	of	the	FCM	on	FLS	described	in	the	
present	study.	Earlier	studies	also	found	that	macrophages	are	able	to	produce	
PGF2α41;42.	In	addition	to	macrophages,	adipocytes,	T	lymphocytes,	or	other	cells	
from	the	stromal	vascular	fraction	might	also	contribute	to	PGF2α production in 
the	IPFP43.
Prostaglandins,	including	PGD2,	PGE2,	PGF2α,	and	PGI2,	are	produced	when	phos-
pholipids	are	cleaved	in	response	to	stimuli,	resulting	in	the	release	of	arachidonic	
acid,	which	 is	 then	metabolized	by	cyclooxygenase	 to	produce	prostaglandins.	
PGF2α	 is	considered	to	be	a	major	and	stable	metabolite	of	PGE244.	Reduction	in	
PGE2	production	is	the	classic	mode	of	action	of	anti-inflammatory	agents	such	
as	nonsteroidal	anti-inflammatory	drugs	(NSAIDs),	which	are	commonly	used	in	
medical	management	of	OA,	and	numerous	studies	have	demonstrated	a	 lower	
PGE2	concentration	in	synovial	fluid	following	NSAID	treatment45;46.	More	recently,	
PGF2α	was	also	found	in	the	synovial	fluid	of	horses,	the	levels	of	which	increased	
after	stimulation	of	acute	 inflammation	and	which	were	shown	to	be	decreased	
after	 the	treatment	of	 inflamed	knees	with	an	NSAID47.	NSAIDs	might,	 therefore,	
also	be	useful	in	the	prevention	of	the	synovial	fibrosis	seen	in	OA.
To	our	knowledge,	this	is	the	first	study	to	examine	the	effect	of	adipose	tissue	
on	the	synovium	and	to	assess	the	potential	involvement	of	the	IPFP	on	the	devel-
opment	of	the	synovial	fibrosis	often	seen	in	OA3.	The	results	of	this	study	indicate	
that	the	IPFP	in	the	knees	of	patients	with	end-stage	OA	not	only	inhibits	catabolic	
mediators	in	cartilage39	but	also	exerts	pro-fibrotic	effects	on	the	synovium,	and	
these	pro-fibrotic	effects	can	be	partially	explained	by	the	presence	of	PGF2α.	How-
ever,	since	not	all	of	the	fibrotic	effects	can	be	explained	by	the	presence	of	PGF2α,	
other	factors	may	also	play	a	role.	Additional	experiments	are	required	to	examine	
the	effect	of	FCM	on	the	entire	OA	fibrotic	process,	and	to	investigate	whether	the	
effect	that	we	found	is	specific	to	the	IPFP	in	end-stage	OA	or	whether	the	IPFP	
from	an	earlier	stage	of	OA	would	have	the	same	pro-fibrotic	effect.	Future	stud-
ies	should	also	investigate	whether	FLS	from	patients	with	OA	in	an	earlier	stage	
would	respond	in	a	manner	comparable	to	that	of	FLS	from	patients	with	end-stage	
OA.	In	addition,	it	should	be	examined	whether	OA	patients	have	increased	levels	
of	PGF2α	in	their	synovial	fluid	and	whether	this	is	associated	with	severe	changes	
in	their	synovium.	The	continuing	expansion	of	this	knowledge	might	eventually	
contribute	to	more	optimal	treatment	or	even	the	prevention	of	OA.
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Supplementary figure 1	The	effect	of	TGFβ/ALK5	(SB505124)	or	PGF2α	signalling	(AL8810)	inhibi-
tion	on	FLS	cultures	on	A)	collagen	production,	B)	Col1α1	gene	expression,	C)	Plod2	gene	expres-
sion,	and	D)	Asma	gene	expression.	All	analyses	were	done	in	triplicate	on	one	FLS	donor.	Bars	
represent	the	mean	+	standard	deviation.
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ABSTRACT
Cartilage	repair	by	bone	marrow	derived	mesenchymal	stem	cells	(MSCs)	can	be	
influenced	by	inflammation	in	the	knee.	Next	to	synovium,	the	infrapatellar	fat	pad	
(IPFP)	has	been	described	as	a	source	for	inflammatory	factors.	Here,	we	inves-
tigated	whether	factors	secreted	by	the	IPFP	affect	chondrogenesis	of	MSCs	and	
whether	this	is	influenced	by	different	joint	pathologies	or	obesity.	Furthermore,	
we	examined	the	role	of	IPFP	resident	macrophages.	First,	we	made	conditioned	
medium	 from	 IPFP	 obtained	 from	osteoarthritic	 joints,	 IPFP	 from	 traumatically	
injured	joints	during	anterior	cruciate	ligament	reconstruction	and	subcutaneous	
adipose	tissue.	Additionally,	we	made	conditioned	medium	of	macrophages	iso-
lated	from	osteoarthritic	IPFP	and	of	polarised	monocytes	from	peripheral	blood.	
We	evaluated	the	effect	of	different	types	of	conditioned	medium	on	MSC	chon-
drogenesis.	Conditioned	medium	 from	 IPFP	decreased	collagen	2	 and	aggrecan	
gene	expression	and	thionin	and	collagen	type	2	staining.	This	anti-chondrogenic	
effect	was	the	same	for	conditioned	medium	from	IPFP	of	osteoarthritic	and	trau-
matically	 injured	 joints.	 Furthermore,	 IPFP	 from	 obese	 (Body	Mass	 Index	 >30)	
donors	did	not	inhibit	chondrogenesis	more	than	that	of	lean	(Body	Mass	Index	
<25)	donors.	Finally,	conditioned	medium	from	macrophages	isolated	from	IPFP	
decreased	 the	 expression	 of	 hyaline	 cartilage	 genes,	 as	 did	 peripheral	 blood	
monocytes	stimulated	with	pro-inflammatory	cytokines.	 	The	 IPFP	and	the	resi-
dent	pro-inflammatory	macrophages	could	therefore	be	targets	 for	 therapies	to	
improve	MSC-based	cartilage	repair.
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INTRODUCTION
Articular	cartilage	has	 limited	self-healing	capabilities	and	surgical	 intervention	
using	bone	marrow	stimulation	techniques,	such	as	the	microfracture	procedure,	
can	be	used	to	activate	mesenchymal	stem	cells	(MSCs)	from	the	underlying	bone	
marrow	 to	 repair	 the	 defect1;2.	 However,	 instead	 of	 a	 normal	 hyaline	 cartilage	
matrix,	a	fibrocartilaginous	cartilage	matrix	fills	up	the	defect1;3;4.	An	explanation	
why hyaline cartilage production is inhibited could be that the cartilage defect 
is	located	in	a	post-traumatic	inflammatory	environment5.	In	this	post-traumatic	
inflammatory	 environment,	 circulating	 inflammatory	 factors	 stimulate	 matrix	
degradation and inhibit chondrogenic differentiation6.
Besides	surgical	intervention,	research	is	currently	focused	on	MSC-based	tissue-
engineered cartilage repair strategies7.	 	 In	 these	 strategies,	 repair	 tissues	 are	
engineered	 in-vitro	 using	 a	 combination	 of	MSCs,	 scaffolds	 and	 growth	 factors	
and	subsequently	implanted	into	the	cartilage	defect.	When	implanted,	the	MSCs	
in	 these	pre-engineered	constructs	will	be	exposed	 to	 the	 same	post-traumatic	
inflammatory	 environment	 as	 the	 MSCs	 after	 the	 microfracture	 procedure.	 An	
inflammatory	environment	can	inhibit	hyaline	cartilage	matrix	production8.	
Another	factor	that	could	influence	MSC	chondrogenic	differentiation	is	obesity.	
The	clinical	results	after	the	microfracture	procedure	are	reported	to	be	worse	in	
patients with obesity9.	Obesity	is	known	to	cause	systemic	metabolic	and	inflam-
matory	changes,	with	increased	circulating	inflammatory	factors10.	
Inflammatory	factors	can	be	produced	by	different	tissues	of	the	knee	joint,	the	
most	well	described	being	the	synovium	and	cartilage.	The	infrapatellar	fat	pad	
(IPFP)	 is	 an	 adipose	 tissue	 located	 extra-synovially	 and	 intra-capsularly.	 It	 is	
richly	vascularised,	innervated	and	known	to	also	secrete	many	adipokines	and	
cytokines11;12.	Adipose	tissue	in	obese	patients	has	been	shown	to	have	an	inflam-
matory	phenotype	with	abundant	immune	cell	infiltration	and	secretion	of	inflam-
matory	 cytokines13.	 Furthermore,	 joint	 trauma	 and	 joint	 degradation	 can	 both	
increase	inflammation	in	the	IPFP	and	the	secretion	of	inflammatory	factors12;	14-16.	
The	IPFP	contains	immune	cells	such	as	macrophages15;17.	Macrophages	play	an	
important	role	in	inflammation	and	wound	healing.	Macrophages	can	be	catego-
rized	into	pro-inflammatory	macrophages	and	anti-inflammatory	or	wound	healing	
macrophages18;19.	Inflammation	or	obesity	often	result	in	increased	numbers	of	in-
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flammatory	macrophages.	Previously	we	have	shown	that	only	pro-inflammatory	
and	not	anti-inflammatory	macrophages	inhibit	MSC	chondrogenesis	in	vitro20.	
Since	the	IPFP	from	end-stage	OA	patients	is	a	source	of	inflammatory	and	cata-
bolic	cytokines12,	 it	 is	to	be	expected	that	 IPFP	secreted	factors	 influence	other	
joint	tissues.	Against	our	expectation	that	the	factors	released	from	IPFP	would	
stimulate	 tissue	 degradation,	 our	 previous	 studies	 demonstrated	 that	 factors	
released	from	IPFP	from	end-stage	OA	patients	inhibit	catabolic	mediators	in	carti-
lage15	and	stimulate	fibrotic	processes	in	synovial	fibroblasts21.	This	indicates	that	
the	factors	released	by	the	IPFP	not	only	have	a	pro-inflammatory	effect	on	joint	
environment	and	that	this	effect	could	be	different	in	each	type	of	joint	tissue.	
Considering	the	IPFP’s	potential	to	produce	factors	that	influence	the	joint	environ-
ment,	and	the	knowledge	that	the	joint	environment	influences	cartilage	repair,	we	
hypothesized	that	factors	secreted	by	the	IPFP	affect	MSC-based	cartilage	repair.	
In	this	study,	we	investigated	whether	and	how	factors	secreted	by	the	IPFP	affect	
the	chondrogenesis	of	MSCs	in	vitro	and	whether	this	could	be	influenced	by	joint	
pathology	or	obesity.	Furthermore,	we	evaluated	whether	macrophages	present	in	
the	IPFP	could	be	responsible	for	the	effect	seen	on	MSC	chondrogenesis.
METHODS
Preparation of adipose tissue conditioned medium (CM)
IPFP	 tissue	 was	 obtained	 as	 leftover	 material	 from	 patients	 with	 OA	 who	 had	
undergone	a	 total	 knee	 replacement	 (Age	66.1	years	 (53.9-80.2);	BMI	29.3	 (21.5-
43.7)),	or	from	patients	during	anterior	cruciate	ligament	(LR)	reconstruction	(Age	
29.3	 (17.6-48.0);	 BMI	 22.8	 (19.3-29.0)),	with	 time	 from	 trauma	 to	 reconstruction	
5.4	 months	 (2-12	 months).	 Subcutaneous	 adipose	 tissue	 (SAT)	 from	 patients	
undergoing	total	hip	replacement	was	used	(Age	63.0	(50.2-79.1);	BMI	31.3	(24.0-
35.8)).	 Consent	was	 given	 in	 accordance	with	 the	 guidelines	 of	 the	 Federation	
of	 Biomedical	 Scientific	 Societies	 (http://www.federa.org)	 after	 approval	 by	 the	
local	ethical	committee	(MEC	2012-267).	All	culture	media	from	now	onwards	were	
supplemented	with	1.5	μg/mL	fungizone	and	50	μg/mL	gentamicin	(both	Gibco).	
To	generate	adipose	 tissue	CM,	adipose	 tissue	was	cut	 into	small	pieces	of	ap-
proximately	9	mm2,	washed	for	two	times	with	saline	and	cultured	at	a	concentra-
tion	of	100	mg/ml	in	Dulbecco’s	Modified	Eagle	Medium	with	Glutamax	(DMEM-HG;	
Gibco)	supplemented	with	1%	insulin-transferrin-selenium	(ITS+;	BD	Biosciences)	
for	24	hours	at	37ºC.	Afterwards,	the	medium	was	harvested,	centrifuged	at	250G	
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for	8	minutes	and	the	supernatant	was	stored	at	-80	ºC	for	culture	experiments.	
Unconditioned		medium	was	generated	by	incubation	of	DMEM-HG	supplemented	
with	ITS+	for	24	hours	at	37ºC,	centrifuged	at	250G	for	8	minutes	and	stored	at	-80	
ºC.	
Isolation of macrophages from adipose tissue and preparation of IPFP 
macrophage CM
To	isolate	macrophages	from	the	stromal	vascular	fraction	of	adipose	tissue,	six	
OA	IPFP	samples	(Age	66.6	(54.1-80.2),	BMI	28.9	(21.9-33.9))	were	used.	Adipose	
tissue	samples	were	cut	into	pieces	of	around	9mm2	and	incubated	overnight	at	
37ºC	with	1	mg/ml	collagenase	B	(Roche,	Germany)	 in	DMEM-HG	with	10%	FCS.	
After	 centrifugation,	 the	 supernatant	 containing	 the	floating	adipocytes	and	 fat	
was	 removed,	 cell	pellet	was	 re-suspended	and	filtered	 through	a	100	µm	filter	
followed	by	a	40	µm	filter.	The	resulting	cell	suspension	was	layered	on	top	of	15	
ml	Ficoll	(Ficoll-Paque™	PLUS,	GE	Healthcare)	and	separated	by	density	gradient	
following	 centrifugation	 at	 1,000g	 for	 15	minutes.	 The	 interphase	was	 removed	
and	washed	with	phosphate	buffered	saline	(PBS;	Gibco)	containing	2%	FCS	fol-
lowed	by	incubation	with	CD45-PE	(BD	Biosciences)	for	1	hour	and	incubation	in	
20	µl	of	anti-mouse-IgG	magnetic	beads	(Miltenyi	Biotec)	per	10.000.000	cells	for	
30	minutes	 in	the	dark	at	4	 ºC.	CD45	positive	cells	were	separated	by	magnetic	
activated	cell	sorting	(MACS,	MACS	Separation	columns	LS	and	MidiMACS™	Sepa-
rator,	Miltenyi	Biotec)	according	to	manufacturer’s	instructions.	Flowcytometric	
analysis	was	performed	to	confirm	a	>90%	CD45+	population	purity.	CD45	reduced	
fraction	contained	<10%	CD45+	cells.	 Isolated	CD45+	cells	were	seeded	at	a	cell	
density	of	100.000	cells/cm2	in	24	wells	plates	and	cultured	overnight	at	37ºC	in	
DMEM-HG	supplemented	with	10%	FCS.	Cells	were	 then	carefully	washed	 twice	
with	PBS	to	remove	non-attached	cells	and	DMEM-HG		with	1%	ITS+	was	added.	
After	24	hours,	IPFP	CD45+	CM	was	harvested,	centrifuged	at	250g	for	8	minutes	
and	stored	at	-80	ºC	for	further	experiments.	
Human monocyte isolation, differentiation and CM preparation
Peripheral	 blood	 monocytes	 were	 isolated	 from	 buffy	 coats	 with	 CD14+	 mag-
netic	beads		(Miltenyi	Biotec)	and	MACS	according	to	manufacturer’s	instructions.	
Monocytes	were	then	seeded	at	500.000	cells/cm2,	stimulated	to	M(LPS+IFN-ɣ)	with	
100	ng/ml	 lipopolysaccharide	(LPS;	Sigma	Aldrich)	and	10	ng/ml	 IFN-ɣ	 (PeproT-
ech)	or	M(IL-4)	with	10	ng/ml	IL-4	(Preprotech)19.	Subsequently,	M(LPS+IFN-ɣ)	and	
M(IL-4)	CM	were	made	as	previously	described20;22.	Samples	of	these	experiments	
were	previously	used	in	Fahy	et	al20,	but	additional	gene	expression	analysis	were	
performed	for	the	current	study.	
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Human dermal fibroblast expansion and CM preparation
Human	 dermal	 fibroblast	 from	 adult	 donors	 (HDFa)	were	 acquired	 from	Gibco	
(Cat.	no.	C-013-5C)	and	were	seeded	at	5000	cells/cm2	in	DMEM-HG	containing	10%	
FCS.	After	reaching	sub-confluency,	HDFas	were	trypsinized	and	seeded	again.	For	
HDFa	CM	preparation,	P4	cells	were	cultured	until	 subconfluency,	washed	with	
PBS	for	three	times	and	DMEM-HG	with	ITS+	was	added.	After	24	hours,	CM	was	
harvested,	centrifuged	at	250g	for	8	minutes	and	stored	at	-80	ºC	for	further	experi-
ments.
Isolation and culture of human MSCs
MSCs	were	isolated	from	heparinized	bone	marrow	aspirates	of	patients	with	OA	
undergoing	total	hip	replacement	(9	donors;	Age	61	years	(32-78)).	Patients	gave	
informed	 consent	 and	 the	 study	was	 approved	 by	 the	 local	 ethical	 committee	
of	 the	Erasmus	MC,	Rotterdam	(MEC	2004-142)	and	Albert	Schweitzer	Hospital,	
Dordrecht		(MEC	2011-07).	Bone	marrow	aspirates	were	plated	and	washed	after	
24	hours	with	PBS	 containing	 2%	 fetal	 calf	 serum	 (FCS;	 Lonza).	MSCs	were	 ex-
panded	in	Minimum	Essential	Medium-Alpha	(α-MEM;	Gibco)	supplemented	with	
10%	FCS,	1	ng/mL	fibroblast	growth	factor	2	(FGF2;	R&D	Systems)	and	25	μg/mL	
ascorbic	acid-2-phosphate	(Sigma-Aldrich).	After	reaching	sub-confluency,	MSCs	
were	trypsinised	and	seeded	again	at	a	density	of	2500	cells/cm2	.	MSCs	of	passage	
3	or	4	were	used.				
Chondrogenic differentiation of MSCs
MSCs	 were	 encapsulated	 in	 1.2%	 alginate	 (CP	 Kelco)	 in	 saline	 at	 a	 density	 of	
4.000.000	 cells/ml.	 Beads	 were	 formed	 by	 purging	 the	 MSC-alginate	 solution	
through	a	23G		needle	and	allowing	droplets	to	fall	into	102	mM	CaCl2	solution.	
Pellets	were	made	by	centrifugation	of	200.000	cells	in	polypropylene	tubes.	Beads	
and	pellets	were	cultured	with	DMEM-HG	with	 ITS+	containing	25%	 IPFP	CM	or	
unconditioned	 medium.	 As	 chondrogenic	 supplements,	 we	 used	 0.1	 µM	 Dexa-
methasone	(Sigma–Aldrich),	10	ng/ml	TGFβ1	(R&D	systems),	25	μg/mL	ascorbic	
acid-2-phosphate	 (Sigma-Aldrich),	40	µg/ml	L-Proline	 (Sigma-Aldrich)	and	1	mM	
sodium	pyruvate	(Gibco).	MSC	beads	were	cultured	in	100	µL	of	medium	per	bead	
and	pellets	were	cultured	in	500	µL	of	medium	per	pellet.	Medium	was	refreshed	3	
times	a	week.	Beads	and	pellets	were	harvested	after	28	days.
For	the	experiments	with	macrophages,	obese	versus	lean	IPFP,	osteoarthritic	ver-
sus	post-joint	trauma	IPFP	and	SAT	versus	IPFP,	beads	were	first	cultured	in	DMEM-
HG	containing	ITS+	and	chondrogenic	supplements	for	14	days.	From	day	14-17,	
parts	of	the	DMEM-HG	with	ITS+	was	replaced	by	conditioned	medium	or	an	equal	
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percentage	of	unconditioned	medium.	For	the	experiments	with	IPFP	and	SAT	CM,	
we	replaced	25%	of	the	DMEM-HG	containing	ITS+.	For	the	macrophages	experi-
ments,	we	replaced	50%	of	the	DMEM-HG	containing	ITS+	with	CD45	CM	or	20%	
with	M(LPS+IFNɣ)/M(IL-4)	CM.	For	the	CD45	experiments,	the	lowest	cell	number	
used	to	generate	CM	(0.23	µg	DNA)	was	set	at	50%	and	for	the	M(LPS+IFNɣ)/M(IL-4)	
experiments,	the	average	cell	number	used	to	generate	CM	(1.64	µg	DNA)	was	set	
at	20%.	All	subsequent	donors	were	corrected	accordingly	to	assure	that	medium	
conditioned	by	an	equal	number	of	cells	was	added.	Chondrogenic	supplements	
were	always	added	after	mixing	the	medium	with	CM	or	unconditioned	medium.	In	
this	way,	all	conditions	had	the	same	final	concentration	of	all	supplements.	Beads	
were	harvested	at	day	17.	All	media	were	refreshed	24	hours	prior	to	harvest.
Gene expression analysis
MSC	 alginate	 beads	were	 harvested	 in	 ice-cold	 55	mM	 sodium	 citrate	 and	 dis-
solved	after	gentle	agitation	at	4	 ºC.	The	solution	was	 then	centrifuged	at	400g 
for	8	minutes	at	4	ºC	and	cell	pellets	were	re-suspended	in	650	µl	RNA-Bee	(TelT-
est,	 USA)	 per	 bead.	 Chloroform	 (Sigma-Aldrich)	 was	 added	 to	 all	 samples	 at	
200	µL/mL	RNA-Bee.	RNA	was	further	purified	using	RNeasy	Micro	Kit	(Qiagen).	
RNA	 concentration	 and	 quality	 was	measured	 using	 NanoDrop	 ND1000	 UV-Vis	
Spectrophotometer	(Isogen	Life	Science).	RNA	was	reverse-transcribed	to	cDNA	
using	 the	RevertAid	 First	 Strand	cDNA	Synthesis	Kit	 (Fermentas,	Germany)	 ac-
cording	to	manufacturer’s	instructions.	qRT-PCR	was	performed	in	10µL	reactions	
on	 cDNA	using	 the	CFX96	Touch™	Real-Time	PCR	Detection	 System	 (BIO-RAD,	
USA).	 Expression	 of	 glyceraldehyde-3-phosphate	 dehydrogenase	 (GAPDH),	 hy-
poxanthine	phosphoribosyltransferase	1	(HPRT1),	collagen	type	 II	a1	(COL2A1),	
aggrecan	(ACAN),	collagen	type	I	(COL1A1)	and	versican	(VCAN)	were	determined	
with	 qRT-PCR.	 The	 genes	GAPDH and HPRT	 were	 used	 as	 housekeepers.	 Gene	
expression	was	analyzed	according	to	the	ΔΔCt	method,	with	the	condition	treated	
with	unconditioned	medium	used	as	control	and	set	at	1.0.	Expression	levels	of	
other	conditions	are	expressed	relative	to	the	this	control	condition.	The	primer	
efficiency for GAPDH	was	1.06,	for	HPRT	0.96,	for	COL2A1	1.02,	for	ACAN	0.95,	for	
COL1A1	0.97	and	VCAN	0.95.	The	mean	Ct	value	for	GAPDH	was	22.9	and	for	HPRT 
28.8.	Difference	in	Ct	values	between	the	samples	within	each	experiment	was	less	
than	1	Ct	and	there	were	no	significant	differences	between	the	conditions	(data	
not	shown).	Gene	expression	values	after	normalization	to	housekeepers	are	used	
to calculate COL2A1/COL1A and ACAN/VCAN	ratios.
Primer	 sequences	 were	 as	 followed:	 GAPDH,	 forward:	 GTCAACGGATTTGGTC-
GTATTGGG,	 reverse:	 TGCCATGGGTGGAATCATATTGG	 and	 probe	 Fam:	 TGGC-
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GCCCCAACCAGCC.	HPRT	forward:	TATGGACAGGACTGAACGTCTTG,	reverse:	CA-
CACAGAGGGCTACAATGTG	and	probe	Fam:	CGCCCAATACGACCAAATCCGTTGAC.	
COL2A1	 forward:	 GGCAATAGCAGGTTCACGTACA,	 reverse:	 CGATAACAGTCTT-
GCCCCACTT	and	probe	Fam:	CCGGTATGTTTCGTGCAGCCATCCT.	ACAN forward: 
TCGAGGACAGCGAGGCC,	reverse:	TCGAGGGTGTAGCGTGTAGAGA	and	probe	Fam:	
ATGGAACACGATGCCTTTCACCACGA.	 COL1A1	 forward:	 CAGCCGCTTCACCTA-
CAGC,	 reverse:	 TTTTGTATTCAATCACTGTCTTGCC	 and	 probe	 Fam:	 CCGGTGT-
GACTCGTGCAGCCATC.	 VCAN	 forward:	 TGGAATGATGTTCCCTGCAA,	 reverse:	
AAGGTCTTGGCATTTTCTACAACAG,	probe:	CTGGCCGCAAGCAACTGTTCCTTT.
Quantification of DNA and GAG content
Alginate	beads	were	dissolved	in	sodium	citrate	and	digested	with	papain.	(Sigma	
Aldrich).	Pellets	were	digested	with	proteinase	K	(Sigma	Aldrich).	DNA	was	subse-
quently	quantified	by	spectrophotometric	detection	of	ethidium	bromide	(Gibco)	
binding	at	340	and	590	nm.	GAG	content	was	determined	with	dimethylmethylene	
blue	(Polysciences)	spectrophotometrically	at	530nm	and	590	nm23	and	at	a	pH	of	
1.75.
Histological evaluation of MSC chondrogenesis in pellet culture
6	µm	 thick	paraffin	sections	were	made	of	 the	pellets	and	 thionin	staining	was	
performed.	 For	 immunohistochemical	 staining,	 sections	 were	 incubated	 with	
monoclonal	antibody	against	collagen	type	2	(DSHB,	#II-II	6B3)	and	collagen	type	1	
(Abcam,	#6308)	or	IgG1	isotype	control	(Dako	Cytomation,	#X0931).	Sections	were	
then	incubated	with	Link	and	Label	(Biogenex,	HK-321-UK)	and	freshly	prepared	
new-fuchsin	was	used	as	substrate.
Evaluation of macrophage subtypes in adipose tissue
10	µm	cryosections	were	made	of	13	samples	of	OA	IPFP	(Age	65.3	(54.3-74.1),	BMI	
28	(21.5-35.8)),	7	samples	of	LR	IPFP	(Age	29.9	(21.3-48),	BMI	25.6	(19.3-38.5))	and	
9	samples	of	SAT	(Age	63.1	(±50.2-79.1),	BMI	32.3	(25.9-47.2)).	After	fixation	in	ac-
etone,	sections	were	incubated	with	monoclonal	antibodies	against	CD68	(DAKO,	
#EMB11),	CD11c	(Chemicon,	#EP1347Y)	and	CD206	(Abcam,	#64693).	Mouse	IgG	
(Dako)	were	used	as	isotype	controls.	Subsequently,	sections	were	incubated	with	
link	and	label	(BioGenex)	and	freshly	prepared	new-fuchsin	was	used	as	substrate.	
A	cell	was	considered	positive	when	stained	red.	Samples	were	ranked	based	on	
their	relative	number	of	positive	cells	in	three	sections	per	sample	by	two	blinded	
observers	 as	 previously	 described15.	 Ranking	 was	 performed	 for	 each	 marker	
separately	and	for	each	sample,	the	average	rank	of	the	two	observers	(WW	and	
RR)	was	used	in	the	analysis.	
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Statistical analysis 
IBM	SPSS	 statistics	 21	 (IBM	Corporation)	was	used	 for	 statistical	 analysis.	The	
Shapiro-Wilk	 test	was	used	 to	 test	data	 for	normality	and	 the	Levene’s	 test	 for	
homogeneity	of	variance.	No	data	were	normally	distributed.	For	gene	analysis	
and	GAG	measurement,	if	not	otherwise	stated,	the	Kruskal-Wallis	test	was	used	
followed	by	a	post-hoc	Bonferroni	correction.	For	immunohistochemical	ranking,	
the	Mann-Whitney	U	test	was	used.	p<0.05	was	considered	statistically	significant.
RESULTS
IPFP negatively impacts chondrogenic differentiation of MSCs
COL2A1 and ACAN	were	only	detectable	after	TGFβ1	was	added	(Figure	1).	IPFP	
from	OA	donors	statistically	significantly	lowered	the	gene	expression	of	MSCs	for	
COL2A1	 (p<0.001),	ACAN	 (p<0.001)	and	VCAN, without affecting COL1A1	 (Figure	
1A).	 This	 resulted	 in	 a	 lower	COL2A1/COL1A1	 (p<0.001)	 and	ACAN/VCAN ratio 
(p<0.05)	(Figure	1A).	This	effect	was	absent	when	CM	was	heated	to	95°C	for	10	
minutes	before	use,	indicating	that	the	effects	are	caused	by	proteins	produced	
by	 IPFP	(Figure	1B).	GAG	content	of	 the	alginate	beads	were	 increased	by	 IPFP	
(Figure	2A).	To	further	investigate	the	effects	of	IPFP	on	matrix	production,	pellet	
culture	was	used.	 IPFP	decreased	thionin	and	 immunohistochemical	staining	of	
collagen	type	2,	whereas	collagen	type	1	staining	was	not	influenced	(Figure	2C).	
Furthermore,	IPFP	decreased	GAG	content	of	pellets	(Figure	2D-E).	
Effect of obese versus lean IPFP and osteoarthritic versus traumatic 
joint IPFP on MSC chondrogenesis
Obesity	 increases	the	release	of	 inflammatory	 factors	by	adipose	tissue.	There-
fore,	we	hypothesized	that	CM	from	obese	IPFP	donors	(BMI	33.1	(30-35.8))	would	
reduce	MSC	chondrogenesis	more	 than	CM	 from	 lean	 IPFP	 (BMI	 23.1	 (21.5-24))	
donors.	 However,	 chondrogenic	markers	 were	 not	more	 inhibited	 by	 CM	 from	
obese	than	by	CM	from	lean	donors	(Figure	3A).	Next,	we	compared	the	effect	of	
CM	from	LR	IPFP	(BMI	22.9	(22.0-25.0))	with	BMI	matched	OA	IPFP	(BMI	23.1	(21.5-
24.0)).	Chondrogenic	gene	expression	was	not	statistically	significantly	different	
between	MSCs	exposed	to	CM	from	LR	IPFP	and	CM	from	OA	IPFP.	Interestingly		LR	
IPFP	CM	statistically	significantly	increased	COL1A1	compared	to	control	and	OA	
IPFP	CM	(p=0.023)		(Figure	3B).	
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Figure 1 IPFP	inhibits	chondrogenic	differentiation	of	MSCs.
A)	MSC	alginate	beads	were	treated	with	25%	IPFP	CM	for	28	days	of	culture	 in	chondrogenic	medium	with	
TGFβ1.	The	control	condition	was	treated	with	25%	unconditioned	medium	with	chondrogenic	medium	with	
TGFβ1.	Relative	gene	expression	COL2A1,	ACAN,	COL1A1	and	VCAN	normalized	to	the	control	condition	and	
COL2A1/COL1A1	and	ACAN/VCAN	ratio.	CM	were	pooled	from	3-5	different	IPFP	donors	and	used	to	treat	3	MSC	
donors,	with	each	condition	performed	in	triplicate.	B)	MSC	alginate	beads	were	treated	with	25%	CM	from	IPFP	
from	day	14-17	of	chondrogenic	stimulation.	CM	or	unconditioned	medium	were	heated	for	10	minutes	at	95°C	
and	allowed	to	cool	down	to	room	temperature	before	addition	to	MSC	alginate	beads.	Relative	gene	expression	
of	COL2A1	and	ACAN	in	MSCs	after	treatment,	normalized	to	the	control	condition.	One	pool	of	CM	from	3	IPFP	
donors	was	used	to	treat	1	MSC	donor	with	each	condition	performed	in	triplicate.	The	mean	Ct	value	in	the	
control	condition	for	COL2A1	was	23.2,	for	ACAN	27.3,	for	COL1A1	19.7	and	for	VCAN	24.3.	Values	represent	the	
mean	±	SD.
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Chondrogenic differentiation of MSCs is more affected by IPFP than 
by SAT
To	investigate	whether	the	effect	of	adipose	tissue	of	the	joint	(IPFP)	is	different	
from	subcutaneous	adipose	tissue	(SAT),	we	added	CM	made	from	SAT	to	MSCs	
during	chondrogenic	differentiation.	 SAT	statistically	 significantly	 lowered	gene	
expression	 of	 COL2A1 and ACAN	 (p<0.01),	 but	 did	 not	 influence	 the	 COL2A1/
COL1A1 and ACAN/VCAN	ratio	(Figure	4A).	To	investigate	whether	this	is	due	to	a	
difference	in	the	concentration	of	factors	released	by	IPFP	and	SAT,	we	increased	
the	percentage	of	SAT	CM	added	to	culture	up	to	50%.	In	contrast	to	the	effect	of	
IPFP,	the	effect	of	SAT	on	chondrogenesis	was	not	dosage	dependent	(Figure	4B).	
Figure 2 IPFP	inhibits	chondrogenic	differentiation	of	MSCs.
All	conditions	were	chondrogenically	stimulated	with	TGFβ1	during	the	entire	culture	period.	 	MSC	alginate	
beads	and	pellets	were	treated	with	25%	IPFP	CM		whereas	the	control	condition	was	treated	with	25%	uncondi-
tioned	medium	for	28	days.	A)	Total	GAG	content	and	B)	total	DNA	content	of	alginate	beads.	C)	Representative	
images	of	pellets	from	1	MSC	donor	stained	for	glycosaminoglycans	with	thionin	or	collagen	type	2	and	collagen	
type	1	using	immunohistochemistry.	D)	Total	GAG	content	and	E)	total	DNA	content	of	pellets.	Different	pools	
of	CM	from	3	different	IPFP	donors	were	used	for	each	experiment.	For	total	GAG	and	DNA	content	in	beads	
(Panel	A),	3	MSC	donors	were	used	with	each	condition	performed	in	triplicate.	For	the	pellet	culture	experi-
ment	(Panel	C-E),	2	MSC	donor	were	used	with	5	pellets	per	condition.		Values	represent	mean	±	SD.	The	Mann-
Whitney	U	test	was	used	to	determine	statistical	significance.
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Difference between IPFP and SAT in number and phenotype of macrophages
We	hypothesized	that	the	difference	in	effects	of	IPFP	and	SAT	on	expression	of	
chondrogenic	and	fibrous	tissue	genes	could	be	due	to	the	type	of	macrophages	
in	 the	 adipose	 tissue.	We	 therefore	 first	 characterized	 the	macrophages	 in	 the	
different	adipose	tissues.	 IPFP	samples	 from	OA	donors	ranked	higher	on	CD68	
(p=0.007	and	p=0.03)	and	CD206	 (p=0.02	and	p=0.049)	positive	 staining	 than	LR	
IPFP	and	SAT	samples	(Figure	5B	and	D).	We	could	not	detect	differences	between	
obese	and	lean	donors.
Macrophages in IPFP contribute to the effects seen on MSC 
chondrogenesis
To	investigate	whether	macrophages	present	in	the	IPFP	were	responsible	for	the	
effect	seen	on	MSC	chondrogenesis,	we	added	CM	from	macrophages	isolated	from	
IPFP	to	MSCs	during	chondrogenesis.	IPFP	macrophages	statistically	significantly	
lowered the COL2A1 and ACAN	gene	expression	(Figure	6A).	Since	we	applied	a	
very	strict	selection	for	CD45+	cells,	the	remainder	fraction	still	contained	a	small	
number	of	CD45+	cells.	This	CD45	reduced	fraction	appeared	to	be	able	to	inhibit	
COL2A1 and ACAN	 gene	expression	as	well	 (Figure	6B).	To	 investigate	whether	
this	effect	was	specific	for	cells	isolated	from	the	IPFP,	we	added	CM	from	human	
dermal	fibroblasts	(HDFA)	to	MSCs	during	chondrogenesis.	CM	from	HDFAs	did	
not	influence	MSC	chondrogenesis	(Figure	6B).	
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Figure 3 Effect	of	obese	versus	lean	IPFP	and	osteoarthritic	versus	traumatic	joint	IPFP	on	MSC	
chondrogenesis.	
All	conditions	were	chondrogenically	stimulated	with	TGFβ1	during	the	entire	culture	period.	MSC	alginate	beads	
were	treated	with	25%	IPFP	CM	from	day	14-17.	The	control	condition	was	treated	with	25%	unconditioned	me-
dium.		Relative	gene	expression	of	COL2A1,	ACAN,	COL1A1	and	VCAN	in	MSCs	after	treatment	with	CM	from	A)	
obese	(BMI>30)	or	lean	(BMI	<25)	OA	IPFP	donors	and	B)	OA	or	BMI	matched	LR	IPFP	donors.	Gene	expression	
was	normalized	to	the	control	condition	per	MSC	donor.	CM	from	6	obese	OA	IPFP,	6	lean	OA	IPFP	and	6	LR	IPFP	
donors	were	used.	Three	different	pools	of	CM	was	made	with	each	pool	a	selection	of	three	different	IPFP	donors.	
Three	MSC	donors	were	used,	with	each	condition	performed	in	triplicate.	Values	represent	the	mean	±	SD.
Anti-chondrogenic effect of IPFP on MSCs 71
4
Finally	we	investigated	whether	the	negative	effects	of	IPFP	derived	macrophages	
on	MSC	chondrogenesis	could	be	explained	by	the	phenotype	of	the	macrophage.	
Due	to	the	low	number	of	macrophages	we	could	obtain	from	IPFP,	we	used	PBMCs	
that	 were	 stimulate	 to	 pro-	 or	 anti-inflammatory	 phenotype.	 MSCs	 exposed	 to	
CM	of	M(LPS+IFNɣ)	macrophages	had	 lower	hyaline	cartilage	genes	expression	
compared	to	control	and	CM	of	M(IL-4)	macrophages	(Figure	6C)
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Figure 4 MSC	chondrogenesis	is	more	influenced	by	IPFP	than	subcutaneous	adipose	tissue	(SAT).
MSC	alginate	beads	were	treated	with	CM	from	IPFP	or	SAT	from	day	14-17	of	culture.	The	control	condition	was	
treated	with	25%	unconditioned	medium.	All	conditions	were	chondrogenically	stimulated	with	TGFβ1	during	
the	entire	culture	period.	A)	25%	of	CM	was	used	and	CM	were	pooled	from	3	pools	of	different	3	IPFP	or	3	pools	
of	different	3	SAT	donors	and	used	to	treat	3	MSC	donors.	Each	experiment	was	performed	in	triplicate.	Relative	
gene	expression	of	COL2A1,	ACAN,	COL1A1,	VCAN,	COL2A1/COL1A1	ratio	and	ACAN/VCAN	ratio	in	MSCs	after	
treatment.	Gene	expression	was	normalized	to	the	control	condition	per	MSC	donor.	B)	Different	percentages	
of	CM	were	used	and	CM	were	pooled	from	3	IPFP	or	3	SAT	donors	and	used	to	treat	1	MSC	donor,	with	each	
condition	performed	in	triplicate.	Relative	gene	expression	of	COL2A1	and	ACAN	compared	to	housekeepers	
in	MSCs	after	treatment	All	conditions	received	the	same	final	concentration	of	all	chondrogenic	supplements.	
Values	represent	the	mean	±	SD.	ap<0.05	versus	Control	using	the	Mann-Whitney-U	test.	
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Figure 5 Macrophages	with	different	phenotypes	are	present	in	adipose	tissue	samples.
13	samples	of	OA	 IPFP,	7	samples	of	LR	 IPFP	and	9	samples	of	SAT	were	used.	A)	Representative	 images	of	
immunohistochemcal	staining	of	CD68,	CD11c	and	CD206	positive	cells	in	OA	IPFP	samples.	Positive	cells	are	
stained	red	and	indicated	with	arrows.	Ranking	of	positive	staining	in	adipose	tissue	samples	for	B)	CD68,	C)	
CD11c	and	D)	CD206.
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Figure 6 Macrophages	in	IPFP	contribute	to	the	effects	seen	on	MSC	chondrogenesis.
MSC	alginate	beads	were	treated	with	CM	from	day	14-17.	The	control	condition	was	treated	with	25%	uncondi-
tioned	medium.	All	conditions	were	chondrogenically	stimulated	with	TGFβ1	during	the	entire	culture	period.	
A)	Effect	of	50%	CM	from	CD45+	cells	from	IPFP	on	MSC	chondrogenesis;	B)	Effect	50%	CM	from	CD45	reduced	
fraction	from	IPFP	or	CM	from	adult	human	dermal	fibroblasts	(HDFa)	on	MSC	chondrogenesis;	C)	Effect	of	20%	
CM	from	M(LPS+IFNɣ)		or	M(IL-4)	macrophages	on	MSC	chondrogenesis.	Relative	gene	expression	of	COL2A1,	
ACAN,	COL2A1/COL1A1	ratio	and	ACAN/VCAN	ratio	in	MSCs	after	treatment.	Gene	expression	was	normalised	
to	the	control	condition	per	MSC	donor.	CM	were	from	6	IPFP	donors,	1	HDFa	donor	or	3	blood	donors	and	used	
to	treat	1	MSC	donor.	Conditions	with	CM	derived	from	IPFP	were	performed	in	single	well	and	all	other	condi-
tions	were	performed	in	triplicate.	Values	represent	the	mean	±	SD.
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DISCUSSION
IPFP	secretes	cytokines,	growth	factors	and	adipokines	which	could	influence	the	
joint	environment11.	 In	this	study	we	have	shown	that	the	 IPFP	released	factors	
that	 inhibit	chondrogenic	differentiation	of	MSCs	and	the	production	of	hyaline	
cartilage	matrix.	This	anti-chondrogenic	effect	was	the	same	for	patients	with	end	
stage	OA	and	patients	with	joint	trauma.	Furthermore,		the	IPFP	of	obese	patients	
did	not	inhibit	chondrogenesis	more	than	IPFP	of	lean	patients.	Finally,	we	have	
indications	that	macrophages	residing	in	the	IPFP	might	play	an	important	role	in	
this	anti-chondrogenic	effect.
Repair	tissue	formed	after	marrow	stimulation	techniques,	such	as	the	microfrac-
ture	procedure,	is	mainly	fibrocartilage	which	is	of	less	biomechanical	quality	than	
native	hyaline	cartilage24.	 In	the	present	study,	the	decrease	in	COL2A1/COL1A1 
and ACAN/VCAN	ratios	suggests	that	IPFP	not	only	inhibits	chondrogenesis,	but	
also	shifts	the	production	from	hyaline	to	fibro-cartilage.	Fibrocartilage	also	con-
tains	proteoglycans,	but	instead	of	aggrecan	this	is	versican.	This	could	be	an	ex-
planation	why	we	found	no	reduction	in	glycosaminoglycan	production	in	alginate	
beads	after	IPFP	CM	treatment,	despite	a	decrease	in	aggrecan	core-protein	gene	
expression.	However,	this	could	also	be	caused	by	interference	of	the	DMMB	assay	
by	alginate	especially	when	low	amount	of	GAG	is	involved23;25.	Analyses	on	matrix	
with	DMMB	and	 immunohistochemistry	can	be	used	more	 reliably	on	pellets26.	
The	reduced	thionin	staining	and	immunohistochemical	staining	for	collagen	type	
2	in	pellets	treated	with	IPFP	CM	supports	the	gene	expression	results	in	alginate	
beads.	Our	findings	indicate	that	fibrocartilage	production	by	MSCs,	taking	place	
after	microfracture	procedure,	could	be	partly	due	to	factors	secreted	by	the	IPFP.	
The	secretion	of	factors	by	IPFP	could	be	influenced	by	the	disease	state	of	the	
joint.	The	microfracture	procedure	and	MSC	based	treatments	are	recommended	
for	the	treatment	of	post-traumatic,	rather	than	end-stage	OA	cartilage	defects27.	
Higher	levels	of	 inflammatory	cytokines	were	found	in	post-traumatic	than	end-
stage	OA	knees28;29.	Gandhi	et	 al	 16	 reported	 that	post-traumatic	 IPFP	expresses	
more	pro-inflammatory	genes	compared	 to	 end-stage	OA	 IPFP.	We	 found	differ-
ences	in	macrophage	number	and	in	particular	CD206	positive	cells	between	IPFP	
from	OA	and	LR	knees,	albeit	factors	secreted	by	both	OA	and	LR	IPFP	inhibited	
chondrogenesis.		However,	we	cannot	exclude	that	these	effects	are	due	to	differ-
ent	cytokines	or	adipokines.
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Another	factor	that	could	influence	both	IPFP	and	the	results	of	microfracture	is	
obesity9.	In	obese	patients,	macrophages	in	adipose	tissue	are	changed	towards	a	
chronic	inflammatory	phenotype	with	increased	production	of	pro-inflammatory	
cytokines10.	 An	 inflamed	 obese	 IPFP	 would	 possibly	 be	 an	 explanation	 for	 the	
worse	results	of	microfracture	in	obese	patients.	In	contrast	to	this	hypothesis,	we	
did	not	detect	an	increased	anti-chondrogenic	effect	of	IPFP	from	obese	compared	
to	lean	donors.	To	investigate	whether	the	OA	process	could	be	of	more	influence	
to	the	factors	secreted	by	IPFP	than	being	obese,	experiments	with	IPFP	donors	
with	a	low	or	high	BMI	but	without	OA	would	be	required.	It	is	however	difficult	to	
obtain	sufficient	IPFP	from	non-OA	donors.	
Independent	 from	 joint	 pathology	 or	 obesity,	 differences	 have	 been	 reported	
between	IPFP	and	other	adipose	tissue.	IPFP	expresses	more	inflammatory	genes,	
release	more	 inflammatory	 factors	and	contains	more	 immune	cells	 than	SAT17.	
In	our	study,	the	anti-chondrogenic	effect	of	 IPFP	was	stronger	than	that	of	SAT	
and	 even	 after	 increasing	 the	 dosage	 of	 SAT	 CM,	 the	 anti-chondrogenic	 effect	
was	not	increased	to	the	level	of	IPFP.	This	suggests	that	the	IPFP	releases	anti-
chondrogenic	factors	not	produced	by	subcutaneous	adipose	tissues.
IPFP	secretes	pro-inflammatory	factors	and	adipokines,	such	as	TNF-α,	IL1β,	IL6	
and	adipokines,	such	as	leptin,	resistin	and	adiponectin12.	These	factors	could	be	
produced	by	 the	fibroblasts,	 adipocytes	and	 immune	cells	 residing	 in	 the	 IPFP.	
A	 large	proportion	of	 the	 immune	cells	 in	 the	 IPFP	are	macrophages15;17.	 Immu-
nohistochemical	 analysis	 on	 IPFP	 and	 SAT	 indicated	 that	 IPFP	 contained	more	
macrophages	 than	 SAT.	 Previously	 we	 have	 shown	 that	 only	 pro-inflammatory	
macrophages	 inhibit	 chondrogenesis20	 and	 in	 the	 current	 study,	 only	 the	 pro-
inflammatory	 macrophages	 shifts	 MSCs	 to	 produce	 fibrocartilage	 matrix.	 As	 a	
proof	of	principle,	we	showed	that	isolated	macrophages	from	the	IPFP	were	anti-
chondrogenic.	Although	we	could	not	exclude	that	other	cells	in	the	IPFP	could	
also	secrete	anti-chondrogenic	factors,	our	study	does	suggest	that	macrophages	
in	the	IPFP	play	a	vital	role	in	inhibiting	production	of	hyaline	cartilage	and	the	
shift	towards	fibrocartilage	matrix	production.	
Next	to	directly	negatively	affecting	chondrogenesis	of	MSCs,	IPFP	can	influence	
other	 joint	 structures	 and	 thereby	 indirectly	 influence	 chondrogenesis.	 IPFP	
factors	 have	 been	 shown	 to	 stimulate	 fibrotic	 processes21 and production of 
pro-inflammatory	factors	in	synovial	fibroblasts30.	In	this	way,	synovium	can	then	
inhibit chondrogenesis20.	In	contrast	to	the	effect	on	synovium,	the	IPFP	inhibits	
catabolic	mediators	in	cartilage	explants	stimulated	with	or	without	IL1β15.	This	
shows	that	different	tissues	in	the	joint	can	react	differently	to	factors	secreted	
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by	the	IPFP	and	the	interplay	between	all	joint	tissues	will	determine	the	eventual	
effect	 on	 cartilage	 repair.	 The	 use	 of	 co-cultures	 of	 several	 joint	 tissues	would	
be	required	to	elucidate	this	in	future	studies	and	to	show	the	potential	effect	of	
modulation.
In	summary,	we	have	shown	that	the	IPFP	is	a	source	of	factors	that	inhibit	chon-
drogenic	differentiation	of	MSCs	and	shifted	the	production	from	hyaline	to	fibro-
cartilage	matrix.	This	anti-chondrogenic	effect	of	adipose	tissue	was	specific	for	
IPFP	and	not	subcutaneous	adipose	tissue.	Furthermore,	this	anti-chondrogenic	
effect	was	not	more	in	obese	donors	than	lean	donors	and	was	not	different	be-
tween	donors	with	post-joint	trauma	or	end-stage	OA.	Finally,	the	IPFP	and	specifi-
cally	the	macrophages	in	the	tissue	could	therefore	be	targets	for	future	therapies	
to	improve	the	joint	environment	for	MSC	chondrogenesis	and	thereby	improve	
the	outcome	of	microfracture	procedure	and	future	MSC-based	treatments	for	the	
repair	of	cartilage	defects.	
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ABSTRACT
Background
Prolonged	inflammation	inhibits	successful	cartilage	repair.	An	inflamed	infrapa-
tellar	fat	pad	(IPFP),	and	in	particular	the	residing	pro-inflammatory	macrophages,	
secrete	 factors	 that	 inhibit	 chondrogenic	 differentiation	 and	 stimulate	 tissue	
degradation.	We	aimed	 to	 reduce	 inflammation	 in	 the	 IPFP	 thereby	creating	 an	
environment	more	suitable	for	cartilage	repair
Hypothesis
The	anti-chondrogenic	and	catabolic	effect	of	IPFP	can	be	reduced	by	influencing	
macrophage	phenotype	with	anti-inflammatory	medication
Study design
Controlled	laboratory	study
Methods
IPFP	explants	obtained	from	12	donors	during	total	knee	arthroplasty	were	cul-
tured	with	celecoxib,	triamcinolone	acetonide	(TAA),	pravastatin	and	fenofibrate	
for	24	hours.	The	effect	of	the	medications	on	IPFP	gene	expression	and	macro-
phage	surface	markers	was	evaluated.	The	effects	of	conditioned	medium	(CM)	
from	IPFP	explants	treated	with	medications	on	chondrogenesis	of	human	bone	
marrow	mesenchymal	stem	cells	(MSC)	and	catabolic	processes	in	osteoarthritic	
synovial	fibroblasts	were	evaluated.
Results
TAA	 significantly	 decreased	 gene	 expression	 of	 tumor	 necrosis	 factor-alpha	
(TNFA),	interleukin(IL)-1β	(IL1B) and IL6	and	increased	expression	of	IL10, cluster 
of differentiation (CD)206	(CD206) and CD163	in	IPFP	explants,	whereas	celecoxib,	
pravastatin,	and	fenofibrate	had	no	effect	on	IPFP	inflammation.	TAA	also	signifi-
cantly	increased	anti-inflammatory	CD14+/CD163+	and	CD14+/CD206+	cells	in	the	
IPFP.	The	decrease	of	collagen	type	2	(COL2A1)	expression	in	chondrogenic	MSCs	
as	a	result	of	CM	from	IPFP	explants	could	be	reduced	by	treating	IPFP	with	TAA	
during	the	production	of	the	CM.	The	increased	matrix	metalloproteinase	(MMP)1	
and MMP13	expression	in	MSCs	and	osteoarthritic	synovial	fibroblasts	as	result	of	
CM	from	IPFP	explants	could	be	significantly	reduced	by	treating	IPFP	with	TAA.
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Conclusions
TAA	 decreases	 IPFP	 inflammation	 by	 increasing	 the	 anti-inflammatory	 macro-
phages	in	IPFP.	TAA	can	be	used	to	decrease	the	anti-chondrogenic	effect	of	IPFP	
on	MSC	chondrogenesis.	Furthermore,	TAA	decreases	the	catabolic	effect	of	IPFP	
on	MSCs	and	synovial	fibroblasts.	
Clinical relevance
TAA	might	be	used	to	modulate	the	IPFP	and	therefore	improve	the	joint	environ-
ment	for	cartilage	repair	procedures.	
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INTRODUCTION
Joint	injuries	are	common	and	often	result	in	cartilage	defects	and	inflammation	
of	 the	 joint.	 Joint	 inflammation	 in	 turn	may	prevent	 successful	 cartilage	defect	
repair	and	without	successful	repair,	cartilage	defects	can	eventually	lead	to	the	
development	of	osteoarthritis	(OA)1.	To	improve	cartilage	repair	and	prevent	the	
development	of	OA,	restoration	of	the	joint	homeostasis	is	necessary.	
Currently,	non-steroid	anti-inflammatory	drugs	such	as	celecoxib	and	glucocorti-
coids	such	as	triamcinolone	acetonide	(TAA)	are	used	to	reduce	inflammation	and	
reduce	 the	symptoms	of	OA2.	Furthermore,	 statins	and	fibrates	are	also	shown	
to	have	anti-inflammatory	properties	besides	their	metabolic	modulatory	proper-
ties3-5.	 The	 effect	 of	 anti-inflammatory	medication	 on	 the	 synovium	membrane,	
cartilage and bone are often studied6;7.	However,	the	infrapatellar	fat	pad	(IPFP)	
also	seems	to	play	an	important	role	in	joint	homeostasis8.	
The	IPFP	is	an	adipose	tissue	located	extra-synovially,	but	intracapsularly	within	
the	knee	joint.	The	IPFP	secretes	factors	that	inhibit	chondrogenic	differentiation	
of	mesenchymal	stem	cells	(MSCs)9	and	stimulate	fibrotic	and	catabolic	processes	
in	synovial	fibroblasts10;11.	Furthermore,	cytokine	secretion	by	the	IPFP	increases	
in	 response	 to	 inflammation4	 and	 IPFP	aggravates	 further	degeneration	of	 trau-
matized	 cartilage12.The	 IPFP	 contains	 many	 pro-	 and	 anti-inflammatory	 macro-
phages9;13.	 Pro-inflammatory	or	M1	macrophages	 are	 indicated	 to	 contribute	 to	
the	anti-chondrogenic	effect	of	the	IPFP9.	M2	macrophages	on	the	other	hand	can	
have	an	anti-inflammatory	or	tissue	repair	phenotype	and	they	did	not	inhibit9;14 
and	could	even	enhance	MSC	chondrogenesis15.	
To	improve	the	joint	environment	for	cartilage	repair	procedures,	we	hypothesized	
that	medication	can	be	used	to	modulate	the	IPFP	and	its	resident	macrophages.	
In	this	way,	secretion	of	anti-chondrogenic	factors	by	the	IPFP	might	reduce.	Fur-
thermore,	catabolic	and	anti-chondrogenic	processes	in	synovium	might	also	be	
reduced	since	the	IPFP	influences	the	synovium5;10;11.	
In	the	current	study,	we	investigated	the	effect	of	celecoxib,	TAA,	pravastatin	and	
fenofibrate	on	IPFP	inflammation.	We	choose	these	four	medications	due	to	their	
wide-spread	clinical	use.	Due	to	the	presence	of	many	macrophages	in	the	IPFP	
and	 the	 importance	 of	macrophages	 in	 inflammation,	 we	 investigated	whether	
macrophage	phenotype	within	 the	 IPFP	was	modulated	by	 the	medications.	 Fi-
nally,	we	investigated	whether	the	anti-chondrogenic	effect	of	IPFP	on	MSCs	and	
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the	pro-fibrotic	and	pro-catabolic	effect	on	synovial	fibroblasts	could	be	reduced	
by	treating	the	IPFP	with	these	medications.
MATERIALS AND METHODS
Treatment of infrapatellar fat pad and preparation of conditioned 
medium (CM)
IPFP	tissue	was	obtained	as	leftover	material	from	12	patients	with	OA	who	had	
undergone	a	total	knee	arthroplasty.	Consent	was	given	in	accordance	with	the	
guidelines	of	the	Federation	of	Biomedical	Scientific	Societies	(http://www.federa.
org),	with	approval	by	the	local	ethical	committee	(Erasmus	MC	University	Medi-
cal	Center,	The	Netherlands,	MEC	2012-267).	The	inner	part	of	the	IPFP	was	cut	
into	 small	 pieces	 of	 approximately	 9	 mm2,	 washed	 two	 times	 with	 saline	 and	
cultured	at	a	concentration	of	100	mg/ml.	As	a	result,	each	sample	contained	0.5	g	
IPFP	tissue	divided	over	10	explants.	Explants	were	cultured	in	Dulbecco’s	Modi-
fied	Eagle	Medium	with	Glutamax	(DMEM-HG;	Gibco™,	Thermo	Fisher	Scientific,	
Waltham,	Massachusetts,	USA)	supplemented	with	1%	 insulin-transferrin-seleni-
um	(ITS+;	BD	Biosciences,	Franklin	Lakes,	New	Jersey,	USA)	at	37ºC.	All	culture	
media	were	 supplemented	with	 1.5	 μg/mL	 fungizone	 and	 50	 μg/mL	 gentamicin	
(both	 Gibco™).	 Triamcinolone	 acetonide	 (TAA;	 #T6501),	 celecoxib	 (#PZ0008),	
pravastatin	(#P4498)	and	fenofibrate	(#F6020)	were	acquired	from	Sigma-Aldrich	
(St.	Louis,	Missouri,	USA).	 	Dimethyl	sulfoxide	(DMSO;	Sigma-Aldrich)	was	used	
to	 dissolve	 all	 four	 medications.	 Used	 end-concentration	 are	 indicated	 in	 the	
respective	graphs.	Medications	were	 further	diluted	 in	DMEM-HG	and	added	to	
IPFP	explants	direct	 from	the	start	of	culture.	The	used	end	concentrations	 for	
the	medications	were	based	on	literature16	and	our	previous	work17;18.	To	take	into	
account	 any	possible	 effect	 of	DMSO,	we	 added	 extra	DMSO	 to	 the	 conditions	
where	 the	medications	were	more	diluted.	As	 a	 result,	 all	 conditions	had	 0,1%	
DMSO	in	the	culture	medium.	After	24	hours	of	culture,	medium	was	harvested,	
centrifuged	at	250	g	for	8	minutes	and	supernatant	was	stored	in	aliquots	of	1	ml	
at	-80	ºC	for	analysis	and	culture	experiments.	IPFP	explants	were	further	used	for	
fluorescence-activated	cell	sorting	(FACS)	analysis	or	were	snap-frozen	in	liquid	
nitrogen	for	gene	analysis.	Unconditioned	medium	was	generated	by	incubation	
of	DMEM-HG	supplemented	with	ITS+	for	24	hours	at	37ºC,	centrifuged	at	250	g for 
8	minutes	and	stored	at	-80	ºC.	
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Cultured	IPFP	explants	were	digested	for	3	hours	at	37°C	in	Hanks’	Balanced	Salt	
solution	(Gibco™)	with	Ca2+	and	Mg2+,	containing	2	mg/ml	Collagenase	IV	(Gibco™)	
and	0.2	mg/ml	Dispase	II	(Roche,	Penzberg,	Upper	Bavaria,	Germany).	We	used	0.5	
g	of	cultured	IPFP	per	condition.	After	incubation,	the	digest	was	neutralized	by	
adding	 fetal	 calf	 serum	(FCS;	Lonza,	Basel,	 Switzerland)	 to	a	final	 solution	con-
centration	of	5%.	Subsequently,	the	solution	was	filtered	through	a	100	µm	filter	
followed	by	twice	a	40	µm	filter.	Cells	were	then	centrifuged	for	8	minutes	at	250	g,	
re-suspended	in	FACSflow	(#342003	BD	Biosciences)	and	counted.	Approximately	
200.000	cells	were	stained	for	each	condition.	Cells	were	re-suspended	in	40	μL	
of	FACSflow	and	incubated	for	15	minutes	at	room	temperature	in	the	dark	with	a	
mixture	of	the	following	antibodies	against	CD14	(APC-H7,	#561384),	CD206	(FITC,	
#551135),	CD163	(PerCP-Cy™5.5,	#563887),	CD80	(PECy™7,	#561135),	and	CD86	
(PE,	 #560957,	 all	 BD	 Biosciences).	 Cells	 were	 fixed	 in	 1.8%	 paraformaldehyde	
for	20	minutes	in	the	dark.	Subsequently,	paraformaldehyde	was	removed,	cells	
were	suspended	in	FACSflow,	and	analyzed	with	FACSJazz™	(BD	Biosciences)	and	
FlowJo	V.10	(FlowJo	LLC,	Ashland,	Oregon)
Isolation and culture of human MSCs
Human	MSCs	were	isolated	from	bone	marrow	aspirates	from	3	end-stage	hip	OA	
patients	undergoing	total	hip	arthroplasty.	Written	informed	consent	was	attained	
and	the	study	was	approved	by	the	local	ethical	committee	(Erasmus	MC	Univer-
sity	Medical	Center,	The	Netherlands,	MEC	2004-142)	and	Albert	Schweitzer	Hos-
pital,	The	Netherlands	(MEC	2011-07).	Aspirates	were	plated	in	expansion	medium	
consisting	of	Minimum	Essential	Medium-Alpha	(α-MEM;	Gibco™)	supplemented	
with	10%	FCS,	1	ng/ml	fibroblast	growth	factor	2	(FGF2;	R&D	Systems)	and	25	μg/
mL	ascorbic	acid-2-phosphate	(Sigma-Aldrich).	After	24	hours,	plates	were	washed	
with	 PBS	 containing	 2%	 FCS.	MSCs	were	 then	 expanded	 in	 expansion	medium,	
trypsinised	after	reaching	sub-confluency	and	seeded	again	at	a	density	of	2500	
cells/cm2.	MSCs	of	passage	4	were	encapsulated	 in	1.2%	alginate	 (CP	Kelco,	At-
lanta,	Georgia,	USA)	in	saline	at	a	density	of	4.000.000	cells/ml.	Beads	were	formed	
by	purging	the	MSC-alginate	solution	through	a	23G	needle	allowing	droplets	to	
fall	into	102	mM	CaCl2	solution.	Beads	were	first	cultured	for	14	days	with	100	µL	
of	DMEM-HG	with	ITS+	per	alginate	bead	supplemented	with	0.1	µM	Dexametha-
sone	 (Sigma-Aldrich),	 25	 μg/mL	 ascorbic	 acid-2-phosphate	 (Sigma-Aldrich),	 40	
µg/ml	 L-Proline	 (Sigma-Aldrich),	 and	 1	mM	 sodium	 pyruvate	 (Gibco™).	 10	 ng/
ml	of	TGFβ1	(R&D	systems;	Minneapolis,	Minnessota,	USA)	was	used	to	 induce	
chondrogenesis.	Medium	was	refreshed	3	times	a	week.	After	14	days,	beads	were	
cultured	with	25%	 IPFP	CM	or	unconditioned	medium.	Supplements	and	TGFβ1	
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were	always	added	after	mixing	the	medium	with	CM	or	unconditioned	medium.	
This	way,	all	the	conditions	had	the	same	final	amount	of	supplements	and	TGFβ1.	
Beads	were	harvested	after	3	additional	days	of	culture	and	medium	was	refreshed	
24	hours	prior	to	harvest.
Isolation and culture of human fibroblast like synoviocytes
Human	 synovium	was	 obtained	 as	 leftover	material	 from	 3	 end-stage	 knee	OA	
patients	who	had	undergone	a	 total	knee	arthroplasty	 (Erasmus	MC	University	
Medical	Center,	The	Netherlands,	MEC	2008-181).	The	synovium	was	separated	
from	the	underlying	fat,	cut	into	small	pieces	and	digested	overnight	with	1	mg/ml	
collagenase	B	(Roche,	Germany)	in	Iscove’s	modified	Dulbecco’s	medium	(IMDM;	
Gibco™)	containing	10%	FCS.	The	cell	suspension	was	then	filtered	through	a	100	
µm	filter,	followed	by	centrifugation	at	250	g	for	8	minutes.	The	resulting	cell	pellet	
was	re-suspended	and	cells	were	plated	at	3500	cells/cm2	in	IMDM	with	10%	FCS.	
After	 reaching	 sub-confluency,	 cells	were	 trypsinised	 and	 re-seeded.	 Fibroblast	
like	 synoviocytes	 (FLS)	 of	 passage	 3	were	plated	 as	monolayer	 at	 50.000	 cells/
cm2	 in	 IMDM	 with	 10%	 FCS	 and	 allowed	 to	 attach.	 After	 72	 hours,	 cells	 were	
washed	3	times	with	saline	and	DMEM-HG	containing	ITS+	with	25%	IPFP	CM	or	
unconditioned	 medium	 were	 added.	 25	 μg/mL	 ascorbic	 acid-2-phosphate	 was	
also	added	to	the	culture	medium.	After	4	days	of	culture,	medium	was	removed	
and	cells	were	harvest	 in	RLT	buffer	 (Qiagen,	Venlo,	The	Netherlands)	with	1%	
β-mercaptoethanol.	Medium	was	refreshed	24	hours	prior	to	harvest.	
RNA extraction and gene expression analysis
Frozen	IPFP	explants	were	homogenized	with	a	Mikro-Dismembrator	(Braun	Bio-
tech	International	GmbH,	Melsungen,	Germany)	re-suspended	in	1.8	ml	RNA-Bee	
(TelTest,	Friendswood,	Texas,	USA).	MSC	alginate	beads	were	dissolved	in	ice-cold	
55	mM	sodium	citrate	at	4	 ºC.	The	solution	was	then	centrifuged	at	400	g	 for	8	
minutes	at	4	ºC	and	cell	pellets	were	re-suspended	in	600	µl	RNA-Bee	per	bead.	
Chloroform	(Sigma-Aldrich)	was	added	to	all	samples	at	200	µL/mL	RNA-Bee.	FLS	
were	harvested	in	RLT	buffer.
RNA	from	IPFP	explants,	MSCs	and	FLS	was	further	purified	using	RNeasy	Micro	
Kit	 (Qiagen)	 according	 to	 manufacturer’s	 instructions.	 RNA	 concentration	 and	
quality	was	measured	using	NanoDrop	ND1000	UV-Vis	Spectrophotometer	(Isogen	
Life	Science,	Veldzicht,	The	Netherlands).	RNA	was	reverse-transcribed	to	cDNA	
using	the	RevertAid	First	Strand	cDNA	Synthesis	Kit	(Thermo	Fisher)	according	to	
manufacturer’s	instructions.	qRT-PCR	was	performed	in	10µL	reactions	on	cDNA	
using	the	CFX96	Touch™	Real-Time	PCR	Detection	System	(Biorad,	Hercules,	Cali-
fornia,	USA).	Expression	of	glyceraldehyde-3-phosphate	dehydrogenase	(GAPDH),	
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tumor	 necrosis	 factor	 alpha	 (TNFA),	 interleukin-1β	 (IL1B),	 IL6,	 cluster	 of	 differ-
entiation (CD)206, CD163	 matrix	 metalloproteinase	 (MMP)-1,	 MMP-13,	 collagen	
type	II	(COL2A1),	aggrecan	(ACAN),	collagen	type	I	(COL1A1),	procollagen-lysine	
2-oxoglutarate	5-dioxygenase	2	(PLOD2),	and	α-smooth	muscle	actin	(ASMA)	were	
determined	with	qRT-PCR.	Gene	expression	was	calculated	according	to	the	ΔΔCt	
method	 and	GAPDH	was	 used	 as	 housekeeper.	 Ct	 values	 between	 the	 samples	
within	each	experiment	differ	less	than	1	Ct	and	there	were	no	significant	differ-
ences	between	the	conditions.	0.1%	DMSO	and	treatment	with	medication	did	not	
interfere	with	GAPDH	level.	Unless	otherwise	stated,	the	condition	treated	with	
unconditioned	medium	and	DMSO	was	used	as	control	and	set	at	1.0.	Expression	
levels	of	other	conditions	are	expressed	relative	to	the	control	condition.	Primer	
sequences	can	be	found	in	the	supplementary	methods,	
Statistical analysis 
IBM	SPSS	statistics	21	(IBM	Corporation,	Armonk,	New	York,	USA)	was	used	for	
statistical	analysis.	All	data	was	not	normally	distributed	according	to	the	Shapiro-
Wilk	test	and	Levene’s	test	for	homogeneity	of	variance.	
If	not	otherwise	stated,	statistical	significance	between	conditions	was	deter-
mined	using	the	Mann-Whitney	U	test.	p<0.05	was	considered	statistically	signifi-
cant.
RESULTS
Triamcinolone acetonide reduces IPFP inflammation
Of	 the	 four	 medications	 tested,	 only	 100	 µM	 TAA	 significantly	 reduced	 TNFA 
(p<0.001), IL1B	 (p<0.001)	 and	 IL6	 (p<0.001)	 and	 increased	 the	 expression	 of	
genes	encoding	for	proteins	related	to	anti-inflammatory	processes,	namely	IL10 
(p<0.05),	CD206	(p<0.001)	and	CD163	(p<0.001)	in	IPFP	explants	(Figure	1).	DMSO	
as	diluent	of	 the	medications	did	not	 significantly	 influence	gene	expression	 in	
IPFP	explants	(Supplementary	figure	1).
Triamcinolone acetonide reduces IPFP inflammation, even at lower 
concentrations
Because	TAA	was	the	only	medication	that	significantly	decreased	the	expression	
of	 genes	 encoding	 for	 pro-inflammatory	 proteins	 and	 increased	 the	 expression	
of	 genes	 associated	with	 anti-inflammatory	 processes,	we	 decided	 to	 focus	 on	
the	effects	of	this	medication.	To	reduce	possible	negative	effects	of	100	µM	TAA,	
we	investigated	whether	a	lower	concentration	of	TAA	would	give	the	same	anti-
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inflammatory	results.	At	a	concentration	of	0.1	µM,	TAA	still	significantly	reduced	
TNFA	(p<0.05)	and	IL1B	(p<0.05)	and	increased	CD206	(p<0.05)	and	CD163	(p<0.05)	
(Figure	2).	10	and	1	µM	of	TAA	also	significantly	increased	IL10	(p<0.05).	IL6	expres-
sion	was	only	significantly	reduced	with	10	µM	of	TAA	or	higher.	TNFA and IL1B 
expression	were	not	significantly	different	between	the	four	concentration	tested.	
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Figure 1 Triamcinolone	acetonide	reduces	IPFP	inflammation
IPFP	explants	were	treated	for	24	hours	with	DMSO,	celecoxib,	triamcinolone	acetonide,	pravastatin	or	fenofi-
brate.		Gene	expression	of	TNFA, IL1B, IL6, IL10, CD206, and CD163	in	IPFP	explants	after	treatment,	compared	
to	the	DMSO	0.1%	treated	condition.	The	gene	expression	of	DMSO	0.1%	treated	sample	was	set	at	1.	IPFP	from	
3	donors	were	cultured	with	2	samples	per	donor	(n=6).	Values	are	mean	±	SD.	*p<0.05	versus	DMSO	treated	
condition.
Triamcinolone acetonide modulates macrophage phenotype in IPFP
Next	we	investigated	whether	TAA	modulates	the	phenotype	of	the	macrophages	
in	 the	 IPFP,	since	macrophages	are	known	to	be	 important	 in	 inflammation.	We	
investigated	the	effect	of	10	and	1	µM	on	macrophages	because	these	two	con-
centrations	already	decreased	pro-inflammatory	and	increased	anti-inflammatory	
genes	expression.	10	µM	of	TAA	significantly	increased	the	percentage	of	CD14+/
CD206+	and	CD14+/CD163+	cells	in	the	IPFP,	indicating	macrophages	with	an	M2-
like	phenotype	(Figure	3).	However,	TAA	did	not	alter	the	percentage	of	CD14+/
CD80+	and	CD14+/CD86+	cells	in	the	IPFP	(Figure	3),	indicating	that	the	percentage	
of	macrophages	with	an	M1-like	phenotype	did	not	change.	
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Figure 2 Triamcinolone	acetonide	reduced	IPFP	inflammation	in	dose	range	of	0.1-100	µM
IPFP	explants	were	treated	for	24	hours	with	triamcinolone	acetonide	in	the	concentrations	0.1µM-100µM.		Gene	
expression	of	TNFA, IL1B, IL6, IL10, CD206, and CD163	in	IPFP	explants	after	treatment,	compared	to	the	condi-
tion	treated	with	0.1%	DMSO	only.	Gene	expression	in	0.1%	DMSO	only	was	set	at	1.	IPFP	from	2	donors	were	
cultured	with	3	samples	per	donor	(n=6).	Values	are	mean	±	SD.	*p<0.05	versus	0.1%	DMSO	treated	samples
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Figure 3 Triamcinolone	acetonide	modulates	macrophages	in	IPFP.
IPFP	explants	were	treated	for	24	hours	with	triamcinolone	acetonide	in	the	concentrations	10	µM	and	1	µM.	In	these	
explants,	percentage	of	CD80,	CD86,	CD206	and	CD163	positive	cells	within	the	CD14	positive	population	(indicating	
macrophages)	was	determined	using	flow	cytometry.	Relative	percentage	of	positive	cells	after	treatment,	compared	
to	the	condition	treated	with	0.1%	DMSO	only.	Condition	treated	with	0.1%	DMSO	only	was	set	at	1.	Values	are	from	5	
IPFP	donors	with	1-3	samples	per	donor	(n=12).	Values	are	mean	±	SD.	*p<0.05	versus	0.1%	DMSO.
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Triamcinolone acetonide reduces anti-chondrogenic and pro-catabolic 
effects of IPFP
Finally,	we	 investigated	whether	TAA	can	 reduce	 the	negative	effect	of	 IPFP	on	
chondrogenesis	of	MSCs	and	the	fibrotic	and	catabolic	processes	in	fibroblast	like	
synoviocytes	 (FLS).	 Factors	 secreted	by	 untreated	 IPFP	 significantly	 decreased	
COL2A1		(p<0.05)	in	chondrogenically	stimulated	MSCs	(Figure	4A).	Treatment	of	
the	IPFP	with	1	µM	and	10	µM	TAA	while	making	the	CM	significantly	reduced	this	ef-
fect,	although	not	entirely.	Factors	produced	by	IPFP	significantly	increased	MMP1 
and MMP13		in	MSCs	(p<0.05)(Figure	4A)	and	FLS	(p<0.05)(Figure	4B).	Treatment	
of	the	IPFP	with	TAA	during	making	of	the	CM	significantly	reduced	the	expres-
sion	of	these	genes	in	MSCs	and	FLS.	Since	TAA	was	also	present	in	the	medium	
conditioned	by	IPFP,	we	also	added	TAA	directly	to	the	chondrogenic	stimulated	
MSC	alginate	beads	and	the	FLS.	COL2A1 and ACAN were significantly reduced in 
MSCs	by	TAA.	COL1A1,	ASMA,	MMP1, and MMP13 were significantly reduced and 
PLOD2	significantly	increased	in	FLS	by	TAA	treatment	(Supplementary	figure	2).	
This	suggests	 that	TAA	mainly	acts	by	reducing	 the	anti-chondrogenic	effect	of	
other	cells	on	MSCs	and	not	through	stimulation	of	chondrogenesis	in	MSCs.
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Figure 4 Triamcinolone	 acetonide	 reduces	 the	 anti-chondrogenic	 and	 pro-catabolic	 effects	 of	
IPFP.	
FLS	and	chondrogenic	stimulated	MSC	alginate	beads	were	treated	with	CM	from	IPFP	treated	without	or	with	
TAA	in	the	concentrations	10	µM	and	1	µM.	A)	COL2A1, ACAN, MMP1, and MMP13	expression	in	chondrogenic	
stimulated	MSC	alginate	beads	relative	to	the	condition	treated	with	TGFβ1	only.	B)	COL1A1, PLOD2, ASMA, 
MMP1, and MMP13	expression	in	FLS	relative	to	the	condition	with	only	FLS	in	culture.	Gene	expression	in	TGFβ1	
only	and	FLS	only	conditions	were	set	at	1.	3	different	pools	of	CM	of	each	from	3
IPFP	donors	were	used	to	treat	3	MSC	donors	and	3	FLS	donors,	with	each	condition	performed	in	triplicate	
(n=9).	Values	represent	mean	±	SD.	*p<0.05	versus	non-treated	controls	(TGFb1	only	or	FLS	only).	#p<0.05	versus	
treated	with	CM	only.	
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DISCUSSION
In	this	study,	we	investigated	whether	anti-inflammatory	medications	can	reduce	
IPFP	 inflammation	and	 thereby	prevent	 the	negative	effect	of	 IPFP	on	chondro-
genic	 MSCs9	 and	 synovial	 fibroblasts10;11.	 We	 have	 tested	 four	 commonly	 used	
medications	 and	 found	 that	 TAA,	 a	 glucocorticoid,	 reduced	 IPFP	 inflammation	
and	modulated	IPFP	macrophage	phenotype.	Furthermore,	TAA	reduced	the	anti-
chondrogenic	effect	of	IPFP	on	MSCs	and	the	pro-catabolic	effect	on	FLS.	
Inflammation	plays	a	major	inhibitory	role	in	joint	repair1	and	macrophages	play	
an	important	role	in	inflammation19.	Next	to	the	synovium,	which		is	often	studied	
in	relation	to	joint	inflammation,	the	IPFP	can	become	inflamed.	The	IPFP	contains	
a	 large	number	of	macrophages,	and	was	proposed	 to	stimulate	synovial	fibro-
sis10 and inhibit of chondrogenesis during cartilage repair9.		In	the	current	study	
study,	TAA	not	only	decreased	expression	of	genes	encoding	for	pro-inflammatory	
proteins	 in	 IPFP	but	 also	 increased	 the	 percentage	 of	macrophages	 expressing	
CD163	and	CD206	protein	on	their	surface	in	the	IPFP.	Anti-inflammatory	or	M2-like	
macrophages	express	CD163	and	CD206.	Furthermore,	they	express	factors	that	
reduce	 inflammation	or	 stimulate	 tissue	 repair,	 such	 as	 IL10	or	CCL1818;	 20.	 The	
increase	of	M2-like	macrophages	in	IPFP	could	either	directly	or	indirectly	affect	
the	M1-like	macrophages.	As	a	result,	the	change	in	favour	of	M2-like	macrophages	
might	have	contributed	to	the	altered	gene	expression	of	inflammatory	cytokines.	
In	this	way,	the	anti-chondrogenic	effect	of	IPFP	on	MSC	and	pro-catabolic	effect	
on	FLS	can	be	reduced.	
The	used	medication	was	choosen	for	their	anti-inflammatory	effects.		However,	
celecoxib,	pravastatin	and	fenofibrate	did	not	influence	IPFP	inflammation	focus-
ing	 on	 genes	 known	 to	 be	 expressed	by	different	macrophage	phenotypes.	We	
therefore	decided	not	to	continue	with	celecoxib,	pravastatin,	and	fenofibrate	in	
the	 current	 study,	 as	 inflammation	 driven	 by	 the	macrophages	 seem	 to	 play	 a	
large	 role	 in	 the	 negative	 effect	 of	 IPFP	 on	 joint	 tissues9;	 10.	We	 cannot	 exclude	
however	 that	 celecoxib,	 pravastatin	 and	 fenofibrate	 might	 have	 an	 effect	 on	
anti-chondrogenic	 and	 catabolic	 properties	 of	 IPFP	 through	 inhibition	 of	 other	
pathways	less	related	to	inflammation	and	via	other	cells	than	the	macrophages.
TAA	is	currently	injected	intra-articularly	as	treatment	of	pain	and	inflammation	
in	early-OA.	Although	symptomatic	relief	does	occur,	no	structural	modifying	ef-
fect on cartilage is seen6.		TAA	does	reduce	catabolic	processes	in	OA	synovium	
explants	co-cultured	with	cartilage	explants17	and	in-vivo	rat	studies	have	shown	
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that	intra-articular	injection	of	TAA	can	reduce	post-traumatic	arthrofibrosis21;22.	
TAA	injected	intra-articularly	directly	after	joint	trauma	could	also	reduce	syno-
vitis23.	 Furthermore,	 unlike	 other	 glucocorticoids,	 it	 is	 not	 toxic	 to	 cartilage	or	
synovium24-26.	 There	 are	 cases	 of	 adipose	 tissue	 atrophy	 described	 after	 TAA	
injection27.		A	systematic	review	by	Brinks	et	al	showed	that	these	adverse	events	
are	rare	and	if	present,	are	relatively	mild28.	Repeated	injections	of	TAA	however,	
increased	collagen	type	2	and	aggrecan	release	and	turnover	in	knee	cartilage	of	
horses29.	To	reduce	the	negative	effects	of	TAA	on	cartilage,	a	dosage	as	low	as	pos-
sible	is	preferred.	In	our	current	study,	expression	of	GAPDH was not influenced 
by	treatment	with	any	of	the	concentrations,	suggesting	that	the	concentrations	
of	TAA	we	used	had	no	gross	overall	effect	on	cell	metabolism.	Furthermore,	TAA	
influenced	IPFP	inflammation	at	a	concentration	of	0.1	µM,	and	reduced	the	anti-
chondrogenic	and	pro-catabolic	effects	of	IPFP	at	1	µM.	This	suggests	that	a	lower	
dose	of	TA	is	sufficient	to	modulate	the	IPFP.
In	rabbits,	a	single	intra-articular	injection	of	the	glucocorticoid	dexamethasone	
reduces	IPFP	cellularity	and	fibrosis	48	hours	after	joint	trauma.	However	it	did	not	
reduce IL1B	expression	nor	were	effects	on	IPFP	cellularity	and	fibrosis	still	present	
after	9	weeks30.		Therefore,	a	higher	dosage	and/or	multiple	intra-articular	injec-
tions	of	medication	might	be	needed	before	a	prolonged	effective	level	is	reached	
in	the	IPFP.	Multiple	injections	that	result	in	a	higher	concentration	of	TAA,	might	
however,	be	negative	for	cartilage	and	MSCs31.	To	reduce	the	number	of	injections	
and	the	side-effects	of	a	high	dosage,	a	slow-release	drug	delivery	system	directly	
in	 the	 IPFP	could	be	a	solution.	 	Besides	a	sustained	delivery	system,	 the	 time	
of	delivery	is	also	crucial.	Directly	after	joint	trauma,	levels	of	pro-inflammatory	
factors	in	the	synovial	fluid	peak32;33.	The	level	of	these	pro-inflammatory	factors	
drops	over	time,	but	are	still	higher	in	injured	knees	than	in	uninjured	knees	up	to	
1	year	after	injury34.	The	timing	of	addition	of	TAA	is	therefore	important	as	well	
as	the	required	dosage,	which	could	change	over	time	depending	on	the	expected	
level	of	inflammation.	
Taken	 together,	 TAA	 reduces	 IPFP	 inflammation	 and	 the	 anti-chondrogenic	 and	
pro-catabolic	effect	of	the	IPFP	on	the	joint.	This	is	possibly	caused	by	modulation	
of	macrophages	in	the	IPFP.	Therefore	TAA	is	a	promising	medication	to	modulate	
the	joint	environment,	thereby	creating	a	better	environment	for	successful	car-
tilage	repair.	
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Supplementary figure 1	DMSO	does	not	significantly	affect	gene	expression	in	IPFP	explants.	
IPFP	explants	were	treated	for	24	hours	with	DMSO.		Gene	expression	of	TNFA, IL1B, IL6, IL10, CD206 and CD163 
compared	to	control.	Gene	expression	of	control	was	set	at	1.	Results	are	from	3	donors	with	2	samples	per	
donor	(n=6).	Values	are	mean	±	SD.	*p<0.05	versus	control.
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Supplementary figure 2	Triamcinolone	acetonide	has	an	effect	on	MSC	and	FLS.	
FLS	and	chondrogenic	stimulated	MSC	alginate	beads	were	treated	with	TAA	in	the	concentrations	10	µM	and	
1	µM.	A)	COL2A1, ACAN, MMP1, and MMP13	expression	in	chondrogenic	stimulated	MSC	alginate	beads	relative	
to	the	condition	treated	with	TGFβ1	only.	B)	COL1A1, PLOD2, ASMA, MMP1, and MMP13	in	FLS	relative	to	the	
condition	with	only	FLS	in	culture.	Gene	expression	in	TGFβ1	only	and	FLS	only	conditions	were	set	at	1.	TAA	
was	used	to	treat	3	MSC	donors	and	3	FLS	donors,	with	each	condition	performed	in	triplicate	(n=9).	Values	
represent	mean	±	SD.	*p<0.05	versus	non-treated	controls	(TGFb1	only	or	FLS	only).	
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ABSTRACT
Objective
Since	statins	and	fibrates	are	capable	of	 improving	 the	metabolic	profile	of	pa-
tients	as	well	as	decreasing	inflammation,	they	are	considered	as	potential	drugs	
for	preventing	OA.	The	goal	of	the	present	study	was	to	investigate	the	effect	of	
these	drugs	in	the	STR/Ort	spontaneous	OA	mouse	model.	
Design
Male	STR/Ort	mice	received	control	diet	or	control	diet	containing	two	different	
dosages	 of	 simvastatin	 or	 fenofibrate	 or	 a	 combination	 of	 both.	Mice	were	 eu-
thanized	after	16	weeks	of	treatment	at	the	age	of	24	weeks.	Serum	analysis	for	
metabolic	and	inflammatory	markers,	histologic	OA	grading	and	μCT	analysis	of	
subchondral	bone	plate	were	performed.	
Results
Simvastatin	treatment	did	not	have	a	statistically	significant	effect	on	any	of	the	
measured	parameters.	Fenofibrate	treated	mice	gained	less	body	weight	and	had	
lower	serum	amyloid	A	(SAA)	levels,	but	higher	IL1α	and	MIP1α	than	other	mice.	
Mice	treated	with	200	mg/kg	BW/day	fenofibrate	had	less	subchondral	bone	plate	
volume	 than	control,	but	no	 statistically	 significant	 reduction	 in	cartilage	dam-
age.	In	the	combination	treatment	group,	body	weight	and	SAA	were	lower	than	
control.	
Overall,	bodyweight,	synovium	membrane	cell	layers	and	SAA	levels	correlated	
to subchondral bone plate changes and subchondral bone plate changes corre-
lated	to	cartilage	damage.
Conclusions
Statins	and	fibrates	did	not	affect	development	of	cartilage	damage	in	the	STR/Ort	
spontaneous	osteoarthritis	mouse	model.	Fenofibrates	however,	had	an	effect	on	
body	weight,	serum	inflammation	markers	and	subchondral	bone	plate	morphol-
ogy.	
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INTRODUCTION
The	current	non	surgical	treatment	options	for	osteoarthritis	(OA)	are	limited	to	
non	pharmacological	interventions	such	as	life	style	changes,	exercise	or	weight	
reduction,	with	pharmacological	 treatment	of	symptoms	if	needed.	No	effective	
disease	modifying	drug	is	currently	on	the	market	for	OA1.	OA	is	a	common	joint	
disease	that	affects	the	entire	joint,	including	the	articular	cartilage,	subchondral	
bone	and	the	synovial	membrane.	High	age	and	obesity	are	both	major	risk	factors	
of	OA.	Prevalence	and	incidence	figures	are	expected	to	rise	with	increasing	life	
expectancy	and	growing	obesity2;	3.	
The	metabolic	 syndrome	 is	 a	 concurrence	of	obesity,	hyperinsulinemia,	dyslip-
idemia	 and	 hypertension4.	Metabolic	 OA	 is	 considered	 one	 of	 the	 subtypes	 of	
OA	and	is	associated	with	the	metabolic	syndrome.	Besides	hyperglycaemia	and	
increased	serum	lipids,	also	the	vascular	pathology	associated	with	the	metabolic	
syndrome	might	have	negative	effects	on	the	cartilage5.	
Statins	 are	 hydroxylmethylglutaryl	 coenzyme-A	 reductase	 inhibitors	 that	 de-
crease	serum	cholesterol	levels,	reduce	systemic	inflammation,	and	decrease	the	
amount	of	cardiovascular	events6;7.	Fibrates	are	ligands	of	Peroxisome	Proliferator	
Activated	Receptor	(PPAR)α.	These	drugs	decrease	serum	triglycerides	and	also	
exert	 anti-inflammatory	 effects	 on	 different	 tissues.	 Like	 statins,	 they	 decrease	
inflammatory	processes	in	cartilage,	synovium	and	intra-articular	adipose	tissue	
in	in-vitro	studies8-14.	Chronic	low	grade	inflammation	plays	an	important	role	in	
the	pathogenesis	of	OA	and	metabolic	syndrome4.	Since	statins	and	fibrates	can	
potentially	 inhibit	 inflammatory	 processes	 in	 the	 joint	 as	 well	 as	 improve	 the	
metabolic	profile	of	patients,	they	might	offer	a	potential	therapeutic	or	preven-
tive	 strategy	 for	OA.	Recently,	we	associated	 the	use	of	 statins	with	decreased	
incidence	and	slower	progression	of	knee	OA	in	the	Rotterdam	Study	on	x-rays15.	
Kadam	et	al	associated	the	use	of	statin	with	decreased	incidence	of	clinical	OA	
in	the	General	Practice	Research	Database	from	the	United	Kingdoms16.	No	direct	
association	between	the	use	of	fibrates	and	incidence	of	OA	has	been	described	
yet17.	Before	starting	a	clinical	trial	that	directly	addresses	the	question	whether	
statins	and	fibrates	are	able	to	prevent	OA	or	OA	progression,	an	in-vivo	animal	
study	should	be	performed.	
In	the	STR/Ort	mouse	strain,	80%	of	the	male	mice	spontaneously	develop	OA	in	
the	tibiofemoral	joint	at	the	age	of	6	month,	particularly	at	the	medial	condyles	with	
similar	histopathological	lesions	as	in	humans18.	STR/Ort	mice	also	spontaneously	
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develop	 obesity19.	 Furthermore,	 serum	 levels	 of	 total	 cholesterol,	 high	 density	
lipoprotein	(HDL)	cholesterol,	LDL	cholesterol,	 triglycerides,	nonesterified	 fatty	
acids,	glucose	and	insulin	are	reported	to	be	increased	in	STR/Ort	mice	compared	
to	C57BL/6J	mice19.	In	addition	it	has	been	suggested	that	STR/Ort	mice	develop	
OA	spontaneously	due	to	the	reduction	of	endogenous	PPARα	or	PPARγ	signalling,	
and	thus	possibly	increasing	inflammation	and	altering	osteoblast	phenotype20.	
For	these	reasons,	the	STR/Ort	mouse	model	seems	eminently	suited	to	investi-
gate	the	effects	of	statins	and	fibrates	on	OA	development.	 In	this	study,	we	in-
vestigated	whether	administration	of	simvastatin	or	fenofibrate	or	a	combination	
of	both	would	prevent	or	delay	the	development	of	OA	in	the	tibiofemoral	joint.	
We	evaluated	the	effect	of	this	treatment	on	serum	cholesterol,	triglyceride,	the	
inflammation	marker	serum	Amyloid	A	(SAA)	and	the	inflammatory	cytokines	in	
the	blood.	Cartilage	damage	was	evaluated	with	histology	and	joint	bone	morphol-
ogy	with	micro	computed	tomography	(μCT).	
METHODS
Animals
Four-week-old	male	STR/Ort	mice	(n=72)	acquired	from	Harlan	Italy	(Udine,	Italy)	
were	 maintained	 at	 the	 animal	 testing	 facilities	 of	 the	 Erasmus	MC	 University	
Medical	Center,	The	Netherlands.	Mice	were	housed	in	groups	of	three	mice	per	
cage	under	standard	conditions	and	had	access	to	water	and	food	ad	libitum.	The	
study	protocol	was	approved	by	the	institutional	Animal	Care	and	Use	Committee	
(Erasmus	MC	University	Medical	Center,	The	Netherlands,	AEC	116-10-01)
Diets and drug intake
Mice	 were	 fed	 semi-synthetic	 non-irradiated	mice	 reference	 diet	 (AbDiets,	Wo-
erden,	The	Netherlands)	for	4	weeks	before	feeding	the	experimental	diets.	Body	
weight	(BW)	was	measured	every	two	weeks	and	food	was	replaced	2-3	times	per	
week.	Average	BW	per	mouse	and	average	 food	 intake	per	 cage	per	day	 could	
thus	be	determined	and	we	could	calculate	the	amount	of	drugs	(mg/kg)	needed	
to	be	mixed	with	reference	diet	for	the	mice	to	receive	the	intended	target	dosage	
(mg/kg	BW/day).	At	the	age	of	8	weeks,	the	mice	were	divided	into	6	experimental	
groups	of	n	=	12.	Group	1	(control)	continued	to	receive	the	non-supplemented	
reference	diet.	Group	2	and	3	received	reference	diet	mixed	with	either	300	or	750	
mg/kg	simvastatin	(Eurogenerics,	Brussel,	Belgium),	which	corresponds	to	dos-
ages	of	40	and	100	mg/kg	BW/day.	Groups	4	and	5	received	reference	diet	mixed	
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with	either	600	or	1500	mg/kg	fenofibrate	(Eurogenerics,	Brussel,	Belgium),	which	
corresponds	to	dosages	of	80	and	200	mg/kg	BW/day.	Finally,	group	6	received	a	
combination	of	simvastatin	(300	mg/kg)	and	fenofibrate	(600	mg/kg)	with	dosages	
40	and	80	mg/kg	BW/day	respectively.	Target	dosages	of	each	drug	were	based	
upon	what	is	often	used	in	the	literature	to	study	the	anti-inflammatory	or	lipid	
lowering effects of these drugs 21.	All	experimental	diets	were	provided	and	mixed	
by	AB	Diets	(Woerden,	The	Netherlands)	and	were	stored	at	4ºC	for	a	maximum	of	
26	weeks.	At	the	age	of	6	months	the	mice	were	sacrificed	via	isoflurane	anesthesia	
and	heart	puncturing.			
One	mouse	 in	 the	 simvastatin	 40mg/kg	 BW/day	 treatment	 group	 rapidly	 lost	
weight	 and	was	euthanized	2	weeks	before	 the	end	of	 the	 study.	Nevertheless,	
having	completed	>90%	of	the	study	period,	we	decided	to	include	the	data	from	
this	mouse	in	all	analyses.
Serum analysis
Blood	was	collected	through	a	cheek	puncture	prior	to	the	start	of	experimental	
diet.	At	end	point,	blood	was	collected	through	a	heart	puncture.	Blood	was	stored	
for	1	hour	at	room	temperature,	followed	by	30	minutes	at	4ºC,	then	centrifuged	
for	5	minutes	at	12.000	rpm	and	serum	was	removed	and	immediately	stored	at	
-80ºC.	 Total	 plasma	 cholesterol	 (Roche	Diagnostics	 kit	 no.1489437)	 and	plasma	
triglyceride	(Roche	diagnostics	kit	no.1488872)	were	determined	after	defrosting.	
Serum	Amyloid	A	(SAA)	was	also	determined	in	each	sample	by	ELISA	(Tridelta	
development,	 Maynooth,	 Ireland)	 according	 to	 the	 manufacturer’s	 instruction.	
Mouse	inflammatory	cytokines	(FGF	basic,	GM-CSF,	IFN-γ,	Interleukin(IL)-1α,	IL-1β,	
IL-2,	IL-4,	IL-5,	IL-6,	IL-10,	IL-12p40/p70,	IL-13,	IL-17,	IP-10,	KC,	MCP-1	MIG,	MIP-1α,	
TNF-α	and	VEGF)	were	measured	using	a	magnetic	20-plex	bead	assay	(Invitrogen,	
Frederick,	MD,	USA)	according	to	manufacturer’s	instructions.				
Due	to	technical	problems	during	sample	processing,	the	serum	samples	of	one	
mouse	in	the	control	group	and	two	of	the	simvastatin	40mg/kg	BW/day	treatment	
group	were	lost.
µCT analysis
The	left	hind	legs	of	all	animals	were	excised	and	fixed	in	4%	buffered	formalin	for	
µCT	and	histology.	We	used	the	Skyscan	1176	X-ray	microtomograph	and	comple-
mentary	dedicated	software	(Bruker	micro-CT,	Kontich,	Belgium)	to	analyze	the	
subchondral	bone	morphology	in	the	proximal	tibia	of	the	left	knee.	The	following	
scan	settings	were	used:	voltage	100	kV;	current	100	µA;	filter	0.5	mm	aluminium;	
image	pixel	 size	 17.92	 μm;	 exposure	 time	 2360	ms;	 frame	 averaging	 3;	with	 0.4	
degree	 rotation	 through	 180	degrees.	 Following	 scanning,	 datasets	were	 recon-
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structed	using	NRecon	(Bruker-Skyscan).	Segmentation	was	performed	with	a	lo-
cal	threshold	algorithm22	and	using	CTAnalyser	(Bruker-Skyscan),	the	medial	and	
lateral	subchondral	bone	plate	(region	of	interest	depth:	1.61	mm	ventro-dorsal,	
starting	 from	the	anterior	 intercondylar	area;	 region	of	 interest	width:	adjusted	
according	to	total	medio-lateral	width	in	each	tibia,	then	split	in	half	in	the	middle	
of	the	intercondylar	eminence,	yielding	a	lateral	and	a	medial	part)	were	selected	
as	regions	of	interest.	Finally,	CTAnalyser	was	used	to	calculate	subchondral	bone	
plate	 bone	 volume	 (BV)	 and	 subchondral	 bone	 plate	 thickness,	 as	 described	
previously23.
Histological analysis
After	μCT	scanning,	the	legs	were	decalcified	in	10%	formic	acid	in	distilled	water	
for	10	days	and	embedded	in	paraffin	and	6	µm	thick	coronal	(frontal)	histological	
sections	were	 cut	 at	 100	µm	 intervals	 through	 the	 joint.	 Sections	were	 stained	
with	 thionine.	 Two	 independent	 blinded	 observers	 scored	 cartilage	 damage	
at	the	medial	and	lateral	sides	of	both	the	femur	and	the	tibia	according	to	the	
semi-quantitative	scoring	system	devised	by	the	Osteoarthritis	Research	Society	
International	(OARSI)	histopathology	initiative	24.	Briefly,	this	scoring	system	has	
a	range	from	0	to	6,	with	0	means	normal	cartilage,	1	small	fibrillations	without	
loss	of	cartilage	and	3-6	erosions	to	the	calcified	cartilage	extending	from	<25%	
to	>75%.	Only	slides	where	all	four	(i.e.	the	medial	and	lateral	sides	of	both	the	
femur	and	tibia)	 locations	were	visible	were	used.	The	mean	score	of	 three	dif-
ferent	slides	was	determined	and	in	case	of	a	>0.5	score	discrepancy	between	the	
first	observers,	a	third	independent	observer	rescored	the	slides.	To	determine	
whether	 treatment	 has	 an	 effect	 on	 synovial	 inflammation,	 the	 number	 of	 cell	
layers	of	the	synovium	membrane	on	the	medial	side	of	the	patella	was	counted.	
The	mean	number	of	cell	layers	of	three	different	slides	was	used	in	the	statistical	
analysis.
Due	to	technical	error	during	analysis,	the	knees	of	one	control	mouse	and	one	
combination	treated	mouse	were	lost.		
Data analysis
Statistical	 analysis	 was	 performed	 in	 IBM	 SPSS	 statistics	 20	 (IBM	 Corporation,	
Armonk,	New	York,	USA)	and	R:	A	language	and	environment	for	statistical	com-
puting	 3.0.2	 (R	 Development	 Core	 Team,	 Vienna,	 Austria).	 Data	 was	 tested	 for	
normality	using	the	Shapiro-Wilk	test	and	for	homogeneity	of	variance	using	the	
Levene’s	test.	The	one	way	ANOVA	with	post-hoc	Bonferroni	correction	was	then	
used	for	BW	at	end	point,	serum	total	cholesterol	and	bone	parameters	because	
these	parameters	were	normally	distributed	and	had	homogeneity	of	 variance.	
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For	other	serum	parameters,	food	intake	and	histological	data,	the	Kruskal-Wallis	
with	post-hoc	Bonferroni	correction	was	used.	The	95%	confidence	interval	(CI)	
of	the	difference	between	conditions	when	the	Kruskal-Wallis	test	was	used,	was	
calculated	using	the	bootstrap	method.	To	assess	the	relationship	between	BW	at	
end	point,	serum	total	cholesterol	and	μCT	data,	the	Pearson’s	correlation	coeffi-
cient	was	used	because	these	parameters	were	normally	distributed.	For	all	other	
association	analyses,	the	Spearman’s	correlation	coefficient	was	used.	p<0.05	was	
considered	statistically	significant.
RESULTS
Simvastatin treatment had no statistically significant effect on serum 
parameters or OA characteristics
Body weight	As	expected,	the	mean	BW	of	the	mice	in	the	control	group	increased	
during	 the	 study,	 reaching	 a	mean	of	 36.8	 (±	 3.2)	 grams	after	 16	weeks	 (Figure	
1).	 In	the	simvastatin	only	treated	groups,	BW	at	end	point	did	not	statistically	
significantly	differ	from	control	(95%	CI:	-3.4	to	4.0	and	-2.6	to	4.7	for	the	difference	
between	control	and	40	or	100	mg/kg	BW/day	of	simvastatin	respectively).		Food	
intake	was	not	statistically	significantly	influenced	by	the	addition	of	simvastatin	
to	the	food	and	the	mice	received	a	median	of	77%	of	the	intended	dosage	of	drug	
(Table	1).
Serum	No	statistical	significant	difference	was	observed	in	serum	total	choles-
terol	(95%	CI:	-0.7	to	0.4	and	-0.6	to	0.6),	serum	total	triglyceride	(95%	CI:	-2.4	to	
1.1	and	-1.0	to	1.6)	and	SAA	levels	(95%	CI:	-286.4	to	680.1	and	-570.0	to	728.4)	after	
both	dosages	of	simvastatin	only	treatments	(Figure	2).	Using	the	multiplex	assay,	
IL1α,	MIP1α	and	IL10	were	detectable	in	the	serum	and	compared	to	control	mice,	
these	were	not	statistically	significantly	different	after	simvastatin	treatment.
OA cartilage damage	 Microscopic	 evaluation	 demonstrated	 variability	 in	
cartilage	 loss	and	the	amount	of	subchondral	bone	in	all	 the	groups	(Figure	3).	
Cartilage	damage	was	most	profound	in	the	medial	compartment	of	the	joint.	The	
median	OARSI	scores	in	the	simvastatin	100	mg/kg	BW/day	treated	group	at	the	
medial	femur	and	tibia	were	lower	than	the	untreated	control	group,	although	this	
difference	was	not	statistically	significant	(95%	CI:	-0.6	to	3.8	for	medial	femur	and	
-1.8	 to	4.6	 for	medial	 tibia	OARSI	score).	We	could	not	detect	a	statistically	sig-
nificant	reduction	of	synovial	hyperplasia	in	the	mice	after	simvastatin	treatment	
compared	to	controls	(95%	CI:	-0.7	to	1.0	and	-0.7	to	1.0	for	the	difference	between	
control	and	40	or	100	mg/kg	BW/day	of	simvastatin	respectively;	Figure	3).		
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Figure 1 Effect	of	treatment	on	body	weight	and	serum	metabolic	markers.	
T	=	0	weeks	represent	start	of	experimental	treatment	at	the	age	of	8	weeks.	Control	group	received	reference	
diet	for	16	weeks.	Treatment	groups	received	simvastatin	and/or	fenofibrate	mixed	into	their	diet	for	16	weeks.	
Indicated	dosages	are	intended	drug	intake/kg	body	weight/day.	Combination	group	received	simvastatin	40	
mg	and	fenofibrate	80	mg.	A)	Body	weight,	B)	Serum	triglyceride,	C)	Serum	total	cholesterol.	Values	indicate	
mean	+	SD	(n=11-12	mice	per	group).	Horizontal	dashed	line:	mean	value	of	T	=	0.*p<0.01	versus	Control	group.	
**p<0.001	versus	Control	group
Table 1 Total	food	intake	and	drug	intake	per	mouse*
Treatment Group
(Intended drug intake)
Average total food 
intake per mouse in 
grams**
P Value Actual drug intake per kg body 
weight per day in mg (% of intended 
drug intake)
Control 492.1	±	15.7
Simvastatin	40	mg 467.1	±	13.8 1.000 30.7	±	1.8	(77)
Simvastatin	100	mg 460.2	±	4.2 0.265 76.2	±	2.6	(76)
Fenofibrate	80	mg 557.5	±	18.8 0.009 74.5	±	2.0	(93)
Fenofibrate	200	mg 524.9	±	8.6 0.265 189.3	±	5.5	(95)
Combination 484.3	±	11.8 1.000 33.5	±	1.4	(84)$
67.0	±	2.8	(84)#
*Treatment	groups	received	simvastatin	and/or	fenofibrate	mixed	with	their	diet	for	16	weeks.	Indicated	dosag-
es	are	intended	drug	intake/kg	body	weight/day.	Combination	group	received	simvastatin	40	mg	and	fenofibrate	
80	mg.	Data	are	mean	±	SD;	Kruskal-Wallis	test	with	post-hoc	Bonferonni	correction	was	performed;	P	values	
indicate	the	statistical	difference	between	treatment	and	control	group;	
**Average	total	food	intake	per	mouse	for	16	weeks
$	Simvastatin	40	mg
#	Fenofibrate	80	mg
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Figure 2 Effect	of	simvastatin	and/or	fenofibrate	on	serum	inflammatory	markers.	
Control	group	received	reference	diet.	Treatment	groups	received	simvastatin	and/or	fenofibrate	mixed	with	
their	diet	 for	16	weeks.	 Indicated	dosages	are	 intended	drug	 intake/kg	body	weight/day.	Combination	group	
received	simvastatin	40	mg	and	fenofibrate	80	mg.	A)	Serum	IL1α,	B)	Serum	MIP1α,	C)	Serum	IL10	and	D)	Serum	
Amyloid	A	levels.	T	=	0:	values	before	treatment	at	the	age	of	8	weeks.	Horizontal	dashed	line	indicates	the	mean	
value	at	the	start	of	treatment	(T	=	0).	Values	indicate	mean	+	SD	(n=11-12	mice	per	group)
Twenty	one	percent	of	the	mice	developed	patella	subluxation	and	the	prevalence	
of	subluxation	was	not	different	between	groups.	Excluding	the	mice	with	patella	
dislocation	from	the	analyses	did	not	alter	the	results	(Supplementary	table	1).
μCT analysis	Both	the	subchondral	bone	volume	(95%	CI:	-0.1	to	0.1	and	-0.1	to	
0.2)	and	plate	thickness	(95%	CI:	-40.6	to	42.1	and	-24.3	to	60.2)	did	not	statistically	
significantly	differ	between	mice	treated	with	simvastatin	and	control	mice	(Figure	
4).	
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Figure 3 Histological	analysis	of	effect	of	simvastatin	and/or	fenofibrate	treatment	on	cartilage	
damage	in	STR/Ort	mice.		
The	coronal	sections	of	cartilage	in	the	weight-bearing	area	of	the	tibiofemoral	compartment	of	the	left	knee	
were	stained	with	thionine	and	severity	of	cartilage	damage	was	scored	on	a	scale	of	0-6	using	the	OARSI	his-
tological	scoring	scale.	Control	group	received	reference	diet	for	16	weeks.	Treatment	groups	received	simvas-
tatin	and/or	fenofibrate	mixed	with	their	diet	for	16	weeks.	Indicated	dosages	are	intended	drug	intake/kg	body	
weight/day.	Combination	group	received	simvastatin	40	mg	and	fenofibrate	80	mg.	A)	Representative	picture	
of	score	0:	normal	cartilage	B)	Representative	picture	of	score	6:	Vertical	clefs/erosion	to	the	calcified	cartilage	
extending	to	>75%	of	the	surface.	Pictures	are	taken	at	40x	magnification.	C)	Quantification	of	OARSI	scores	of	
the	medial	femur.	D)	Quantification	of	OARSI	scores	of	the	medial	tibia.	E)	Number	of	cell	layers	in	the	synovial	
membrane.	Each	dot	represents	an	individual	mouse	(n=11-12	mice	per	group)	Horizontal	line	indicates	median	
value	per	group	in	C	and	D.	Mean	±	SD	is	shown	in	E.	
Statins and fibrates in the STROrt mouse model 109
6







 
 





 
 





 
 





 

 


















 

 






 


 







 
 





 
 





 
 





 

 















 

 







 



 
Figure 4 Effect	of	simvastatin	and/or	fenofibrate	treatment	on	subchondral	bone	plate	bone	vol-
ume	and	thickness	of	the	tibia	plateau	in	STR/Ort	mice.	
Control group received	reference	diet	for	16	weeks.	Treatment	groups	received	simvastatin	and/
or	fenofibrate	mixed	with	their	diet	for	16	weeks.	Indicated	dosages	are	intended	drug	intake/kg	
body	weight/day.	Combination	group	received	simvastatin	40	mg	and	fenofibrate	80	mg.	A)	Sub-
chondral	bone	plate	bone	volume	B)	Subchondral	bone	plate	thickness,	Values	indicate	mean	+	
SD	(n=11-12	mice	per	group)
Fenofibrate treatment reduced body weight, SAA and subchondral bone
Body weight	Mice	treated	with	200	mg/kg	BW/day	fenofibrate	had	the	lowest	mean	
BW	at	end	point	compared	to	the	control	group	(p<0.001;	Figure	1).	All	fenofibrate	
treated	mice	ate	more	compared	to	the	control	group,	although	only	the	fenofi-
brate	80	mg/kg	BW/day	treated	group	ate	statistically	significantly	more	(Table	1).	
No	signs	of	diarrhoea	were	observed.	The	mice	received	a	median	of	94%	of	the	
intended	drug	dosage.	
Serum markers	We	did	not	detect	a	statistically	significant	effect	of	fenofibrate	
treatment	on	serum	total	triglyceride	(95%	CI:	-0.5	to	2.2	and	-0.8	to	2.0	for	the	dif-
ference	between	control	and	80	or	200	mg/kg	BW/day	of	fenofibrate	respectively)	
and	on	serum	total	cholesterol	(95%	CI:	-0.9	to	0.3	and	-0.8	to	0.4;	Figure	2).	SAA	
levels	 in	 fenofibrate	 treated	groups	did	not	change	after	start	of	 treatment	and	
at	 end	 point	were	 significantly	 lower	 than	 in	 the	 control	 group	 (95%	CI:	 9.5	 to	
828.0	 and	10.8	 to	 829).	On	 the	multiplex	 assay	only	 IL1α,	MIP1α	 and	 IL10	were	
detectable	in	the	serum	(Figure	2).	IL1α	and	MIP1α	levels	were	significantly	higher	
in	fenofibrate	treated	mice	than	in	control	mice.	
OA cartilage damage	We	could	not	detect	a	statistically	significant	reduction	of	
medial	femur	(95%	CI:	-2.8	to	3.4	and	-3.5	to	2.6)	and	tibia	(95%	CI:	-4.3	to	4.6	and	-3.4	
to	4.3)	OARSI	scores	and	synovial	hyperplasia	(95%	CI:	-1.7	to	1.8	and	-0.6	to	1.3)	in	
the	fenofibrate	treated	mice	compared	to	controls	(Figure	3).	
μCT analysis	Mice	treated	with	200	mg/kg	BW/day	fenofibrate	had	a	lower	sub-
chondral	bone	volume	and	plate	thickness	than	the	control	group	although	only	
the	lower	subchondral	bone	volume	was	statistically	significant	(Figure	4).		
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Effects of combination treatment of simvastatin and fenofibrate
The	mean	BW	of	the	mice	treated	with	a	combination	of	simvastatin	and	fenofi-
brate	at	the	end	of	the	study	was	lower	than	the	mean	BW	in	the	control	group	
(p=0.003,	Figure	1).	The	mice	received	84%	of	the	intended	dosage	simvastatin	and	
fenofibrate	(Table	1).
Only	 serum	 amyloid	 A	 was	 statistically	 significantly	 different	 between	 mice	
treated	with	a	combination	of	simvastatin	and	fenofibrate	and	controls	(Figures	
2,	3	and	4)
Correlation between body weight, serum markers, cartilage damage, 
synovial hyperplasia and bone changes.
Body	weight	 at	 end	 point	 correlated	with	 serum	 total	 triglyceride	 (p<0.001),	 IL1α 
(p<0.001)	and	MIP1α	(p=0.001)	and	subchondral	bone	volume	(p=0.01).	In	none	of	the	
treatment	groups,	serum	inflammation	markers	correlated	statistically	significantly	
with	OA	cartilage	damage	(Table	2).	SAA	levels	did	not	differ	between	mice	with	and	
without	 cartilage	 damage.	 SAA	 levels	 correlated	 to	 subchondral	 bone	 volume	
(p=0.008)	 	Both	subchondral	bone	volume	(p=0.002),	plate	thickness	(p<0.001)	and	
synovial	hyperplasia	(p<0.001)	correlated	with	cartilage	damage.	(Table	2)	
Table 2 Correlation	between	body	weight	serum	markers,	OARSI	cartilage	scores,	synovial	hyper-
plasia	and	µCT	data.
Body Weight
(end point)
OARSI Score Synovium
 cell layers
Subchondral
bone plate 
volume
Subchondral
bone plate 
volume
Total Femur Tibia
Body weight 
(end	point)
0.14 0.04 0.19 0.32 0.31 0.22
Serum
  Total cholesterol 0.09 0.07 0.02 0.05 0.04 -0.26 -0.23
  Total triglyceride 0.45 0.12 0.10 0.10 0.28 0.03 0.04
		Amyloid	A 0.21 -0.01 -0.08 0.08 0.12 0.34 0.19
		IL1α -0.52 -0.07 -0.09 -0.04 -0.09 -0.09 -0.13
		MIP1α -0.44 -0.09 -0.13 -0.02 -0.05 -0.01 -0.06
		IL10 0.11 -0.08 -0.14 0.03 -0.01 -0.01 -0.11
Synovium	cell	layers 0.33 0.62 0.32 0.42
Subchondral bone 
plate	volume
0.31 0.37
Subchondral bone 
plate	thickness
0.22 0.49
Serum	markers	were	measured	at	end	point	after	16	weeks	of	treatment;	OARSI	scores	for	the	total	
joint,	both	femur	and	tibial	compartments;	Correlations	between	body	weight	at	end	point,	serum	
total	cholesterol	and	µCT	data	were	calculated	using	the	Pearson	correlation	coefficient;	Correlations	
between	all	other	parameters	were	calculated	using	the	Spearman	correlation	coefficient;	Significant	
correlations	(p<0.05)	are	shown	in	bold.
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DISCUSSION
In	this	study	we	investigated	whether	drugs	often	used	to	reduce	the	morbidity	
and	mortality	 of	metabolic	 syndrome	 and	 obesity	 could	 serve	 as	 a	 therapy	 to	
prevent	or	treat	OA.	We	did	not	find	a	statistically	significantly	reduction	of	the	
severity	of	cartilage	damage	in	STR/Ort	mice	with	neither	simvastatin,	fenofibrate	
nor	the	combination	treatment,	although	fenofibrate	treatment	prevented	a	high	
subchondral	bone	volume.	
The	STR/Ort	strain	was	carefully	chosen	for	this	study	because	these	mice	have	
been	 described	 to	 develop	 OA	 and	 metabolic	 syndrome	 spontaneously	 at	 a	
relatively	young	age19,	thus	resembling	patients	with	metabolic	OA4.	Since	statins	
and	fibrates	are	used	to	improve	the	metabolic	profile	of	patients,	the	use	of	this	
strain	seemed	to	match	the	subgroup	of	metabolic	OA	patients	that	could	benefit	
from	treatment	with	these	drugs.	In	addition	to	hyperlipidemia	and	obesity,	other	
possible	causes	for	OA	predisposition	in	the	STR/Ort	strain	have	been	discussed,	
such	as	the	role	of	patella	subluxation18;25.	When	patella	subluxation	occurs,	it	is	
a	major	biomechanical	risk	factor	and	disease	modifying	effects	of	simvastatin	or	
fenofibrate	would	be	highly	unlikely.	 In	our	study,	patella	subluxation	occurred	
in	 21%	 of	 the	 mice	 throughout	 all	 the	 groups.	 Although	 all	 mice	 with	 patella	
subluxation	had	extensive	cartilage	damage,	not	all	mice	with	extensive	cartilage	
damage	had	patella	subluxation.	This	suggests	that	patella	subluxation	is	not	the	
main	cause	of	OA	in	these	mice	and	is	not	likely	to	mask	the	effects	of	simvastatin	
or	fenofibrate.
In	a	previous	human	cohort	study	we	found	that	statin	use	was	associated	with	a	
lower	incidence	and	reduced	progression	of	knee	OA	on	x-rays15.	In	an	other	study	
statin	use	was	associated	with	lower	incidence	of	clinical	OA16.	In	the	present	study	
with	STR/Ort	mice,	simvastatin	did	not	lower	the	serum	total	cholesterol	level.	This	
could	be	explained	by	a	different	cholesterol	metabolism	pathway	in	mice	than	in	
humans26-28.	The	absence	of	a	statistically	significant	effect	of	simvastatin	on	OA	
in	our	study	could	indicate	that	cholesterol	and	OA	might	be	linked	to	each	other	
and	that	lowering	cholesterol	by	statins	is	important	to	reduce	OA	development.	
Furthermore,	different	types	of	statins	were	included	in	the	human	clinical	studies.	
These	different	types	of	statins	have	been	described	to	have	different	therapeutic	
effects29.	The	serum	 levels	of	 total	cholesterol	 in	 the	control	mice	 in	our	study	
were	comparable	to	a	previous	study19.	Serum	cholesterol	can	be	increased	with	a	
high	fat	diet	in	mice	and	decreases	after	treatment	with	statin30;31.	In	addition,	we	
have	previously	reported	that	statin	treatment	decreased	the	development	of	OA	
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in	mice	on	a	high	fat	diet32.	This	suggests	that	the	effect	of	statin	treatment	could	
also	depend	on	the	type	of	diet.	However,	this	conclusion	should	be	drawn	with	
caution,	because	the	studies	of	Fraulob31	and	Gierman32	used	rosuvastatin	and	the	
study	of	Paraskevast30	atorvastatin,	whereas	we	administered	simvastatin.	As	with	
humans,	 these	different	 types	of	 statins	have	been	described	 to	have	different	
therapeutic	effects	in	mice21.
The	result	of	our	study	that	simvastatin	could	not	statistically	significantly	reduce	
OA	cartilage	damage	 is	 also	not	 consistent	with	 a	previous	 study	by	Yudoh	et	
al14,	who	reported	a	statistically	significant	decrease	in	OA	cartilage	score	in	STR/
Ort	 mice	 after	 12	 and	 24	 weeks	 of	 simvastatin	 (40	 mg/kg	 BW/day)	 treatment.	
This	inconsistency	could	be	due	to	differences	in	strains:	Yudoh	and	colleagues	
used	STR/OrtCrlj	mice	obtained	from	Charles	River	Japan	whereas	we	used	STR/
OrtOlaHsd	mice	obtained	from	Harlan,	Italy.	Response	to	simvastatin	could	have	
been	different	between	these	two	populations	of	mice.	Furthermore,	in	the	study	
by	Yudoh	et	al,	the	cartilage	damage	in	the	untreated	group	at	the	age	of	24	weeks	
was	less	severe	than	in	the	control	group	in	our	study.	This	indicates	that	simvas-
tatin	might	be	more	effective	in	slowly	developing	or	less	severe	OA.	Lastly,	Yudoh	
et	al	administrated	the	drugs	by	daily	gavage	instead	of	mixing	it	with	the	food	and	
therefore	a	different	therapeutic	level	might	be	reached	in	the	mice.	
Fenofibrate	is	another	lipid	lowering	drug,	widely	used	to	lower	serum	lipids	in	
patients	with	hypertriglyceridemia.	Serum	triglyceride	was	not	lowered	after	treat-
ment	with	fenofibrate	in	our	study,	but	the	treated	mice	gained	less	weight.	BW	
was	however	moderately	correlated	to	serum	triglyceride	suggesting	that	weight	
reduction	could	 reduce	serum	 triglyceride.	Control	mice	continued	 to	gain	BW	
over	time,	reaching	a	mean	weight	of	36.8	±	3.2	grams	at	the	age	of	24	weeks.	This	
is	 comparable	 to	previous	 studies19;33.	The	 reduction	 in	BW	gain	by	 fenofibrate	
treatment	however,	did	not	protect	the	mice	from	developing	cartilage	damage.	
This	absence	of	correlation	between	BW	and	incidence	of	cartilage	damage	con-
firms	our	earlier	findings32	that	obesity	does	not	increase	OA	cartilage	damage	by	
biomechanical	overloading.	
In	our	study,	serum	cholesterol	and	serum	triglyceride	were	both	not	correlated	
with	cartilage	damage.	This	suggests	that	in	the	STR/Ort	mice	lipid	metabolism	
is	not	the	primary	cause	of	spontaneous	OA	cartilage	damage	development.	Next	
to	their	effect	on	lipid	metabolism,	statins	and	fibrates	are	known	to	have	an	ef-
fect	on	inflammation8;9;11-13.	SAA,	a	marker	for	systemic	inflammation,	increased	in	
control	mice	with	aging.	SAA	has	been	associated	with	inflammatory	processes	in	
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artherosclerosis	and	rheumatoid	arthritis34-36,	is	increased	in	obesity37 and clinical 
studies	have	shown	that	SAA	can	be	lowered	by	fenofibrate	and	simvastatin	treat-
ment38-40.	 In	the	present	study	with	STR/Ort	mice,	SAA	levels	were	only	lowered	
after	 fenofibrate	 treatment.	 SAA	 is	 described	 to	 be	 induced	 by	 the	 cytokines	
IL1β,	 IL6	 and	TNF-α	 and	 it	 can	activate	 the	NF-ĸB pathway34;35;41.	Kyostio-Moore	
et al42	 reported	elevated	 inflammatory	 cytokines	 in	 the	 serum	of	 STR/Ort	mice	
including	IL1β,	IL12p70	and	IL5,	and	these	changes	were	correlated	with	cartilage	
damage.	We	were	able	to	detect	IL1α,	MIP1α	and	IL10	in	the	serum	of	the	mice,	
but	other	cytokines	were	not	detected.	Surprisingly,	IL1α,	and	MIP1α	levels	were	
significantly	higher	in	mice	that	received	fenofibrate	treatment.	This	suggests	that	
different	aspects	of	inflammation	might	occur	that	possibly	counteract	each	other.	
Furthermore,	 we	 found	 no	 correlation	 between	 individual	 serum	 inflammatory	
markers	and	synovial	hyperplasia,	suggesting	that	systemic	inflammation	is	not	
directly	related	to	local	inflammatory	changes	in	the	knee	in	our	STR/Ort	mice
Fenofibrate	 lowers	 lipid	 levels	by	 activating	PPARα.	 It	 has	been	 suggested	 that	
STR/Ort	 mice	 have	 reduced	 endogenous	 PPARα	 signalling.	 This	 reduction	 of	
PPARα signalling could be associated with increased osteogenic differentiation 
and	reduced	adipogenic	and	chondrogenic	differentiation	of	bone	marrow	derived	
mesenchymal	stem	cells		and	thus	be	associated	with	the	development	of	OA	in	
these	mice20.	 In	our	 study,	PPARα	 activation	with	200mg/kg	BW/day	 fenofibrate	
did	 indeed	 reduce	 the	 total	 bone	 volume	 in	 the	 subchondral	 bone.	 	We	 could	
however,	 not	 detect	 a	 significant	 reduction	 of	 cartilage	 damage	 in	 our	 study.	
Changes	in	cartilage	and	subchondral	bone	during	OA	development	are	thought	
to be correlated to each other43	and	we	did	find	a	moderate	correlation	between	
cartilage	damage	and	subchondral	bone	parameters.	The	absence	of	a	statistically	
significant	reduction	of	cartilage	damage	might	be	due	to	the	limited	sensitivity	
of	the	histological	cartilage	damage	scoring	or	to	the	high	variation	in	incidence	
of	spontaneous	OA	cartilage	damage	in	these	mice.	In	the	present	study,	60%	of	
the	animals	had	developed	OA	cartilage	damage	at	24	weeks	of	age,	which	is	less	
than	the	80%	reported	in	other	studies	that	we	used	for	our	power	calculation18.	
Moreover,	 since	 we	 used	 a	 spontaneous	model	 of	 OA	 development,	 individual	
mice	developed	OA	at	a	different	speed25	which	might	explain	the	large	variation	
in	cartilage	damage	in	the	control	group.
Alternatively,	it	is	possible	that	the	mice	treated	with	fenofibrate	are	at	a	different	
phase	in	OA	development.	During	OA	development	in	mice,	a	biphasic	subchon-
dral	bone	turnover	process	is	taking	place,	with	initial	loss	of	subchondral	bone,	
followed	by	increased	volume	and	thickening	of	the	subchondral	bone	plate23;44.	
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In	the	fenofibrate	treated	mice,	initial	OA	development	could	have	been	delayed	
as	demonstrated	by	the	lower	subchondral	bone	volume	whereas	the	other	mice	
already	progressed	to	a	thickening	of	the	subchondral	plate.	Further	investigation	
with	time	series	is	needed	to	confirm	this	hypothesis.	
Possible	side	effects	of	statins	and	fenofibrates	are	muscle	pain	and	elevated	liver	
enzymes.	 Furthermore,	 toxicology	 studies	 performed	 on	mice	 showed	 that	 ad-
ministration	of	very	high	dosages	of	simvastatin	or	fenofibrate	for	72	weeks	could	
possibly	induce	liver	carcinomas45;	46.	In	our	study,	we	did	not	analyse	the	livers	
of	our	mice	at	age	20	weeks	for	the	presence	of	liver	carcinomas,	so	we	cannot	
exclude	the	presence	of	these	tumours.	We	included	one	group	of	mice	that	was	
treated	with	a	combination	of	simvastatin	and	fe	nofibrate.	This	combination	has	
been	shown	in	clinical	studies	to	be	more	effective	in	decreasing	cardiovasculair	
mortality47,	 treating	 dyslipidemia48	 and	 decreasing	 inflammation49	 compared	 to	
monotherapy.	Because	the	combination	is	demonstrated	to	be	more	effective47-49,	
a lower dose of both drugs can be used and therefore less side effects will occur50.	
Unfortunately,	we	 did	 not	 see	 synergistic	 effects	 of	 the	 combination	 treatment	
in	our	study.	Simvastatin	and	 fenofibrate	are	both	metabolised	 in	 the	 liver	and	
thereby	lowering	the	levels	that	are	reached	locally	in	the	knee	or	subchondral	
bone.	Methods	to	increase	the	levels	of	both	drugs	locally,	such	as	intra-articularly	
or	subcutaneously	injections	might	provide	options	to	increase	the	local	effects	
and	reduce	the	systemic	side	effects.		
In	summary,	we	could	not	detect	a	statistically	significantly	decrease	of	simvas-
tatin	or	fenofibrate	treatment	on	the	development	of	cartilage	damage	in	6	months	
old	 STR/Ort	mice.	On	 the	other	hand,	 the	 effect	 of	 fenofibrate	on	 subchondral	
bone	morphology	and	the	correlation	between	subchondral	bone	morphology	and	
cartilage	damage	suggests	there	might	be	a	mild	effect	on	OA	development	that	is	
masked	by	the	insensitivity	of	the	cartilage	score	or	the	high	variation	in	cartilage	
damage	in	mice	of	6	months	old.	Furthermore,	our	data	suggest	that	biomechani-
cal	changes	due	to	overweight	or	patella	subluxation	and	spontaneous	metabolic	
changes	are	not	the	primary	cause	of	OA	in	the	STR/Ort	mouse.	Complex	inflam-
matory	processes	occur	in	these	mice	that	did	not	affect	the	cartilage	directly.
Nonetheless,	we	do	not	exclude	that	lipid	lowering	drugs	can	still	be	beneficial	in	
other	subtypes	of	OA	such	as	high	fat	diet	induced	metabolic	OA	as	indicated	by	
our	previous	studies.	This	emphasizes	the	importance	of	further	subtyping	OA	to	
find	possibilities	for	pharmacological	treatment	of	OA.			
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ABSTRACT
Obesity	 is	a	well-known	risk	 factor	 for	osteoarthritis,	but	 it	 is	unknown	what	 it	
does	on	cartilage	repair.	Here	we	investigated	whether	a	high	fat	diet	(HFD)	influ-
ences	cartilage	repair	in	a	mouse	model	of	cartilage	repair.	 	We	fed	DBA/1	mice	
control	or	HFD	(60%	energy	from	fat).	After	two	weeks,	a	full	thickness	cartilage	
defect	was	made	in	the	trochlear	groove.	Mice	were	sacrificed,	1,	8	and	24	weeks	
after	 operation.	 Cartilage	 repair	 was	 evaluated	 on	 histology.	 Serum	 glucose,	
insulin	and	amyloid	A	were	measured	24h	before	operation	and	at	endpoints.	Im-
munohistochemical	staining	was	performed	on	synovium	and	adipose	tissue	to	
evaluate	macrophage	infiltration	and	phenotype.	One	week	after	operation,	mice	
on	HFD	had	defect	 filling	with	 fibroblast-like	 cells	 and	more	 cartilage	 repair	 as	
indicated	by	a	lower	Pineda	score.	After	8	weeks,	mice	on	a	HFD	still	had	a	lower	
Pineda	score.	After	24	weeks,	no	mice	had	complete	cartilage	repair	and	we	did	
not	detect	a	significant	difference	in	cartilage	repair	between	diets.	Bodyweight	
was	increased	by	HFD,	whereas	serum	glucose,	amyloid	A	and	insulin	were	not	in-
fluenced.	Macrophage	infiltration	and	phenotype	in	adipose	tissue	and	synovium	
were	not	 influenced	by	HFD.	 	 In	contrast	 to	common	wisdom,	HFD	accelerated	
intrinsic	cartilage	repair	in	DBA/1	mice	on	the	short	term.	Resistance	to	HFD	in-
duced	inflammatory	and	metabolic	changes	could	be	associated	with	accelerated	
cartilage	repair.
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INTRODUCTION
Traumatic	 articular	 cartilage	 injury,	 a	 common	 pathology	 of	 the	 knee1,	 results	
in	considerable	morbidity	and	disabilities	and	could	eventually	lead	to	osteoar-
thrithis	 (OA).	Articular	cartilage	has	 low	self-repair	capabilities2	and	the	micro-
fracture	procedure	 is	used	 to	 induce	 intrinsic	cartilage	 repair	by	mesenchymal	
stem	cells	(MSCs)3	The	microfracture	procedure	leads	to	significant	symptomatic	
improvements	 in	most	patients4;5	The	clinical	 improvements	are	reported	to	be	
less in patients with obesity6	and	these	patients	are	now	often	excluded	from	treat-
ments7.	However,	there	is	no	information	about	the	structure	of	the	newly	formed	
cartilage	or	mechanisms	explaining	the	relationship	between	obesity	and	worse	
clinical	outcome.	
Obesity	is	a	major	health	problem	in	the	Western	society	and	the	number	of	persons	
with	obesity	is	increasing.	Obesity	could	lead	to	systemic	metabolic	and	inflamma-
tory	changes	such	as	hyperglycemia,	hyperinsulinemia,	increased	serum	amyloid	
A	and	infiltration	of	adipose	tissue	by	pro-inflammatory	macrophages8.	Obesity	is	
a	well-known	major	risk	factor	for	the	development	of	OA9.	Furthermore,	obesity	
exaggerated	post-traumatic	arthritis10	and	rheumatoid	arthritis11 and could lead 
to	impaired	wound	healing	after	an	operation12.	However,	it	is	unknown	what	the	
precise	effect	is	of	obesity	on	intrinsic	cartilage	defect	repair.	
To	optimize	cartilage	repair	treatment	results	in	obese	patients,	it	is	therefore	es-
sential	to	investigate	whether	and	how	obesity	negatively	influences	cartilage	re-
pair.	To	answer	this	question,	we	performed	an	in-vivo	mouse	study	to	investigate	
the	direct	effect	of	obesity	on	intrinsic	cartilage	repair.	In	our	study,	a	high	fat	diet	
(HFD)	was	used	to	increase	weight	and	mimic	human	obesity	in	mice13.		HFD	has	
been	shown	to	increase	weight	and	to	be	detrimental	to	cartilage	and	cause	OA	
in	the	C57/BL6	strain	of	mice12;14.	Furthermore,	HFD	decreases	the	chondrogenic	
differentiation	potential	of	MSCs	from	C57/BL6	mice15
Our	hypothesis	was	that	HFD	would	negatively	influence	intrinsic	cartilage	repair.	
Since	C57/BL6	mice	had	been	shown	not	to	possess	intrinsic	repair	capabilities	of	
cartilage defects16,	they	were	unsuitable	for	our	study.	Therefore,	we	used	male	
DBA/1	mice	which	possess	capabilities	to	repair	a	full	thickness	cartilage	defect16 
and	gain	weight	on	a	HFD17.		This	strain	of	mice	is	therefore	suitable	to	study	the	
possible	negative	effects	of	a	HFD	on	cartilage	repair.	
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METHOD
Animals and diet
Eight-weeks-old	 male	 DBA/1OlaHsd	 mice	 were	 acquired	 from	 Harlan	 UK	 and	
maintained	at	the	animal	testing	facilities	of	the	Erasmus	MC	University	Medical	
Center,	The	Netherlands.	Mice	were	housed	in	groups	of	three	or	four	mice	per	
cage	under	12	hours	light-dark	cycle	and	had	access	to	water	and	food	ad	libitum.	
The	study	protocol	was	approved	by	the	institutional	Animal	Care	and	Use	Com-
mittee	(Erasmus	MC	University	Medical	Center,	The	Netherlands,	AEC	116-12-05).	
Mice	were	allowed	to	acclimatize,	were	fed	regular	chow	for	two	weeks	and	were	
allocated	randomly	to	the	diet	groups.	At	the	age	of	10	weeks,	mice	were	fed	with	
a	HFD	(D12492;	Research	Diets,	60%	kcal	from	fat)	or	control	diet	(D12450B;	Re-
search	Diets,	10%	kcal	from	fat).	Both	diets	contained	4057	kcal	per	kilogram	dry	
weight.	Mice	were	weighted	every	two	weeks	and	the	mice	continued	to	receive	
their	respective	diets	until	they	were	killed.
Operative procedure
At	the	age	of	12	weeks	mice	were	anesthetized	with	an	isoflurane/O2	mixture	and	
a	full	thickness	cartilage	defect	was	created	as	previous	described16.	The	left	hind	
leg	was	shaved	and	disinfected	using	alcohol.	An	incision	using	a	nr	11	microsur-
gical	scalpel	was	made	medially	and	proximally	 from	the	 insertion	of	 the	patel-
lar	 tendon	on	 the	 tibia	 towards	 the	 attachment	of	 the	quadriceps	muscle.	The	
joint	capsule	was	opened	with	a	small	incision	and	the	joint	was	fully	extended	
to	dislocate	the	patella	 laterally.	The	knee	 joint	was	then	 fully	flexed	to	expose	
the	trochlear	groove	articular	surface.	A	full	thickness	cartilage	defect	was	then	
made	using	a	25G	needle	by	scratching	the	articular	surface.	The	joint	was	flushed	
with	saline	and	closed	using	6-0	Vicryl	(Ethicon).	The	skin	was	closed	using	6-0	
Ethilon	 (Ethicon).	 The	mice	 were	 given	 one	 dose	 of	 analgesic	 subcutaneously	
preoperatively	(Temgesic,	0.05	mg/kg).	Mice	were	allowed	to	move	freely	post	op-
eration	and	to	be	full	weight	bearing.	Mice	were	sacrificed	1,	8	and	24	weeks	after	
operation	with	a	heart	puncture	under	isoflurane/O2	anesthesia.	All	mice	reached	
end-point	without	disease.	34%	of	the	operated	mice	had	a	patella	dislocation	and	
were	excluded	from	the	analysis.	These	mice	were	equally	distributed	over	both	
groups:	patella	dislocation	 rate	was	35%	 for	 the	control	group	and	32%	 for	 the	
HFD	 fed	 group.	We	 continued	 to	 operate	mice	 until	 there	were	 at	 least	 5	mice	
per	group.	The	time	points	and	minimum	number	of	mice	per	group	needed	were	
based	on	previous	study	by	Eltawil	et	al16.		The	final	number	of	mice	on	a	control	
diet	included	for	analysis	was	8	mice	at	1	week,	9	mice	at	8	weeks	and	6	mice	at	24	
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weeks.	For	the	mice	on	a	HFD,	the	number	of	mice	included	was	6	mice	at	1	week,	
9	mice	at	8	weeks	and	6	mice	at	24	weeks.	
Serum collection and analysis
Blood	was	collected	through	a	cheek	puncture	one	day	before	the	operation	and	
through	a	heart	puncture	at	end	points.	We	collected	three	drops	of	blood	during	
the	cheek	puncture	and	1	ml	of	blood	through	the	heart	puncture.	There	was	no	
noticeable	difference	in	bleeding	tendency	between	animals.	Mice	were	fasted	for	
4	hours	before	blood	collection.	Blood	was	stored	for	1	hour	at	room	temperature,	
followed	by	30	minutes	at	4°C,	then	centrifuged	for	5	minutes	at	250g.	Serum	was	
removed	and	immediately	stored	at	-80°C.	Serum	glucose	was	determined	using	a	
blood	glucose	meter	(FreeStyle	Freedom	Lite,	Abbott	Laboratories).	Serum	insulin	
(Alpco,	#80-INSMS-E01)	and	serum	amyloid	A	(SAA,	Alpco,	#41-SAAMS-E01)	were	
determined	by	Enzyme-Linked	 Immuno	Sorbent	Assay	(ELISA)	according	 to	 the	
manufacturer’s	instructions.	
Tissue preparation for histological analysis
The	skin	of	both	hind	legs	of	all	animals	was	opened.	The	patella	with	surrounding	
synovium	was	removed,	placed	in	Tissue	Tek®	(Sakura	Finetek,	the	Netherlands)	
and	snap	frozen	in	liquid	nitrogen.	6	µm	thick	cryosections	were	made	of	the	pa-
tella	with	surrounding	synovium.	Subcutaneous	adipose	tissue	of	5	mice	per	diet	
at	time	point	8	weeks	after	the	operation	were	fixed	in	4%	buffered	formalin	for	1	
hour,	embedded	in	paraffin	and	6	µm	thick	paraffin	sections	were	made.	The	knees	
of	all	animals	were	excised	and	fixed	in	4%	buffered	formalin	for	7	days,	decalcified	
in	10%	formic	acid	in	distilled	water	for	7	days	and	embedded	in	paraffin.	6	µm	
thick	paraffin	sections	were	made	of	the	knees	as	described	by	Eltawil	et	al16.	
Evaluation of cartilage repair
Paraffin	 sections	 were	 stained	 with	 thionin	 or	 immunohistochemically	 stained	
with	a	monoclonal	 antibody	against	 collagen	 type	2.	 For	 immunohistochemical	
staining,	 collagen	 type	 2	 antibody	 (DSHB,	 #	 II-II	 6B3)	 or	 IgG1	 isotype	 control	
(Dako	Cytomation	#X0931)	were	first	pre-coupled	with	biotin-SP	F(ab)2	(Jackson,	
#115-066-062).	Sections	were	then	incubated	with	the	coupled	antibody	complex,	
followed	by	Label	(Biogenex,	HK-321-UK)	and	freshly	prepared	new-fuchsin	was	
used	as	substrate.	Pictures	were	taken	using	an	Olympus	SC30	camera.		The	size	
of	the	defect	and	percentage	of	defect	filled	was	quantified	using	ImageJ	software	
(National	 Institutes	 of	Health,	 Bethesda,	MD,	USA).	 The	 number	 of	 cells	 in	 the	
defect	was	determined	in	ImageJ	and	expressed	as	per	100µm2.	Cartilage	repair	
was	assessed	using	the	scoring	system	devised	by	Pineda	et	al18,	in	which	filling,	
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reconstruction	 of	 osteochondral	 junction,	matrix	 staining	 and	 cell	morphology	
were	 taken	 into	 account.	The	Pineda	 scoring	 system	has	a	 range	of	 0	 to	 14,	 in	
which	0	means	complete	repair	and	14	no	repair	at	all.	Osteoarthritic	damage	in	
the	cartilage	surrounding	the	defect	was	assessed	using	a	modified	Mankin	scor-
ing	system19.	Both	scoring	systems	were	performed	by	two	independent	observ-
ers	(WW	and	MS)	while	being	blinded	to	the	group	assignment.	The	mean	score	
of	 three	different	 slides	was	determined	and	 in	 case	of	 a	 >1	 score	discrepancy	
between	the	two	observers,	rescoring	was	performed	together	by	the	two	observ-
ers.	
Evaluation of local and systemic inflammation  
Cryosection	of	the	patella	with	surrounding	synovium	were	fixed	in	acetone	and	
stained	with	 hematoxylin	 and	 eosin	 (H&E).	 For	 immunohistochemical	 staining,	
sections	were	 incubated	with	monoclonal	 antibody	 against	 F4/80	 (eBioscience,	
#14-4801),	polyclonal	antibodies	against	 iNOS	 (Abcam,	#15323)	and	CD206	 (Ab-
cam,	#64693).	Rat	IgG2a	antibody	(eBioscience,	#14-4321-82)	were	used	as	isotype	
control	for	F4/80	and	rabbit	IgG	antibody	(Dako	Cytomation	#X0903)	were	used	as	
isotype	control	for	iNOS	and	CD206.	Subsequently,	F4/80	sections	were	incubated	
with	biotinylated	rabbit-anti-rat	IgG	(Vector,	#BA-4000)	and	iNOs	and	CD206	sec-
tions	were	 incubated	with	Rabbit-Link	(Biogenex,	HK-326-UR).	All	sections	were	
afterwards	 incubated	 with	 Label	 (BioGenex,	 HK-321-UK)	 and	 freshly	 prepared	
new-fuchsin	was	used	as	substrate.	A	cell	was	considered	positive	when	stained	
red.
Synovial	inflammation	was	evaluated	using	the	histological	scoring	system	devised	
by	Krenn	et	al20.	To	determine	whether	HFD	had	an	effect	on	synovial	macrophage	
phenotype,	immunohistochemically	stained	samples	were	ranked	based	on	their	
relative	number	of	positive	cells	in	three	sections	per	sample	by	two	independent	
observers	 (WW	and	MS).	Scoring	and	ranking	were	performed	 for	each	marker	
separately	and	the	average	rank	for	each	sample	between	the	two	observers	was	
used	in	the	analysis.	
Paraffin	sections	of	subcutaneous	adipose	tissue	were	deparafinized,	treated	with	
proteinase	 k	 solution	 (Sigma-Aldrich)	 for	 antigen	 retrieval	 and	 followed	by	 the	
same	 immunohistochemical	staining	procedure	 for	F4/80	as	the	synovium.	Two	
independent	observers	 (WW	and	MS)	counted	 the	number	of	crown	 like	struc-
tures	per	area	of	random	100	adipocytes	for	3	sections	per	sample	and	the	average	
number	between	the	two	observers	was	used	in	the	analysis.
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Statistical analysis
Statistical	 analysis	 was	 performed	 in	 IBM	 SPSS	 statistics	 20	 (IBM	 Corporation,	
Armonk,	New	York,	USA).	The	Shapiro-Wilk	test	was	used	to	test	data	for	normality	
and	the	Levene’s	test	for	homogeneity	of	variance.	Histological	data	was	analyzed	
using	the	Mann-Whitney-U	test.	Weight,	serum	data	and	defect	filling	were	normally	
distributed	and	unless	otherwise	stated,	statistical	differences	between	diets	were	
determined	 using	 an	 unpaired	 T-test.	 Differences	 were	 considered	 statistically	
significant when p<0.05.
RESULTS
High fat diet accelerates cartilage repair early after cartilage damage
One	week	after	the	creation	of	the	defect,	in	mice	on	a	HFD,	spindle	shaped	cells	
had	partially	filled	the	defect	(Figure	1A).	A	higher	percentage	of	the	defect	was	
filled	in	the	mice	on	a	HFD	than	on	control	diet	(Figure	1A	and	D),	although	this	
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Figure 1 High	fat	diet	feeding	improves	cartilage	repair.	
10	weeks	old	male	DBA/1	mice	were	fed	with	control	or	high	fat	diet.	After	2	weeks	of	feeding,	full	thickness	
cartilage	defects	were	created.	A)	Representative	pictures	of	thionin	stained	knees;	non-operated,	1	weeks	and	
8	weeks	after	defect	creation,	B)	immunohistological	staining	with	antibodies	against	collagen	type	2,	8	weeks	
after	defect	creation.	This	is	the	from	the	same	knee	as	the	thionin	staining.	There	is	an	artifact	shown	in	the	
staining.	C)	Representative	pictures	of	thionin	stained	knees;	24	weeks	after	defect	creation	and	corresponding	
non-operated	knees,	D)	percentage	of	defect	filled,	E)	number	of	cells	 in	the	defect	per	100µm2,	F)	cartilage	
repair	evaluated	using	the	Pineda	scoring	method.	Values	are	mean	±	SD	(n=6-9	mice	per	group).
126 CHAPTER 7
was	not	statistically	significant	(Figure	1D;	95%	CI:	63-91%	versus	38-77%;	p=0.15).	
After	8	weeks,	almost	all	the	mice	had	filling	of	the	defect	(Figure	1D),	however	
only	the	HFD	fed	mice	had	defects	filled	with	chondrocyte-like	cells	surrounded	
with	positive	thionin	and	collagen	type	2	staining	(Figure	1A	and	B).	In	addition,	
the	number	of	cells	 in	 the	defect	was	higher	 in	HFD	 fed	mice	compared	 to	 the	
control	mice	(Figure	1E).	Finally,	the	Pineda	score	was	lower	1	week	(p=0.04)	and	8	
weeks	(p=0.01)	after	operation	in	mice	on	a	HFD	compared	to	control	diet	(Figure	
1F	and	Table	1).
Table 1 High	fat	diet	improves	cartilage	repair
Control	diet High	fat	diet
F R M C Total F R M C Total
1	week 2.0	
(±1.1)
2.0	
(±0.0)
3.4	
(±0.7)
3.1	
(±0.9)
10.5	
(±1.4)
1.3	
(±0.5)
2.0	
(±0.0)
2.7	
(±0.8)
2.3	
(±0.5)
8.5 
(±0.7)
8	weeks 0.8	
(±0.8)
1.9	
(±0.3)
3.1	
(±0.3)
2.8	
(±0.4)
8.7	
(±1.3)
0.8	
(±1.3)
1.3	
(±0.7)
2.0 
(±1.1)
2.1	
(±1.3)
5.3 
(±3.0)
24	
weeks
0.8	
(±0.8)
1.2	
(±0.4)
1.9	
(±0.9)
2.1	
(±1.0)
6.0	
(±2.4)
0.8	
(±0.8)
1.8	
(0.4)
2.2	
(0.8)
2.2	
(0.8)
7.0	
(±2.0)
Cartilage	repair	evaluated	using	the	Pineda	scoring	method.	The	different	components	of	the	Pineda	scoring	
method	are	showed.	Lower	score	represents	better	cartilage	repair	results.	F:	Filling	of	the	defect	(-1-4),	R:	Re-
construction	of	osteochondral	junction	(0-2),	M:	Matrix	staining	(0-4)	and	C:	Cell	morphology	(0-4).	Values	are	
mean	(±SD).	Bold	indicates	p<0.05	versus	Control	diet.	
High fat diet does not cause major systemic or local metabolic and 
inflammatory changes in DBA/1 mice
24	hours	before	 the	operation,	high	 fat	diet	 fed	mice	were	heavier	 (26.2	grams	
versus	23.3	grams;	p=0.004)	and	had	higher	serum	glucose	(p=0.01)	than	mice	re-
ceiving	a	control	diet	(Figure	2A-B).	Serum	insulin	and	amyloid	were	not	different	
between	the	two	groups.	Eight	weeks	after	the	operation	the	mice	on	HFD	were	
still	heavier	and	had	higher	fasting	serum	glucose,	although	the	glucose	level	was	
not	different	from	1	week	after	operation.	(Figure	2B).	Serum	insulin	and	amyloid	
A	were	not	affected	by	HFD	(Figure	2C	and	D).	As	seen	on	histology,	HFD	induced	
adipocyte	hypertrophy	(Figure	2E).	There	was	less	than	one	crown	like	structure	
(CLS)	per	100	adipocytes	and	there	was	no	significant	difference	between	control	
and	HFD	fed	mice.	Finally,	we	investigated	whether	HFD	influenced	local	inflamma-
tion	in	the	joint	and	specifically	the	synovium.	The	synovium	was	more	inflamed	1	
week	after	the	operation	compared	to	8	weeks	(Figure	3A-B).	There	was	no	detect-
able	synovial	inflammation	in	the	non-operated	knees.	No	statistically	significant	
effect	of	the	HFD	on	synovitis	and	rank	of	F4/80,	iNOS	or	CD206	positive	cells	was	
detected	(Figure	3B-E).	
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Long term effects of high fat diet and cartilage damage in DBA/1 mice
Long	term	feeding	with	HFD	significantly	increased	the	weight	of	the	mice	(Figure	
2A,	41.1	grams	versus	30.3	grams;	p=0.008),	but	did	not	influence	serum	metabolic	
and	 inflammatory	markers	(Figure	2B-D).	A	small	 loss	of	 thionin	staining	of	 the	
cartilage	 surrounding	 the	defect	 in	 the	operated	knees	was	visible	 (Figure	1C).	
There	was	however	no	major	cartilage	loss	or	structural	changes	indicating	os-
teoarthritis	after	24	weeks	in	the	operated	knees,	not	even	in	combination	with	a	
HFD	(Table	2,	Figure	1C).	There	was	no	cartilage	loss	in	the	non-operated	knees	
(Figure	1C,	Table	2)
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Figure 2 High	fat	diet	increases	body	weight,	but	does	not	cause	major	systemic	metabolic	and	
inflammatory	changes	in	DBA/1	mice.	
Mice	were	fasted	for	4	hours	prior	to	serum	collection.	A)	Body	weight	of	the	mice.	Fasting	serum	B)	glucose,	C)	
insulin	and	D)	amyloid	A	at	1,	8	and	24	weeks	after	operation.	Timepoint	0	represents	24	hours	before	operation.	
E)	Representative	pictures	of	subcutaneous	adipose	tissue	stained	with	antibodies	against	F4/80	at	8	weeks	af-
ter	operation.	Positive	cells	are	indicated	with	arrows.	Bar	values	are	mean	±	SD	(n=6-9	mice	per	group).	*p<0.01	
versus	control	diet.	**p<0.05	versus	control	diet.
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DISCUSSION
Obesity,	a	major	risk	 factor	 for	 joint	diseases9,	has	been	reported	to	negatively	
influence the clinical results of cartilage repair procedures6;21.	The	present	study	is	
to	our	knowledge	the	first	one	that	investigated	the	direct	effect	of	a	HFD	induced	
weight	 gain	 on	 intrinsic	 repair	 of	 cartilage	 defects	 in	 an	 experimental	 mouse	
model	 for	 cartilage	 repair.	 In	 contrast	 to	our	hypothesis,	mice	on	a	HFD	had	a	
better	Pineda	score	than	the	mice	on	a	control	diet.	This	difference	was	already	
detectable	1	week	after	making	the	defect,	but	became	more	obvious	after	8	weeks.	
We	could	not	detect	a	significant	difference	in	cartilage	repair	anymore	between	
the	two	diet	groups	after	24	weeks,	suggesting	that	HFD	only	accelerated	and	not	
improved	cartilage	repair.
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Figure 3 High	fat	diet	does	not	influence	operation	induced	synovial	inflammation.	
A)	Representative	pictures	of	synovium	with	immunohistochemical	staining	with	antibodies	against	F4/80,	iNOS	
and	CD206,	1	and	8	weeks	after	operation.	B)	Synovitis	score	and	ranking	score	of	positive	cells	for	C)	F4/80,	D)	
iNOS	and	E)	CD206.	Bar	values	are	mean	±	SD		(n=6-9	per	group).	#p<0.01	versus	non-operated	knees
Table 2: Long	term	effects	of	high	fat	diet	on	osteoarthritis	development.
Control	diet High	fat	diet P-Value
Modified	Mankin	score	
(non-operated	knee)
0	(No	OA) 0	(No	OA) 1.0
Modified	Mankin		score	
(operated	knee)
1.5	(±0.5) 1.7	(±0.5) 1.0
P-Value p<0.01 p<0.01
Osteoarthritis	scores	24	weeks	after	operation.	Values	are	mean	(±	SD)	(n=6	mice	per	group)
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Previous	reports	on	HFD	have	all	shown	detrimental	effects	of	an	HFD	on	cartilage.	
Wu	et	al12	showed	that	HFD	reduced	ear	wound	healing	and	accelerated	the	pro-
gression	to	OA	after	destabilization	of	the	medial	meniscus.	Louer	et	al10 showed 
that	HFD	accelerated	post-traumatic	arthritis.	However,	these	studies	used	young	
adult	C57BL/6	mice	and	this	strain	of	mice,	in	contrast	to	DBA/1	mice,	does	not	
possess cartilage repair capabilities16;22;23	Next	to	DBA/1	mice,	MRL/MpJ	mice	are	
known	to	possess	cartilage	repair	capabilities24;25.	Interestingly,	these	mice	gained	
weight	and	 fat	mass,	but	did	not	develop	 the	major	metabolic	changes	seen	 in	
C57BL/6	mice	after	being	fed	a	HFD17;26.	Our	mice	gained	weight,	even	only	after	2	
weeks	of	HFD	and	continued	to	increase	weight	during	the	24	weeks	of	the	study,	
but	did	not	develop	major	metabolic	changes.	This	suggests	 that	 the	degree	of	
metabolic	response	to	HFD	and	ability	to	repair	cartilage	damage	might	be	associ-
ated.
Individual	differences	 in	 response	 to	being	obese	are	 also	known	 in	humans.	
Accumulation	of	macrophages	in	crown	like	structures	(CLS)	in	obese	subjects	is	
associated	with	hyperinsulinemia	and	 increased	systemic	 inflammation27;	 28 and 
metabolically	healthy	obese	subjects	do	not	have	these	CLS	in	their	adipose	tis-
sue.	The	absence	of	CLS	in	the	adipose	tissue	of	the	DBA/1	mice	on	a	HFD	again	
indicates	that	the	DBA/1	mice	are	resistant	to	HFD-induced	metabolic	and	inflam-
matory	changes.	
Previously	we	have	shown	that	the	level	of	inflammatory	response	to	a	HFD	was	
associated	with	the	development	of	OA29.	An	initial	higher	inflammatory	response	
in	CRP-C57BL/6	mice	to	a	HFD	with	increased	serum	levels	of	human	C-reactive	
protein	(hCRP)	was	correlated	to	OA	development.	Furthermore,	rosiglitazone,	a	
peroxisome	proliferator-activated	receptors	(PPAR)γ	agonist	with	anti-inflamma-
tory	 properties,	 decreased	HFD	 associated	 inflammation	 and	OA	development,	
even	though	it	increased	weight	gain	in	these	mice.	In	the	present	study,	HFD	did	
not	induce	systemic	and	local	inflammatory	changes	in	male	DBA/1	mice	based	on	
the	serum	amyloid	A	measurements	and	immunohistological	staining	for	macro-
phages	in	the	synovium	and	adipose	tissue.	These	mice	also	did	not	develop	more	
OA,	even	in	the	presence	of	a	cartilage	defect.	This	again	suggests	that	susceptibil-
ity	to	developing	inflammatory	changes	might	be	associated	to	the	development	
of	OA.	However,	this	may	only	account	for	HFD	induced	inflammatory	changes,	be-
cause	inhibition	of	spontaneous	occurring	obesity	related	inflammatory	changes	
in	STR/Ort	mice	with	fenofibrates	did	not	inhibit	the	development	of	OA30.	
The	male	DBA/1	mice	on	a	control	diet	in	our	study	showed	cartilage	repair	after	
8	weeks,	albeit	not	to	the	same	degree	as	described	by	Eltawil	et	al16.	Although	
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the	mice	used	were	of	the	same	DBA/1OlaHsd	strain	from	the	same	company,	we	
have	made	the	defects	at	the	age	of	12	weeks	instead	of	8	weeks,	as	in	the	study	
by	Etawil	et	al.	Intrinsic	cartilage	repair	capabilities	might	have	been	reduced	with	
increasing	age,	however	younger	DBA/1	mice	would	very	likely	have	adapted	to	
a	HFD	and	not	gained	weight11.	The	choice	to	use	12	weeks	old	DBA/1	mice	might	
make	translation	of	the	results	of	our	study	to	older	individuals	difficult.	However,	
the	current	model	has	limited	us	not	to	use	older	mice.	Finally,	we	used	D12450B	
as	 the	 control	 diet	 as	 advised	by	 the	diet	manufacturer	 (Research	Diets).	This	
control	diet	contains	10%	kcal	 from	fat	and	35%	kcal	 from	sucrose.	Eltawil	et	al	
used	chow	which	has	lower	amount	of	kcal	from	sucrose.	We	cannot	exclude	that	
the	high	sucrose	could	have	reduced	cartilage	repair.	
Furthermore,	cartilage	repair	could	be	influenced	by	weight	bearing	activities	
after surgery31.	Although	it	has	been	shown	that	HFD	does	not	influence	activity	
level	in	C57BL/6	mice,	we	cannot	exclude	that	HFD	could	have	influenced	activity	
level	of	the	mice	in	our	study12.
Although	 HFD	 had	 no	 effect	 on	 inflammation,	 it	 slightly	 increased	 the	 serum	
glucose	before	creation	of	the	defect	and	serum	glucose	levels	remained	higher	
8	weeks	after	the	defect	was	made.	This	higher	glucose	level	may	have	improved	
the	initial	cartilage	repair	process	after	cartilage	damage,	because	differentiation	
to	 chondrocytes	 and	 synthesis	 of	 extracellular	matrix	 requires	 a	 large	 amount	
of	 nutrients.	An	 abundance	of	 nutrients	might	 also	have	 increased	 the	 activity	
of	mammalian	target	of	rapamycin	(mTOR),	which	is	known	to	support	skeletal	
growth	and	extracellular	matrix	production32.	
However,	a	higher	mTOR	expression	in	cartilage	is	also	correlated	to	cartilage	
damage	 and	 mTOR	 inhibition	 by	 rapamycin	 could	 prevent	 post-traumatic	 OA	
development33.	 Increased	mTOR	 expression	 could	 have	 played	 a	 role	 in	 initial	
cartilage	repair	in	DBA/1	mice,	but	in	the	long	term	mTOR	might	have	been	sup-
pressed	to	increase	autophagy	and	protect	the	cartilage.	
Next	to	hyperglycemia,	a	HFD	can		lead	to	hypercholesterolemia.	Recently	it	has	
been	shown	 that	cholesterol	metabolism	and	cartilage	development	and	repair	
could	be	related.	Statins	are	used	to	reduce	serum	cholesterol	through	inhibition	
of	the	enzyme	HMG-CoA	and	statins	could	be	a	potential	therapy	for	developmen-
tal	diseases	such	as	achondroplasia	and	might	stimulate	chondrogenic	potential	
of	intervertebral	disc	cells.34;	35	However,	it	is	known	that	a	HFD	does	not	increase	
serum	total	cholesterol	in	male	DBA/1	mice	17.	It	could	be	that	the	enzyme	HMG-
CoA	or	another	enzyme	in	the	mevalonate	pathway	is	less	active	in	DBA/1	mice	
and	that	this	could	be	related	to	increased	cartilage	repair	in	this	mouse	strain.	
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Besides	 serum	 metabolic	 changes,	 cartilage	 repair	 could	 also	 be	 directly	
influenced	by	the	fat	content	of	HFD.	HFD	contains	mainly	saturated	and	mono-
unsaturated	fatty	acids	which	reduces,	rather	than	stimulates,	the	chondrogenic	
potential	of	MSCs	from	C57BL/6	mice15.	However,	MSCs	isolated	from	DBA/1	mice	
have	been	reported	to	have	a	better	chondrogenic	potential	than	those	isolated	
from	C57BL/6	mice36.	The	effect	of	HFD	on	MSC	chondrogenesis	could	therefore	be	
different	in	different	strain	of	mice.	
In	conclusion,	our	study	shows	that	HFD	and	increased	body	weight	in	the	DBA/1	
mice	 do	 not	 negatively	 impair	 cartilage	 repair,	 but	 can	 even	 accelerate	 it.	 The	
precise	mechanism	in	how	HFD	influences	cartilage	repair	in	DBA/1	is	unknown.	
However,	 our	 data	 suggests	 that	 resistance	 to	 HFD	 induced	 inflammatory	 and	
metabolic	 changes	 could	 be	 associated	 with	 accelerated	 cartilage	 repair	 and	
reduced	OA	susceptibility.	Further	research	is	necessary	to	elucidate	the	complex	
relationships	between	a	high	fat	diet,	metabolic	and	inflammatory	changes,	carti-
lage	degeneration	and	regeneration.	For	the	clinical	practice,	our	study	suggests	
that	not	all	obese	patients	should	be	excluded	 from	treatment.	 Investigation	of	
their	metabolic	and	inflammatory	state	could	be	helpful	in	making	the	decision	to	
start	cartilage	repair	treatments.
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SUMMARY AND GENERAL DISCUSSION
The	most	characteristic	changes	in	obesity	are	an	increase	in	adipose	tissue	mass	
and	adipose	 tissue	 inflammation.	This	 in	 turn	 leads	 to	 increased	 loading	of	 the	
joints	and	systemic	metabolic	and	inflammatory	changes.	Because	adipose	tissue	
is	 a	major	 contributor	 to	 the	 inflammation	 in	 obesity,	we	have	 focused	on	 the	
effect	of	adipose	tissue	on	different	tissue	in	the	knee	joint	and	cartilage	repair.	
LOCAL EFFECTS OF ADIPOSE TISSUE
The infrapatellar fat pad, an adipose tissue not changed by obesity
The	infrapatellar	fat	pad	(IPFP)	is	an	intra-articular	adipose	tissue	in	direct	contact	
with	the	synovium	membrane	and	can	therefore	influence	the	knee	joint	environ-
ment.	 It	can	play	an	role	 in	biomechanics	of	 the	knee,	act	as	a	shock	absorber	
and	is	a	reservoir	of	inflammatory	and	regenerative	cells1-3.	Adipose	tissue	in	gen-
eral	functions	as	a	reservoir	for	excess	nutrients	and	increases	in	size	in	obesity.	
However,	MRI	studies	suggest	that,	unlike	most	other	adipose	tissues	in	the	body,	
IPFP	size	is	not	correlated	to	body	mass	index	(BMI)4-6.	Furthermore,	unlike	in	sub-
cutaneous	and	visceral	adipose	tissue,	the	adipocyte	size	in	osteoarthritic	(OA)	
IPFP	was	not	correlated	to	BMI	(Chapter 2).	Besides	adipocyte	hypertrophy,	an	
increased	 infiltration	of	pro-inflammatory	macrophages	and	 formation	of	crown	
like	structures	in	adipose	tissue	are	generally	considered	to	be	characteristics	for	
obesity7.	However,	we	could	not	detect	a	difference	in	macrophage	infiltration	in	
IPFP	between	obese	and	non-obese	donors	in	our	previous	work8 nor in Chapter 
4.	An	in-vivo	study	in	high	fat	diet	fed	C57BL/6	mice	has	confirmed	our	finding	that	
adipocyte	size	and	infiltration	of	macrophages	are	not	changed	by	weight	gain9.	
Obesity	 increases	 secretion	 of	 pro-inflammatory	 factors	 such	 as	 TNFα,	 IL1β,	
MCP-1,	IL6	and	leptin	by	adipose	tissue10.	However,	we	have	previously	shown	by	
multiplex	ELISA	analysis	that	secretion	of	cytokines	by	OA	IPFP	is	not	associated	
to	BMI11.	Finally,	all	the	effects	the	IPFP	had	on	cartilage,	synovial	fibroblasts	and	
MSCs	were	not	correlated	to	BMI	(Chapter 3 and 4)8,.	This	all	suggests	that	IPFP,	
unlike	subcutaneous	and	visceral	adipose	tissue,		is	not	influenced	by	obesity.	
The IPFP and inflammation
Although	 the	 IPFP	seems	not	 to	be	 influenced	by	obesity,	 it	 could	still	become	
inflamed	after	joint	trauma	and	surgery12-14.	Inflammatory	cytokines	such	as	IL1β 
can	increase	the	secretion	of	inflammatory	factors	by	IPFP11.	With	more	inflamma-
tory	stimuli,	there	is	an	increased	secretion	of	inflammatory	factors	by	the	IPFP.	
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Because	the	synovium	does	not	have	a	basal	membrane,	the	only	barrier	for	mol-
ecules	between	the	synovial	fluid	and	the	IPFP	is	the	extracellular	matrix	(ECM)	
of	 the	synovial	 interstitium.	 In	this	case,	 the	smaller	 the	molecule,	 the	easier	 it	
can	freely	diffuse	through	the	synovial	interstitium15.	We	investigated	in	Chapter 
4	the	effect	of	IPFP	secreted	factors	on	cartilage	repair,	and	found	that	they	could	
inhibit	MSC-based	cartilage	repair.	Next	to	directly	influencing	the	repair	process,	
factors	secreted	by	 IPFP	also	 influence	the	synovium	membrane	by	stimulating	
pro-fibrotic processes (Chapter 3)	and	pro-catabolic	processes	in	synovial	fibro-
blasts16( Chapter 5).	In	turn,	this	can	lead	to	an	increase	in	inflammatory	factors	
in	the	synovial	fluid	and	further	deterioration	of	the	joint	environment	for	repair.	
Studies	 have	 shown	 an	 increased	 amount	 of	 pro-inflammatory	 cytokines	 such	
as	 IL1α/β,	 IL6,	 IL8,	 and	TNFα,	 in	 synovial	 fluids	 of	 patients	with	 focal	 cartilage	
defects17;	 18,	 ACL	 rupture19-21	 or	 OA22	 knees	 compared	 to	 healthy	 knees.	 Pro-
inflammatory	cytokines	such	as	IL1α/β,	IL6,	IL17,	IFNƴ,	TNFα,	MCP1	can	all	inhibit	
MSC	chondrogenesis23-26	 	and	increase	catabolic	processes	 in	the	synovium	and	
cartilage27.	Reduction	of	the	secretion	of	these	cytokines	by	the	IPFP	or	inhibiting	
the	effects	of	these	cytokines	could	be	promising	strategies	to	improve	the	joint	
environment	and	cartilage	repair.	One	should	be	careful	however	with	inhibition	
of	inflammation.	Studies	in	MRL/MpJ	mice,	who	possess	super	healing	capacities,	
have	shown	that	inflammation	is	necessary	for	successful	wound	healing28;	29.	Find-
ing	 the	 right	balance	between	sufficient	 inflammation	 to	 initiate	wound	healing	
and	reduce	chronic	inflammation	to	inhibit	catabolic	processes	is	necessary	for	
successful	cartilage	repair.	
The	IPFP	consists	mainly	of	adipocytes,	stem	cells	and	inflammatory	cells	such	as	
macrophages.	In	Chapter 4	we	have	shown	that	pro-inflammatory	macrophages	
in	 IPFP	contribute	to	the	anti-chondrogenic	effect	of	 IPFP.	Macrophages	play	an	
important	role	in	inflammation	and	tissue	repair.	Pro-inflammatory	macrophages	
secrete	TNFα,	IL1β	and	IL630	and	could	therefore	inhibit	cartilage	repair	in	vitro,	in-
duce catabolic processes in cartilage31	and	pro-fibrotic	processes	in	synovial	fibro-
blasts (Addendum figure 1).	An	animal	study	reports	that	ablation	of	all	synovial	
macrophages	could	inhibit	development	of	OA32.	Anti-inflammatory	macrophages	
however,	do	not	inhibit	cartilage	repair	(Chapter 4)33	and	might	be	even	beneficial	
to	cartilage	repair	in	vitro34.	Furthermore,	Axolotls,	which	are	known	to	be	able	
to	regenerate	 limbs,	cannot	regenerate	without	 the	presence	of	macrophages35.	
The	right	balance	between	pro-	and	anti-inflammatory	macrophages	seems	to	be	
crucial	for	successful	cartilage	repair.	In	Chapter 5	we	used	different	medications	
to	modulate	the	macrophages	inside	the	IPFP	towards	a	more	anti-inflammatory	
phenotype.	Of	the	medications	we	tested,	only	triamcinolone	acetonide	(TAA)	was	
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able	 to	 reduce	 inflammation	 in	 IPFP	and	modulate	 the	macrophages	 towards	a	
anti-inflammatory	phenotype.	The	anti-chondrogenic	and	pro-catabolic	effects	of	
the	IPFP	were	also	reduced	by	TAA.	This	suggests	that	modulation	of	macrophage	
phenotype	by	medication	might	 improve	 the	 joint	 environment	 to	 reduce	 joint	
disease	and	be	better	suitable	for	cartilage	repair.	
Although	 the	 adipocyte	 size,	 macrophage	 phenotype	 in	 and	 the	 secretion	 of	
inflammatory	cytokines	by	IPFP	are	not	influenced	by	obesity,	the	IPFP	remains	
a	large	source	of	inflammatory	factors	that	affects	the	joint	environment.	Next	to	
inflammatory	cytokines,	the	adipocytes	in	IPFP	secrete	many	adipokines	such	as	
leptin36,	adiponectin36,	resistin	and	visfatin11.	Leptin,	resistin	and	visfatin	stimulates	
catabolic processes in cartilage1,	synovium1	and	meniscus37.	The	role	of	adiponec-
tin	is	not	yet	fully	understood.	Adiponectin	increases	ATDC5-cell	proliferation	and	
chondrogenesis38,	however	it	is	also	associated	with	cartilage	damage	in	OA	and	
could	increase	MMP13	activity	and	PGE2	release	in	OA	chondrocytes39.	However	
blocking	adiponectin	and	 leptin	did	not	 inhibit	 the	pro-catabolic	effects	of	 IPFP	
on	 OA	 chondrocytes	 and	 synovial	 fibroblasts36.	 The	 effect	 of	 these	 adipokines	
on	MSC	chondrogenesis	is	still	unknown,	but	reduction	of	catabolic	processes	in	
general	would	eventually	benefit	the	joint	environment.	Glucocorticoids	modulate	
adipokines	secretion	by	adipose	tissue40-42.	Therefore,	the	reduction	of	catabolic	
processes in Chapter 5	by	 treatment	with	TAA	could	also	have	 taken	place	via	
modulation	of	adipokine	secretion	by	the	IPFP,	next	to	modulation	of	macrophages	
and	their	secretion	profile.	
The	IPFP	and	adipocytes	also	release	prostaglandins.	Prostaglandins	are	a	group	
of	lipids	that	play	an	important	role	in	inflammation43,	cartilage	metabolism44;45 and 
pathogenesis	of	OA46;47.	In	Chapter 3	we	describe	that	prostaglandin	F2α	(PGF2α)	
secreted	 by	 IPFP	 is	 involved	 in	 pro-fibrotic	 processes	 in	 synovial	 fibroblasts.	
However,	PGF2α	does	not	inhibit	MSC	chondrogenesis	(Addendum figure 2),	but	
even	enhances	chondrogenesis	in	ATDC5	cells45	and	matrix	deposition	by	articular	
chondrocytes44.	Next	to	PGF2α,	the	IPFP	also	secretes	prostaglandin	E2	(PGE2)48;	49,	
which	 stimulates	pro-catabolic	 processes	 in	 synovial	 fibroblasts48.	 Inhibition	of	
prostaglandin	secretion	 is	possible	through	inhibition	of	cyclooxygenase	(COX)	
activity.	Non-specific	COX	inhibitors	such	as	non-steroid	anti-inflammatory	drugs	
(NSAIDs)	 and	 specific	COX-2	 inhibitors	 such	 as	 celecoxib	 are	 already	 clinically	
used	to	reduce	inflammation	and	the	symptoms	of	OA.	Although	COX	inhibition	
could be beneficial to reduce pro-fibrotic and catabolic processes47,	non-specific	
COX-inhibition	also	inhibits	MSC	chondrogenesis50.	On	the	other	hand,	a	specific	
COX-2	inhibitor	is	less	detrimental	to	chondrogenesis50-52.	Therefore,	specific	COX-2	
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inhibitors	such	as	celecoxib	are	possible	candidates	to	improve	the	joint	environ-
ment	for	cartilage	repair.	Surprisingly,	celecoxib	did	not	reduce	IPFP	inflammatory	
genes	expression	in	Chapter 5	and	because	reduction	of	general	IPFP	inflammation	
is	important	to	improve	the	joint	environment,	we	did	not	further	investigate	the	
effects	of	celecoxib	on	cartilage	repair.	 In	Chapter 5	we	demonstrated	a	reduc-
tion	 in	anti-chondrogenic	and	pro-catabolic	effects	of	 IPFP	after	 treatment	with	
TAA.	TAA	is	an	often	used	glucocorticoid	and	glucocorticoids	are	known	to	inhibit	
prostaglandin synthesis53.	However,	it	also	inhibits	other	pro-inflammatory	path-
ways	and	therefore	targeting	prostaglandin	synthesis	alone	might	be	insufficient	
to	improve	the	joint	environment	for	cartilage	repair.		
Next	to	prostaglandins,	there	are	also	other	lipids	in	the	synovial	fluid	of	the	knee	
joint49;54.	One	group	of	 lipids	are	 the	 fatty	acids	and	 these	 fatty	acids	are	being	
extensively	studied.	Fatty	acids	can	stimulate	or	inhibit	inflammatory	processes55 
and	 influence	 cartilage	 loss	 in	 OA	 cartilage56.	 An	 increased	 intake	 of	 omega-3	
fatty	acids	could	decrease	chronic	inflammation57 and dietary fatty content could 
regulate	wound	healing	in	mice58.	It	is	therefore	interesting	to	investigate	whether	
changing	diet	is	a	possible	strategy	to	modulate	IPFP	inflammation	and	thereby	
improve	cartilage	 repair	procedures.	 Furthermore,	 future	 research	could	be	 fo-
cused	on	using	medications	to	modify	the	levels	of	specific	types	of	fatty	acids	and	
in	that	way	influence	cartilage	repair.	In	Chapter 5	we	used	statins	and	fibrates,	
two	often	used	serum	lipid	lowering	drugs,	to	reduce	IPFP	inflammation.	However,	
we	did	not	see	an	effect	on	IPFP	inflammatory	genes	expression.	These	medica-
tions	are	known	to	reduce	systemic	inflammation	so	they	could	still	be	useful	in	
improving	 the	general	 joint	health	during	cartilage	repair	procedures,	although	
more	investigation	is	necessary.	
Removal of the IPFP 
Instead	of	modulation	of	the	IPFP,	it	is	also	possible	to	surgically	remove	the	IPFP2.	
During	total	knee	arthroplasty,	the	IPFP	is	often	removed	to	improve	visibility	dur-
ing the surgical procedure59;60.	However	the	removal	of	the	IPFP	during	total	knee	
arthroplasty is under debate61 because it is associated with shortened patellar 
tendon	and	anterior	knee	pain.	Even	subtotal	removal	of	 the	 IPFP	with	arthros-
copy could lead to patellar tendon shortening60;62-64.	This	supports	the	theory	that	
the	IPFP	has	a	mechanical	function	that	is	necessary	for	proper	joint	movement.	
Besides	adipocytes	and	macrophages,	there	are	also	MSCs	in	the	IPFP65-67.	These	
MSCs	have	been	shown	to	have	chondrogenic66;67	as	well	as	immunomodulatory68 
capacities	 and	 some	 authors	 have	 proposed	 to	 use	 these	MSCs	 in	MSC-based	
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cartilage repair procedures66;69.	It	might	also	be	possible	that	MSCs	from	the	IPFP	
migrate	to	a	cartilage	defect	and	contribute	to	repair,	although	currently	there	is	
no	study	that	have	shown	this.	MSCs	from	the	bone	marrow70	and	synovial	mem-
brane71	could	migrate	towards	a	cartilage	defect.	Peripheral	mononucleated	cells	
migrate	from	the	blood	circulation	to	a	cartilage	defect	in	rats72,	so	future	research	
might	show	that	MSCs	from	IPFP	could	also	do	this.
Furthermore,	we	have	previously	shown	that	OA	IPFP	conditioned	medium	inhib-
its	catabolic	mediators	in	bovine	cartilage8.	This	means	that	the	effect	of	IPFP	on	
the	separate	joint	structures	could	be	different.	Hence,	complete	removal	of	the	
IPFP	could	change	the	joint	environment	too	much	and	remove	the	beneficial	cells	
in	the	IPFP	that	might	contribute	to	successful	cartilage	repair	in	the	knee.	
Other intra-articular adipose tissues
Most	synovial	joints	have	adipose	tissue	filling	the	synovial	folds	around	the	ar-
ticular	margin.	These	fat	depots	possibly	act	as	cushions	during	joint	movement73.	
Although	the	IPFP	is	the	largest	intra-articular	adipose	tissue,	it	is	not	the	only	one	
in	the	knee.	In	the	knee	there	are	also	the	supra-patellar	fat	pad,	located	beneath	
the	quadriceps	tendon74;75,	and	the	pre-femoral	fat	pad,	located	at	the	anterior	side	
of	the	femur.	Signal	alterations	on	MRI	of	these	fat	pads	are	associated	to	synovi-
tis,	anterior	knee	pain	and	structural	abnormalities74;76;77.	Due	to	their	proximity	
to	the	IPFP	and	because	they	are	in	contact	with	the	same	synovial	synovial	fluid,	
it	might	be	expected	that	the	same	inflammatory	signals	that	would	influence	the	
IPFP	would	also	influence	these	fat	pad	depots.	
Besides	 the	 knee,	 the	 ankle	 and	 the	 hip	 also	 have	 an	 intra-articular	 adipose	
tissue.	In	the	ankle	it	is	called	the	Kager’s	fat	pad	and	is	located	posterior	to	the	
ankle	joint,	anterior	to	the	Achilles	tendon78.	The	Kager’s	fat	pad	is	also	known	as	
the	pre-Achilles	 fat	pad.	Trauma	to	 the	calcaneus	or	Achilles	 tendinopathy	can	
influence	the	Kager’s	fat	pad78;79.	The	intra-articular	adipose	tissue	in	the	hip	has	
only been recently described80	and	is	similar	to	the	IPFP	in	tissular	phenotype81.	
Not	much	 is	known	about	this	adipose	tissue,	but	 it	can	become	 impinged	and	
cause	pain	during	hip	movement80.
With	more	understanding	of	the	role	of	these	other	intra-articular	adipose	tis-
sues,	we	might	improve	our	understanding	of	the	role	of	the	IPFP	in	the	knee	joint.	
Furthermore,	these	other	intra-articular	adipose	tissue	might	also	be	targeted	to	
modify	the	joint	environment.	
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SYSTEMIC EFFECTS OF ADIPOSE TISSUE  
Besides	the	local	effects	of	adipose	tissue	on	joint	disease	and	repair,	the	systemic	
effects	 has	 also	been	 a	 focus	 of	 investigation.	 Especially	 the	 systemic	 changes	
that	occur	in	obesity	is	being	extensively	studied.	Obesity	increases	the	chance	
of	 developing	 the	 metabolic	 syndrome,	 which	 is	 characterized	 by	 low	 grade	
systemic	inflammation,	dyslipidemia,	hyperinsulinemia	and	hyperglycemia.	Meta-
bolic	syndrome	has	been	shown	to	be	a	risk	factor	for	the	development	of	OA82;	83.	
Obesity	and	the	resulting	metabolic	syndrome	are	caused	by	an	interplay	between	
behavioral,	 environmental	 and	 genetic	 factors84;	 85.	 Although	our	work	 suggests	
that	 the	 IPFP	 is	 possibly	 not	 influenced	by	 obesity,	 subcutaneous	 and	 visceral	
adipose	tissues	become	inflamed	due	to	obesity86.	In	adipose	tissue	inflammation,	
there	 is	more	 infiltration	of	pro-inflammatory	macrophages,	 formation	of	crown	
like	structures	and	there	is	an	increase	in	secretion	of	inflammatory	factors	such	
as	TNFα,	IL1β,	MCP-1,	IL6	and	leptin86.	To	investigate	the	effect	of	metabolic	and	in-
flammatory	systemic	changes	on	joint	disease	and	cartilage	repair,	we	performed	
two	in-vivo	studies	with	mice.	
Obesity related metabolic and inflammatory changes on cartilage 
damage
In Chapter 6	we	used	the	STR/Ort	strain	of	mice.	These	mice	develop	metabolic	
and	 inflammatory	changes	spontaneously	on	a	normal	diet	 (Chapter 6,87).	This	
is	not	caused	by	overeating	as	compared	to	the	OB/OB	strain	of	mice,	which	due	
to	their	leptin	deficiency,	does	not	stop	eating88.	Next	to	developing	spontaneous	
metabolic	syndrome89,	male	STR/Ort	mice	are	also	known	to	develop	spontaneous	
cartilage	damage90.	This	mouse	model	 therefore	 seemed	 to	us	very	well	 suited	
to	 investigate	 whether	 development	 of	 spontaneous	 metabolic	 syndrome	 and	
cartilage	damage	are	linked	and	whether	cartilage	damage	could	be	prevented.	In	
Chapter 6	we	fed	male	STR/Ort	mice	chow	mixed	with	simvastatin	and	fenofibrate.	
These	two	lipid	 lowering	medications	are	commonly	used	to	treat	dyslipidemia	
and	 to	 reduce	 cardiovascular	morbidity	 and	mortality91;92.	 Statin	 use	 has	 been	
associated	with	decreased	incidence	and	progression	of	knee	OA93.	Furthermore,	
statins	and	fibrates	also	reduce	systemic	inflammation94;95.	In	Chapter 5	we	have	
shown	that	statins	and	fibrates	did	not	reduce	IPFP	inflammation,	suggesting	that	
these	medications	might	only	have	systemic	effects.	In	our	in-vivo	study,	The	STR/
Ort	mice	developed	dyslipidaemia	and	simvastatin	and	fenofibrate	did	not	have	
an	effect	on	dyslipidaemia	 in	 these	mice.	Fenofibrate	 reduced	weight,	 systemic	
inflammation	and	volume	of	subchondral	bone,	whereas	simvastatin	did	not	have	
an	effect.	However,	 in	contrast	 to	what	we	expected,	cartilage	damage	was	not	
reduced	by	these	two	medications.	Our	results	suggest	that	development	of	car-
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tilage	damage	in	STR/Ort	mice	is	not	primarily	linked	to	metabolic	inflammation,	
but	is	multi-factorial.	This	shows	that	a	combination	of	metabolic	inflammatory	
changes	 and	genetic	predisposition	 are	 the	 cause	of	 cartilage	damage	 in	 these	
mice.	This	also	suggest	that	being	obese	does	not	always	lead	to	cartilage	damage.	
Obesity and cartilage repair 
When	cartilage	damage	have	occurred	in	obese	patients,	we	need	to	repair	it	to	
prevent	the	development	of	OA.	The	clinical	results	of	cartilage	repair	in	obese	pa-
tients	is	worse,	but	there	is	no	information	on	the	structural	outcomes.	In	Chapter 
7	we	investigated	whether	a	high	fat	diet	(HFD)	induced	obesity	reduces	cartilage	
repair	in	DBA/1	mice.	Surprisingly,	the	HFD	did	not	negatively	influence	cartilage	
repair,	but	even	accelerated	it.	This	was	in	contrast	to	common	knowledge	and	
what	we	hypothesized.	Furthermore,	although	these	mice	are	known	to	be	resistant	
to	OA	development	after	cartilage	damage,	they	did	not	even	develop	OA	after	car-
tilage	damage	in	combination	with	a	HFD.	The	DBA/1	mice	on	a	HFD	gained	weight,	
but	did	not	have	serum	inflammatory	and	metabolic	changes.	Furthermore,	the	
subcutaneous	adipocytes	of	these	mice	on	a	HFD	became	hypertrophic,	but	there	
was	no	increased	infiltration	of	macrophages	nor	formation	of	crown	like	struc-
tures.	This	is	in	stark	contrast	to	the	STR/Ort	mice	we	used	in	Chapter 6,	which	
developed	 metabolic	 and	 inflammatory	 changes	 spontaneously.	 This	 suggests	
that	resistance	to	HFD	induced	inflammatory	and	metabolic	changes	is	associated	
with	accelerated	cartilage	repair	and	reduced	OA	susceptibility.	In	humans,	some	
individuals	 are	 prone	 to	 development	 of	metabolic	 syndrome84,	 but	 some	 also	
gain	weight	and	become	obese,	but	do	not	develop	the	accompanying	metabolic	
and	 inflammatory	changes.	This	group	of	obese	 individuals,	 also	known	as	 the	
metabolic	 healthy	 obese,	 are	 often	 characterized	 by	 less	 serum	 inflammation,	
less	visceral	fat,	less		macrophage	infiltration	in	adipose	tissue	and	less	adipocyte	
hypertrophy96;97.	It	remains	inconclusive	whether	the	risk	of	cardiovascular	heart	
disease	is	different	 in	this	group	of	 individuals97	compared	to	obese	individuals	
with	metabolic	changes.	Furthermore,	it	is	unknown	whether	these	individuals	are	
protected	from	joint	disease	or	have	improved	repair	capabilities.	Future	research	
investigating	whether	these	individuals	are	protected	against	joint	disease	or	have	
improved	repair	might	provide	us	with	new	treatment	targets.	
The	 results	 of	 our	 two	 in-vivo	 studies	 indicate	 that	 the	 link	 between	 obesity	
related	metabolic	and	inflammatory	changes,	degenerative	joint	disease	and	car-
tilage	repair	 is	complex.	Furthermore,	there	is	heterogeneity	in	 individuals	who	
are	obese.	A	study	by	Green	et	al	has	shown	that	there	are	multiple	types	of	obese	
individuals,	who	all	have	their	specific	causes	for	obesity	and	related	diseases98.	
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The	authors	have	concluded	that	treatment	strategies	for	obesity	should	not	tar-
get	obese	individuals	as	a	whole,	but	subgroup	specific	strategies	should	be	used.	
To	better	understand	how	obesity	influences	the	joint,	it	is	therefore	important	to	
take	into	account	this	heterogeneity	of	obesity.	Repetition	of	our	in-vivo	studies	
using	different	animal	models	should	take	this	heterogeneity	into	account.	
FUTURE PERSPECTIVES
Obesity, adipose tissue and the joint environment  
Adipose	tissue	is	not	only	a	storage	site	for	excess	energy,	but	is	also	an	endocrine	
organ,	which	secretes	large	amounts	of	immunological,	endocrine	and	hormonal	
factors.	Adipose	tissue	inflammation	plays	an	important	role	in	the	pathophysi-
ology	of	metabolic	dysregulation	 in	obesity.	Much	 is	known	about	 the	changes	
that	occur	in	subcutaneous	and	visceral	adipose	tissue	in	obesity.	Less	is	known,	
however,	about	obesity	related	changes	in	intra-articular	adipose	tissue.	Obesity	
is	a	well-known	risk	factor	for	joint	diseases	and	has	been	extensively	studied	in	
animal	and	clinical	studies.	Due	to	the	intra-articular	location	of	IPFP,	it	has	long	
been	 thought	 that	 the	 IPFP	would	play	an	 important	 role	 in	obesity	associated	
joint	inflammation.	However,	we	have	shown	that	the	IPFP	might	not	be	influenced	
by	obesity	and	that	obesity	causes	degenerative	joint	diseases	via	other	pathways	
and	not	via	IPFP	inflammation.	This	could	be	through	increased	systemic	inflam-
mation	or	metabolic	dysregulation	due	to	inflammation	of	the	bigger	subcutane-
ous	and	visceral	adipose	tissue	depots.	
However,	the	effects	of	obesity	could	vary	between	individuals.	We	have	now	shown	
in	animal	studies	that	obesity	is	not	always	negative	or	the	relationship	between	the	
changes	caused	by	obesity	on	degenerative	joint	disease	is	not	always	completely	
clear.	The	obesity	epidemic	will	only	increase	in	the	future	and	research	will	con-
tinue	 in	this	field.	New	targets	 for	strategies	to	 improve	the	 joint	environment	 in	
obesity	might	be	found	in	research	focusing	on	subgroups	of	individuals	who	are	
less	susceptible	to	developing	obesity	related	changes.	It	would	be	interesting	to	
investigate	whether	these	individuals	are	also	protected	against	joint	diseases.
Modulation of the infrapatellar fat pad to improve the joint 
environment for cartilage repair
Irrespectively	to	the	effects	of	adipose	tissue	related	systemic	changes	have	on	the	
local	 joint	environment,	 the	 IPFP	secretes	a	 large	amount	of	different	adipokines	
and	fatty	acids.	These	individual	factors	might	have	anabolic	or	catabolic	effects	on	
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different	joint	structures.	With	in-vitro	experiments	using	IPFP	conditioned	medium,	
we	have	shown	what	the	effects	are	of	IPFP	secreted	factors	on	the	joint.	Further-
more,	we	have	shown	that	we	can	modulate	in-vitro	the	secretion	of	factors	by	the	
IPFP	and	the	resident	macrophages	with	a	commonly	used	glucocorticoid.	The	next	
step	could	be	an	in-vivo	animal	study	to	test	the	hypothesis	that	using	TAA	the	IPFP	
can	be	modulated	 to	be	beneficial	 for	 the	 joint	 environment.	Most	 experimental	
studies	on	the	effect	of	inflammatory	modulation	on	joint	disease	are	first	performed	
in	 rodents.	However,	 due	 to	 the	 small	 size	of	 the	 rodent	 knee,	 specific	 targeting	
the	IPFP	is	difficult,	although	not	impossible.	Future	experiments	using	canine	or	
ovine	models	could	be	considered	to	investigate	whether	IPFP	modulation	would	be	
feasible	to	improve	the	joint	environment	for	cartilage	repair.		It	would	also	be	pos-
sible	to	directly	perform	a	human	study,	because	TAA	is	currently	already	injected	
intra-articularly	 as	 an	 anti-inflammatory	 treatment.	The	next	 step	would	only	be	
injection	of	a	dosage	of	TAA	in	the	IPFP	following	microfracture	surgery.	
Currently,	 the	effect	of	different	 intra-articular	strategies	using	pharmacological	
drugs	and	immuno	modulator	cells	is	being	studied	for	use	to	improve	the	joint	
environment	for	cartilage	repair	or	directly	influence	cartilage	repair	itself99.	Next	
to	 the	effect	on	cartilage	 repair,	 the	effect	of	 these	 intra-articular	 strategies	on	
synovium	is	also	important.	The	synovium	can	become	inflamed	and	is	a	source	of	
catabolic	and	anti-chondrogenic	factors.	On	the	other	hand,	with	the	experiments	
performed	in	this	thesis,	we	have	shown	that	the	IPFP	is	an	important	tissue	in	
the	joint	environment	as	well.	The	IPFP	can	stimulate	catabolic	processes	in	the	
synovium,	although	this	could	also	be	vice-versa,	where	synovium	inflammation	
could	stimulate	catabolic	processes	in	the	IPFP.	Nevertheless,	it	is	possible	that	
any	future	intra-articular	therapy	administered	could	influence	the	IPFP	and	via	
the	 IPFP	 influence	 the	 synovium.	 Therefore,	 IPFP	 changes	 should	 be	 carefully	
monitored	during	experimental	treatments	and	reduction	of	inflammation	in	the	
IPFP	could	be	considered	as	one	of	the	secondary	outcomes.	
Concluding remarks 
In	conclusion,	this	thesis	shows	that	the	IPFP	is	not	an	ordinary	adipose	tissue	and	
that	it	secretes	specific	factors	that	locally	influence	the	knee	joint	and	cartilage	
repair.	In	the	future,	it	is	possible	to	use	medication	to	specifically	modulate	the	
IPFP	to	improve	the	joint	environment	for	cartilage	repair.	Furthermore,	this	thesis	
provides	evidence	that	there	is	variability	in	how	obesity	related	systemic	effects	
can	affect	degenerative	 joint	disease	and	cartilage	repair.	Future	studies	on	the	
relationship	between	obesity,	adipose	tissue	and	cartilage	repair	could	focus	on	
this	variability	to	uncover	novel	therapeutic	targets.	
148 CHAPTER 8
REFERENCES
1.	 Clockaerts	S,	Bastiaansen-Jenniskens	YM,	Runhaar	J,	et	al.	2010.	The	infrapatellar	fat	pad	should	
be	considered	as	an	active	osteoarthritic	joint	tissue:	a	narrative	review.	Osteoarthritis	Cartilage	
18:876-882.
2.	 Dragoo	JL,	Johnson	C,	McConnell	J.	2012.	Evaluation	and	treatment	of	disorders	of	the	infrapatellar	
fat	pad.	Sports	Med	42:51-67.
3.	 Fontanella	CG,	Carniel	EL,	Frigo	A,	et	al.	2016.	Investigation	of	biomechanical	response	of	Hoffa’s	fat	
pad	and	comparative	characterization.	J	Mech	Behav	Biomed	Mater	67:1-9.
4.	 Cai	J,	Xu	J,	Wang	K,	et	al.	2015.	Association	Between	Infrapatellar	Fat	Pad	Volume	and	Knee	Struc-
tural	Changes	in	Patients	with	Knee	Osteoarthritis.	J	Rheumatol	42:1878-1884.
5.	 Chuckpaiwong	B,	Charles	HC,	Kraus	VB,	 et	 al.	 2010.	Age-associated	 increases	 in	 the	 size	of	 the	
infrapatellar	fat	pad	in	knee	osteoarthritis	as	measured	by	3T	MRI.	J	Orthop	Res	28:1149-1154.
6.	 Duran	S,	Aksahin	E,	Kocadal	O,	et	al.	2015.	Effects	of	body	mass	index,	infrapatellar	fat	pad	volume	
and	age	on	patellar	cartilage	defect.	Acta	Orthop	Belg	81:41-46.
7.	 Apovian	CM,	Bigornia	S,	Mott	M,	et	al.	2008.	Adipose	macrophage	 infiltration	 is	associated	with	
insulin	 resistance	 and	vascular	 endothelial	 dysfunction	 in	 obese	 subjects.	Arterioscler	Thromb	
Vasc	Biol	28:1654-1659.
8.	 Bastiaansen-Jenniskens	YM,	Clockaerts	S,	Feijt	C,	et	al.	2012.	Infrapatellar	fat	pad	of	patients	with	
end-stage	osteoarthritis	inhibits	catabolic	mediators	in	cartilage.	Ann	Rheum	Dis	71:288-294.
9.	 Chang	W	DC,	Kent	C,	Kovats	S,	Garteiser	P,	Doblas	S,	Towner	R,	Griffin	TM.	2011.	Infrapatellar	fat	
pad	hypertrophy	without	inflammation	in	a	diet-induced	mouse	model	of	obesity	and	osteoarthri-
tis.	Osteoarthritis	Cartilage	19:S53–S236.
10.	 Grant	RW,	Dixit	VD.	2015.	Adipose	tissue	as	an	immunological	organ.	Obesity	(Silver	Spring)	23:512-
518.
11.	 Clockaerts	S,	Bastiaansen-Jenniskens	YM,	Feijt	C,	et	al.	2012.	Cytokine	production	by	infrapatellar	
fat	pad	can	be	stimulated	by	interleukin	1beta	and	inhibited	by	peroxisome	proliferator	activated	
receptor	alpha	agonist.	Ann	Rheum	Dis	71:1012-1018.
12.	 Abreu	MR,	Chung	CB,	Trudell	D,	 et	 al.	 2008.	Hoffa’s	 fat	pad	 injuries	 and	 their	 relationship	with	
anterior	cruciate	ligament	tears:	new	observations	based	on	MR	imaging	in	patients	and	MR	imag-
ing	and	anatomic	correlation	in	cadavers.	Skeletal	Radiol	37:301-306.
13.	 Gandhi	R,	Takahashi	M,	Virtanen	C,	et	al.	2011.	Microarray	analysis	of	the	infrapatellar	fat	pad	in	
knee	osteoarthritis:	relationship	with	joint	inflammation.	J	Rheumatol	38:1966-1972.
14.	 Solbak	NM,	Heard	BJ,	Achari	Y,	et	al.	2015.	Alterations	in	Hoffa’s	fat	pad	induced	by	an	inflammatory	
response	following	idealized	anterior	cruciate	ligament	surgery.	Inflamm	Res	64:615-626.
15.	 Evans	CH,	Kraus	VB,	Setton	LA.	2014.	Progress	in	intra-articular	therapy.	Nat	Rev	Rheumatol	10:11-
22.
16.	 Eymard	F,	Pigenet	A,	Citadelle	D,	et	al.	2017.	Knee	and	hip	intra-articular	adipose	tissues	(IAATs)	
compared	with	autologous	subcutaneous	adipose	tissue:	a	specific	phenotype	for	a	central	player	
in	osteoarthritis.	Ann	Rheum	Dis.
17.	 Tsuchida	AI,	 Beekhuizen	M,	Rutgers	M,	 et	 al.	 2012.	 Interleukin-6	 is	 elevated	 in	 synovial	 fluid	 of	
patients	with	focal	cartilage	defects	and	stimulates	cartilage	matrix	production	in	an	in	vitro	regen-
eration	model.	Arthritis	Res	Ther	14:R262.
18.	 Tsuchida	AI,	Beekhuizen	M,	t	Hart	MC,	et	al.	2014.	Cytokine	profiles	in	the	joint	depend	on	pathol-
ogy,	but	are	different	between	synovial	fluid,	cartilage	tissue	and	cultured	chondrocytes.	Arthritis	
Res	Ther	16:441.
Summary and general discussion 149
8
19.	 Bigoni	M,	Sacerdote	P,	Turati	M,	et	al.	2013.	Acute	and	late	changes	in	intraarticular	cytokine	levels	
following	anterior	cruciate	ligament	injury.	J	Orthop	Res	31:315-321.
20.	 Irie	K,	Uchiyama	E,	Iwaso	H.	2003.	Intraarticular	inflammatory	cytokines	in	acute	anterior	cruciate	
ligament	injured	knee.	Knee	10:93-96.
21.	 Marks	PH,	Donaldson	ML.	2005.	Inflammatory	cytokine	profiles	associated	with	chondral	damage	
in	the	anterior	cruciate	ligament-deficient	knee.	Arthroscopy	21:1342-1347.
22.	 Beekhuizen	M,	Gierman	LM,	 van	 Spil	WE,	 et	 al.	 2013.	An	 explorative	 study	 comparing	 levels	 of	
soluble	mediators	in	control	and	osteoarthritic	synovial	fluid.	Osteoarthritis	Cartilage	21:918-922.
23.	 Harris	Q,	Seto	J,	O’Brien	K,	et	al.	2013.	Monocyte	chemotactic	protein-1	inhibits	chondrogenesis	of	
synovial	mesenchymal	progenitor	cells:	an	in	vitro	study.	Stem	Cells	31:2253-2265.
24.	 Jagielski	M,	Wolf	J,	Marzahn	U,	et	al.	2014.	The	influence	of	IL-10	and	TNFalpha	on	chondrogenesis	
of	human	mesenchymal	stromal	cells	in	three-dimensional	cultures.	Int	J	Mol	Sci	15:15821-15844.
25.	 Kondo	M,	Yamaoka	K,	Tanaka	Y.	2014.	Acquiring	chondrocyte	phenotype	from	human	mesenchymal	
stem	cells	under	inflammatory	conditions.	Int	J	Mol	Sci	15:21270-21285.
26.	 Wei	H,	Shen	G,	Deng	X,	et	al.	2013.	The	role	of	IL-6	in	bone	marrow	(BM)-derived	mesenchymal	stem	
cells	(MSCs)	proliferation	and	chondrogenesis.	Cell	Tissue	Bank	14:699-706.
27.	 Lieberthal	J,	Sambamurthy	N,	Scanzello	CR.	2015.	Inflammation	in	joint	injury	and	post-traumatic	
osteoarthritis.	Osteoarthritis	Cartilage	23:1825-1834.
28.	 Canhamero	T,	Garcia	LV,	De	Franco	M.	2014.	Acute	Inflammation	Loci	Are	Involved	in	Wound	Healing	
in	the	Mouse	Ear	Punch	Model.	Adv	Wound	Care	(New	Rochelle)	3:582-591.
29.	 Gourevitch	D,	Kossenkov	AV,	Zhang	Y,	et	al.	2014.	Inflammation	and	Its	Correlates	in	Regenerative	
Wound	Healing:	An	Alternate	Perspective.	Adv	Wound	Care	(New	Rochelle)	3:592-603.
30.	 Mosser	DM,	Edwards	JP.	2008.	Exploring	the	full	spectrum	of	macrophage	activation.	Nat	Rev	Im-
munol	8:958-969.
31.	 Utomo	L,	Bastiaansen-Jenniskens	YM,	Verhaar	JA,	et	al.	2016.	Cartilage	 inflammation	and	degen-
eration	is	enhanced	by	pro-inflammatory	(M1)	macrophages	in	vitro,	but	not	inhibited	directly	by	
anti-inflammatory	(M2)	macrophages.	Osteoarthritis	Cartilage	24:2162-2170.
32.	 Blom	AB,	van	Lent	PL,	Libregts	S,	et	al.	2007.	Crucial	role	of	macrophages	 in	matrix	metallopro-
teinase-mediated	cartilage	destruction	during	experimental	osteoarthritis:	involvement	of	matrix	
metalloproteinase	3.	Arthritis	Rheum	56:147-157.
33.	 Fahy	N,	de	Vries-van	Melle	ML,	Lehmann	J,	et	al.	2014.	Human	osteoarthritic	synovium	impacts	
chondrogenic	differentiation	of	mesenchymal	stem	cells	via	macrophage	polarisation	state.	Osteo-
arthritis	Cartilage	22:1167-1175.
34.	 Sesia	SB,	Duhr	R,	Medeiros	da	Cunha	C,	et	al.	2015.	Anti-inflammatory/tissue	repair	macrophages	
enhance	 the	 cartilage-forming	 capacity	 of	 human	 bone	 marrow-derived	 mesenchymal	 stromal	
cells.	J	Cell	Physiol	230:1258-1269.
35.	 Godwin	JW,	Pinto	AR,	Rosenthal	NA.	2013.	Macrophages	are	required	 for	adult	salamander	 limb	
regeneration.	Proc	Natl	Acad	Sci	U	S	A	110:9415-9420.
36.	 Gross	JB,	Guillaume	C,	Gegout-Pottie	P,	et	al.	2016.	The	infrapatellar	fat	pad	induces	inflammatory	
and	degradative	effects	in	articular	cells	but	not	through	leptin	or	adiponectin.	Clin	Exp	Rheumatol.
37.	 Nishimuta	JF,	Levenston	ME.	2015.	Meniscus	is	more	susceptible	than	cartilage	to	catabolic	and	
anti-anabolic	effects	of	adipokines.	Osteoarthritis	Cartilage	23:1551-1562.
38.	 Challa	TD,	Rais	Y,	Ornan	EM.	2010.	Effect	of	adiponectin	on	ATDC5	proliferation,	differentiation	and	
signaling	pathways.	Mol	Cell	Endocrinol	323:282-291.
39.	 Francin	PJ,	Abot	A,	Guillaume	C,	et	al.	2014.	Association	between	adiponectin	and	cartilage	degra-
dation	in	human	osteoarthritis.	Osteoarthritis	Cartilage	22:519-526.
150 CHAPTER 8
40.	 Fain	JN,	Madan	AK,	Hiler	ML,	et	al.	2004.	Comparison	of	the	release	of	adipokines	by	adipose	tissue,	
adipose	tissue	matrix,	and	adipocytes	from	visceral	and	subcutaneous	abdominal	adipose	tissues	
of	obese	humans.	Endocrinology	145:2273-2282.
41.	 Fardet	L,	Antuna-Puente	B,	Vatier	C,	et	al.	2013.	Adipokine	profile	in	glucocorticoid-treated	patients:	
baseline	plasma	leptin	level	predicts	occurrence	of	lipodystrophy.	Clin	Endocrinol	(Oxf)	78:43-51.
42.	 Heard	BJ,	Solbak	NM,	Chung	M,	et	al.	2016.	The	infrapatellar	fat	pad	is	affected	by	injury	induced	
inflammation	in	the	rabbit	knee:	use	of	dexamethasone	to	mitigate	damage.	Inflamm	Res	65:459-470.
43.	 Ricciotti	E,	FitzGerald	GA.	2011.	Prostaglandins	and	inflammation.	Arterioscler	Thromb	Vasc	Biol	
31:986-1000.
44.	 Jakob	M,	Demarteau	O,	Suetterlin	R,	et	al.	2004.	Chondrogenesis	of	expanded	adult	human	articular	
chondrocytes	is	enhanced	by	specific	prostaglandins.	Rheumatology	(Oxford)	43:852-857.
45.	 Kim	J,	Shim	M.	2015.	Prostaglandin	F2alpha	receptor	(FP)	signaling	regulates	Bmp	signaling	and	
promotes	chondrocyte	differentiation.	Biochim	Biophys	Acta	1853:500-512.
46.	 Attur	M,	Al-Mussawir	HE,	Patel	J,	et	al.	2008.	Prostaglandin	E2	exerts	catabolic	effects	in	osteoar-
thritis	cartilage:	evidence	for	signaling	via	the	EP4	receptor.	J	Immunol	181:5082-5088.
47.	 Zweers	MC,	de	Boer	TN,	van	Roon	J,	et	al.	2011.	Celecoxib:	considerations	regarding	its	potential	
disease-modifying	properties	in	osteoarthritis.	Arthritis	Res	Ther	13:239.
48.	 Eymard	 F,	 Pigenet	 A,	 Citadelle	D,	 et	 al.	 2014.	 Induction	 of	 an	 inflammatory	 and	 prodegradative	
phenotype	in	autologous	fibroblast-like	synoviocytes	by	the	infrapatellar	fat	pad	from	patients	with	
knee	osteoarthritis.	Arthritis	Rheumatol	66:2165-2174.
49.	 Gierman	LM,	Wopereis	S,	van	El	B,	et	al.	2013.	Metabolic	profiling	reveals	differences	in	concentra-
tions	of	oxylipins	and	 fatty	acids	secreted	by	 the	 infrapatellar	 fat	pad	of	donors	with	end-stage	
osteoarthritis	and	normal	donors.	Arthritis	Rheum	65:2606-2614.
50.	 Pountos	I,	Giannoudis	PV,	Jones	E,	et	al.	2011.	NSAIDS	inhibit	in	vitro	MSC	chondrogenesis	but	not	
osteogenesis:	 implications	 for	mechanism	of	 bone	 formation	 inhibition	 in	man.	 J	 Cell	Mol	Med	
15:525-534.
51.	 Welting	TJ,	Caron	MM,	Emans	PJ,	et	al.	2011.	Inhibition	of	cyclooxygenase-2	impacts	chondrocyte	
hypertrophic	differentiation	during	endochondral	ossification.	Eur	Cell	Mater	22:420-436;	discus-
sion	436-427.
52.	 Caron	MM,	Emans	PJ,	Sanen	K,	et	al.	2016.	The	Role	of	Prostaglandins	and	COX-Enzymes	in	Chon-
drogenic	Differentiation	of	ATDC5	Progenitor	Cells.	PLoS	One	11:e0153162.
53.	 Goppelt-Struebe	M,	Wolter	D,	Resch	K.	1989.	Glucocorticoids	inhibit	prostaglandin	synthesis	not	
only	at	the	level	of	phospholipase	A2	but	also	at	the	level	of	cyclo-oxygenase/PGE	isomerase.	Br	J	
Pharmacol	98:1287-1295.
54.	 Kim	IC,	Cohen	AS.	1966.	Synovial	fluid	fatty	acid	composition	in	patients	with	rheumatoid	arthritis,	
gout	and	degenerative	joint	disease.	Proc	Soc	Exp	Biol	Med	123:77-80.
55.	 Soto-Vaca	A,	Losso	JN,	McDonough	K,	et	al.	 2013.	Differential	effect	of	14	 free	 fatty	acids	 in	 the	
expression	of	inflammation	markers	on	human	arterial	coronary	cells.	J	Agric	Food	Chem	61:10074-
10079.
56.	 Bastiaansen-Jenniskens	YM,	Siawash	M,	van	de	Lest	CH,	et	al.	2013.	Monounsaturated	and	Satu-
rated,	but	Not	n-6	Polyunsaturated	Fatty	Acids	Decrease	Cartilage	Destruction	under	Inflammatory	
Conditions:	A	Preliminary	Study.	Cartilage	4:321-328.
57.	 Simopoulos	AP.	2002.	Omega-3	fatty	acids	in	inflammation	and	autoimmune	diseases.	J	Am	Coll	Nutr	
21:495-505.
58.	 Wu	CL,	Jain	D,	McNeill	JN,	et	al.	2015.	Dietary	fatty	acid	content	regulates	wound	repair	and	the	
pathogenesis	of	osteoarthritis	following	joint	injury.	Ann	Rheum	Dis	74:2076-2083.
Summary and general discussion 151
8
59.	 Van	Beeck	A,	Clockaerts	S,	Somville	J,	et	al.	2013.	Does	infrapatellar	fat	pad	resection	in	total	knee	
arthroplasty	impair	clinical	outcome?	A	systematic	review.	Knee	20:226-231.
60.	 White	L,	Holyoak	R,	Sant	J,	et	al.	2016.	The	effect	of	 infrapatellar	fat	pad	resection	on	outcomes	
post-total	knee	arthroplasty:	a	systematic	review.	Arch	Orthop	Trauma	Surg	136:701-708.
61.	 Bos	PK.	2014.	CORR	Insights	(R):	The	effect	of	infrapatellar	fat	pad	excision	on	complications	after	
minimally	invasive	TKA:	a	randomized	controlled	trial.	Clin	Orthop	Relat	Res	472:702-703.
62.	 Pinsornsak	 P,	 Naratrikun	K,	 Chumchuen	 S.	 2014.	 The	 effect	 of	 infrapatellar	 fat	 pad	 excision	 on	
complications	after	minimally	invasive	TKA:	a	randomized	controlled	trial.	Clin	Orthop	Relat	Res	
472:695-701.
63.	 Takatoku	K,	Sekiya	H,	Hayashi	M,	et	al.	2005.	Influence	of	fat	pad	removal	on	patellar	tendon	length	
during	growth.	Knee	Surg	Sports	Traumatol	Arthrosc	13:706-713.
64.	 Ye	C,	Zhang	W,	Wu	W,	et	al.	2016.	Influence	of	the	Infrapatellar	Fat	Pad	Resection	during	Total	Knee	
Arthroplasty:	A	Systematic	Review	and	Meta-Analysis.	PLoS	One	11:e0163515.
65.	 Garcia	J,	Wright	K,	Roberts	S,	et	al.	2016.	Characterisation	of	synovial	fluid	and	infrapatellar	fat	pad	
derived	mesenchymal	stromal	cells:	The	influence	of	tissue	source	and	inflammatory	stimulus.	Sci	
Rep	6:24295.
66.	 Neri	S,	Guidotti	S,	Lilli	NL,	et	al.	2016.	Infrapatellar	fat	pad-derived	mesenchymal	stromal	cells	from	
osteoarthritis	patients:	In	vitro	genetic	stability	and	replicative	senescence.	J	Orthop	Res.
67.	 Wickham	MQ,	 Erickson	 GR,	 Gimble	 JM,	 et	 al.	 2003.	Multipotent	 stromal	 cells	 derived	 from	 the	
infrapatellar	fat	pad	of	the	knee.	Clin	Orthop	Relat	Res:196-212.
68.	 Maumus	M,	Manferdini	C,	Toupet	K,	et	al.	2013.	Adipose	mesenchymal	stem	cells	protect	chondro-
cytes	from	degeneration	associated	with	osteoarthritis.	Stem	Cell	Res	11:834-844.
69.	 Tangchitphisut	P,	Srikaew	N,	Numhom	S,	et	al.	2016.	Infrapatellar	Fat	Pad:	An	Alternative	Source	of	
Adipose-Derived	Mesenchymal	Stem	Cells.	Arthritis	2016:4019873.
70.	 Shapiro	F,	Koide	S,	Glimcher	MJ.	1993.	Cell	origin	and	differentiation	in	the	repair	of	full-thickness	
defects	of	articular	cartilage.	J	Bone	Joint	Surg	Am	75:532-553.
71.	 Hunziker	 EB,	 Rosenberg	 LC.	 1996.	 Repair	 of	 partial-thickness	 defects	 in	 articular	 cartilage:	 cell	
recruitment	from	the	synovial	membrane.	J	Bone	Joint	Surg	Am	78:721-733.
72.	 Okano	T,	Wakitani	S,	Okabe	T,	et	al.	2014.	Nucleated	cells	circulating	in	the	peripheral	blood	con-
tribute	to	the	repair	of	osteochondral	defects	only	in	the	early	phase	of	healing.	J	Tissue	Eng	Regen	
Med	8:414-420.
73.	 Fontanella	CG,	Carniel	EL,	Frigo	A,	et	al.	2017.	Investigation	of	biomechanical	response	of	Hoffa’s	fat	
pad	and	comparative	characterization.	J	Mech	Behav	Biomed	Mater	67:1-9.
74.	 Schweitzer	ME,	Falk	A,	Pathria	M,	et	al.	1993.	MR	imaging	of	the	knee:	can	changes	in	the	intracap-
sular	fat	pads	be	used	as	a	sign	of	synovial	proliferation	in	the	presence	of	an	effusion?	AJR	Am	J	
Roentgenol	160:823-826.
75.	 Staeubli	HU,	Bollmann	C,	Kreutz	R,	et	al.	1999.	Quantification	of	intact	quadriceps	tendon,	quadri-
ceps	tendon	insertion,	and	suprapatellar	fat	pad:	MR	arthrography,	anatomy,	and	cryosections	in	
the	sagittal	plane.	AJR	Am	J	Roentgenol	173:691-698.
76.	 Tsavalas	N,	Karantanas	AH.	2013.	Suprapatellar	fat-pad	mass	effect:	MRI	findings	and	correlation	
with	anterior	knee	pain.	AJR	Am	J	Roentgenol	200:W291-296.
77.	 Wang	J,	Han	W,	Wang	X,	et	al.	2014.	Mass	effect	and	signal	intensity	alteration	in	the	suprapatellar	
fat	pad:	associations	with	knee	symptoms	and	structure.	Osteoarthritis	Cartilage	22:1619-1626.
78.	 Ly	JQ,	Bui-Mansfield	LT.	2004.	Anatomy	of	and	abnormalities	associated	with	Kager’s	fat	Pad.	AJR	
Am	J	Roentgenol	182:147-154.
79.	 Pingel	J,	Petersen	MC,	Fredberg	U,	et	al.	2015.	Inflammatory	and	Metabolic	Alterations	of	Kager’s	
Fat	Pad	in	Chronic	Achilles	Tendinopathy.	PLoS	One	10:e0127811.
152 CHAPTER 8
80.	 Jayasekera	N,	Aprato	A,	Villar	RN.	2014.	Fat	pad	entrapment	at	the	hip:	a	new	diagnosis.	PLoS	One	
9:e83503.
81.	 Eymard	F,	Pigenet	A,	Citadelle	D,	et	al.	2016.	Knee	and	hip	intra-articular	adipose	tissues	share	a	
common	phenotype	in	osteoarthritis.	Osteoarthritis	Cartilage	24	(2016)	S63-S534.
82.	 Berenbaum	F,	Griffin	TM,	Liu-Bryan	R.	2017.	Review:	Metabolic	Regulation	of	Inflammation	in	Osteo-
arthritis.	Arthritis	Rheumatol	69:9-21.
83.	 Zhuo	Q,	Yang	W,	Chen	J,	et	al.	2012.	Metabolic	syndrome	meets	osteoarthritis.	Nat	Rev	Rheumatol	
8:729-737.
84.	 Albuquerque	D,	Stice	E,	Rodriguez-Lopez	R,	et	al.	2015.	Current	review	of	genetics	of	human	obesity:	
from	molecular	mechanisms	to	an	evolutionary	perspective.	Mol	Genet	Genomics	290:1191-1221.
85.	 Bouchard	C.	2007.	The	biological	predisposition	to	obesity:	beyond	the	thrifty	genotype	scenario.	
Int	J	Obes	(Lond)	31:1337-1339.
86.	 Abranches	MV,	Oliveira	FC,	Conceicao	LL,	et	al.	2015.	Obesity	and	diabetes:	the	link	between	adi-
pose	tissue	dysfunction	and	glucose	homeostasis.	Nutr	Res	Rev	28:121-132.
87.	 Uchida	K,	Satoh	M,	Inoue	G,	et	al.	2015.	CD11c(+)	macrophages	and	levels	of	TNF-alpha	and	MMP-3	
are	increased	in	synovial	and	adipose	tissues	of	osteoarthritic	mice	with	hyperlipidaemia.	Clin	Exp	
Immunol	180:551-559.
88.	 Pelleymounter	MA,	Cullen	MJ,	Baker	MB,	et	al.	1995.	Effects	of	the	obese	gene	product	on	body	
weight	regulation	in	ob/ob	mice.	Science	269:540-543.
89.	 Uchida	K,	Urabe	K,	Naruse	K,	et	al.	2009.	Hyperlipidemia	and	hyperinsulinemia	in	the	spontaneous	
osteoarthritis	mouse	model,	STR/Ort.	Exp	Anim	58:181-187.
90.	 Mason	RM,	Chambers	MG,	Flannelly	J,	et	al.	2001.	The	STR/ort	mouse	and	its	use	as	a	model	of	
osteoarthritis.	Osteoarthritis	Cartilage	9:85-91.
91.	 Fulcher	J,	O’Connell	R,	Voysey	M,	et	al.	2015.	Efficacy	and	safety	of	LDL-lowering	therapy	among	
men	and	women:	meta-analysis	of	individual	data	from	174,000	participants	in	27	randomised	trials.	
Lancet	385:1397-1405.
92.	 Keene	D,	Price	C,	Shun-Shin	MJ,	et	al.	2014.	Effect	on	cardiovascular	risk	of	high	density	lipoprotein	
targeted	drug	treatments	niacin,	fibrates,	and	CETP	inhibitors:	meta-analysis	of	randomised	con-
trolled	trials	including	117,411	patients.	BMJ	349:g4379.
93.	 Clockaerts	S,	Van	Osch	GJ,	Bastiaansen-Jenniskens	YM,	et	al.	2012.	Statin	use	 is	associated	with	
reduced	incidence	and	progression	of	knee	osteoarthritis	in	the	Rotterdam	study.	Ann	Rheum	Dis	
71:642-647.
94.	 Izadpanah	R,	Schachtele	DJ,	Pfnur	AB,	et	al.	2015.	The	impact	of	statins	on	biological	characteris-
tics	of	stem	cells	provides	a	novel	explanation	for	their	pleiotropic	beneficial	and	adverse	clinical	
effects.	Am	J	Physiol	Cell	Physiol	309:C522-531.
95.	 Zhang	O,	Zhang	J.	2015.	Atorvastatin	promotes	human	monocyte	differentiation	toward	alterna-
tive	 M2	 macrophages	 through	 p38	 mitogen-activated	 protein	 kinase-dependent	 peroxisome	
proliferator-activated	receptor	gamma	activation.	Int	Immunopharmacol	26:58-64.
96.	 Denis	GV,	Obin	MS.	2013.	 ‘Metabolically	healthy	obesity’:	origins	and	 implications.	Mol	Aspects	
Med	34:59-70.
97.	 Navarro	E,	Funtikova	AN,	Fito	M,	et	al.	2015.	Can	metabolically	healthy	obesity	be	explained	by	diet,	
genetics,	and	inflammation?	Mol	Nutr	Food	Res	59:75-93.
98.	 Green	MA,	Strong	M,	Razak	F,	et	al.	2016.	Who	are	the	obese?	A	cluster	analysis	exploring	subgroups	
of	the	obese.	J	Public	Health	(Oxf)	38:258-264.
99.	 Zhang	Y,	Pizzute	T,	Pei	M.	2014.	Anti-inflammatory	strategies	in	cartilage	repair.	Tissue	Eng	Part	B	
Rev	20:655-668.
Addendum figures 153
8
ADDENDUM FIGURES
COL1A1
FLS only +M1 CM +M2 CM
0.0
0.5
1.0
1.5
2.0
R
el
at
iv
e
to
FL
S
on
ly
ASMA
FLS only +M1 CM +M2 CM
0.0
0.5
1.0
1.5
R
el
at
iv
e
to
FL
S
on
ly
PLOD2
FLS only +M1 CM +M2 CM
0
20
40
60
80
R
el
at
iv
e
to
FL
S
on
ly
*
Addendum figure 1	Pro-inflammatory	M1	macrophages	secrete	pro-fibrotic	factors.	
Human	peripheral	blood	monocytes	(pBMC)	were	stimulated	to	M1	or	M2	phenotype	and	conditioned	medium	
(CM)	was	made.	Synovial	fibroblasts	(FLS)	were	treated	with	M1	or	M2	macrophage	CM	for	4	days.	Relative	
expression	of	COL1A1,	ASMA	and	PLOD2	in	FLS	treated	with	25%	CM.	Gene	expression	was	normalized	to	the	
FLS	only	condition	per	donor.	CM	from	3	pBMC	donors	were	used	to	treat	3	FLS	donors,	with	each	condition	
performed	in	triplicate	(n=9).	Values	represent	mean±SD.	*p<0.05	versus	FLS	only.
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Addendum figure 2	Effect	of	PGF2α	on	MSC	chondrogenesis.	
Chondrogenic	stimulated	MSC	alginate	beads	were	treated	with	PGF2α,	AL8810	inhibitor	or	CM	from	IPFP.	Rela-
tive	 expression	of	COL2A1,	ACAN,	MMP1	and	MMP13	 in	 chondrogenic	 stimulated	MSC	alginate	beads	after	
treatment.	Two	pools	of	CM	from	3	different	IPFP	donors	each	pool	were	used	to	treat	2	MSC	donors,	with	each	
condition	performed	in	triplicate	(n=6).	Values	represent	mean±SD.	*p<0.05	versus	non-treated	controls.
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De	knie	heeft	gewrichtsvlakken	die	bedekt	worden	door	kraakbeen.	Kraakbeen	is	
een	bindweefsel	met	een	elastische	karakter,	het	zorgt	ervoor	dat	de	gewrichtsvlak-
ken	soepel	over	elkaar	heen	kunnen	glijden	en	het	geeft	schokdemping.	Kraakbeen	
kan	beschadigd	raken	en	indien	de	kraakbeenschade	niet	hersteld	wordt,	kan	dit	
uiteindelijk	leiden	tot	artrose.	De	symptomen	van	artrose	zijn	onder	andere	pijn	
en	verminderde	bewegelijkheid.	Bij	artrose	is	niet	alleen	het	kraakbeen	aangetast	
maar	de	 gehele	 knie,	 inclusief	 het	 bot,	 ligamenten	 en	het	 synovium.	Artrose	 is	
niet	te	genezen;	alleen	de	symptomen	zijn	te	behandelen.	In	het	eindstadium	van	
artrose	kan	het	gehele	kniegewricht	vervangen	worden	door	een	prothese.	
Kraakbeen	herstelt	uit	zichzelf	nauwelijks.	Dit	komt	doordat	het	geen	zenuwen	en	
geen	bloedvaten	bevat.	Daarnaast	bestaat	het	kraakbeen	vooral	uit	tussencelstof	
en	maar	voor	een	klein	gedeelte	uit	kraakbeencellen.	Indien	er	sprake	is	van	een	
kraakbeendefect,	is	er	momenteel	een	aantal	methodes	om	het	defect	te	herstel-
len.	De	meest	 gangbare	 is	de	microfracture	procedure.	Tijdens	deze	procedure	
worden	 er	 gaten	 gemaakt	 in	 het	 bot	 onder	 het	 kraakbeen.	Hiermee	worden	de	
mesenchymale	stamcellen	in	het	beenmerg	gestimuleerd	om	het	kraakbeendefect	
op	te	vullen	met	littekenweefsel.	
De	 resultaten	 van	 deze	 operaties	 kunnen	 door	 ontsteking	 negatief	 beïnvloed	
worden.	In	een	ontstoken	knie	zijn	er	veel	ontstekingsfactoren	die	ervoor	zorgen	
dat	stamcellen	niet	goed	veranderen	naar	kraakbeencellen	en	daarom	niet	goed	
nieuw	kraakbeen	kunnen	produceren.	De	 resultaten	van	de	kraakbeenoperaties	
kunnen	ook	negatief	beïnvloed	worden	door	obesitas.	Bij	obesitas	zijn	de	vetcel-
len	 vergroot.	 Daarnaast	 is	 er	meer	 infiltratie	 van	 ontstekingscellen,	 waaronder	
macrofagen.	 Macrofagen	 zijn	 witte	 bloedcellen	 die	 een	 belangrijk	 rol	 spelen	
in	ons	afweersysteem.	Er	 zijn	 in	het	 lichaam	pro-inflammatoire	macrofagen	 	 en	
weefselherstellende/anti-inflammatoire	macrofagen.	Het	vetweefsel	is	bij	obesitas	
ontstoken	 door	 onder	 andere	 een	 verhoogde	 infiltratie	 van	 pro-inflammatoire	
macrofagen	en	scheidt	dan	ook	meer	ontstekingsfactoren	uit.	Het	meeste	vet	 in	
het	lichaam	bevindt	zich	onder	de	huid.	De	ontstekingsfactoren	bereiken	de	knie	
systemisch	via	de	bloedbaan.	Echter	in	de	knie	zelf	bevindt	zich	ook	vetweefsel.	
Het	grootste	vetweefsel	 in	de	knie	is	het	infrapatellair	vet	weefsel,	ofwel	Hoffa’s	
vetweefsel.	Het	Hoffa’s	vetweefsel	 ligt	direct	 tegen	het	synovium	aan.	Het	heeft	
als	functie	schokdemping	en	het	helpen	verspreiden	van	synoviale	vloeistof.	Het	
Hoffa’s	 vetweefsel	 kan	 ontstoken	 raken	 en	 daarbij	 stoffen	 uitscheiden	 die	 het	
kraakbeen	beïnvloeden.	
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In Hoofdstuk 2	beschreven	wij	of	het	Hoffa’s	vetweefsel	ook	daadwerkelijk	veran-
derd	is	door	obesitas.	Wij	hebben	daarbij	stukjes	Hoffa’s	vetweefsel	gebruikt	van	
patiënten	 die	 een	 totale	 knieprothese	 kregen	 en	 stukjes	 onderhuids	 vetweefsel	
van	patiënten	die	een	 totale	heupprothese	kregen.	Wij	analyseerden	de	grootte	
van	de	vetcellen	met	histologie.	Obesitas	leidt	tot	vergroting	van	de	onderhuidse	
vetcellen	en	dit	is	een	aanwijzing	voor	vetweefsel	ontsteking.	Wij	konden	geen	ver-
schil	in	grootte	vinden	tussen	vetcellen	van	het	Hoffa’s	vetweefsel	van	patiënten	
met	 een	 body	 mass	 index	 (BMI)	 van	 <25kg/m2	 en	 >30	 kg/m2.	 Wij	 concluderen	
hieruit	dat	de	vetcellen	in	het	Hoffa’s	vetweefsel	waarschijnlijk	niet	door	obesitas	
beïnvloed	worden.	Dit	suggereert	verder	dat	het	Hoffa’s	vetweefsel	niet	hetzelfde	
is	als	onderhuids	vetweefsel.	
Obesitas	 is	een	risicofactor	voor	artrose.	Een	van	de	kenmerken	van	artrose	 is	
stijfheid	 van	 het	 gewricht.	 Dit	 wordt	 deels	 veroorzaakt	 door	 fibrosering,	 ofwel	
verlittekening	 van	 het	 synovium.	 	 Dit	 proces	 ontstaat	 	 doordat	 fibroblasten	 in	
het	 synovium	meer	 fibrotisch	weefsel	 gaat	 produceren.	 De	 fibroblasten	 produ-
ceren	meer	fibrotisch	weefsel	door	aanwezigheid	van	ontstekingsfactoren	of	een	
overdaad	aan	groeifactoren.	Het	Hoffa’s	vetweefsel	ligt	in	de	knie	direct	tegen	het	
synovium	 aan.	 Het	 synovium	wordt	 dus	mogelijk	 continue	 beïnvloed	 door	 het	
Hoffa’s	vetweefsel.	 In	Hoofdstuk 3	hebben	wij	beschreven	dat	 	 factoren	die	het	
Hoffa’s	vetweefsel	uitscheidt	synoviale	fibrose	kan	veroorzaken.	 	Dit	hebben	wij	
onderzocht	door	eerst	de	factoren	die	het	Hoffa’s	vetweefsel	uitscheidt	op	te	van-
gen	in	kweekmedium.	Daarna	hebben	wij	fibroblasten	uit	het	synovium	geïsoleerd	
en	deze	 gekweekt	met	het	 kweekmedium.	Wij	 zagen	hierbij	 dat	de	fibroblasten	
meer	 fibrotische	 eigenschappen	ontwikkelden.	We	merkten	ook	op	dat	 er	 geen	
verschil	was	 in	effect	 tussen	kweekmedium	gemaakt	van	Hoffa’s	vetweefsel	van	
obese	 en	 van	 niet-obese	 donoren.	 Verder	 ontdekten	 we	 dat	 prostaglandine	 F2a 
(PGF2a)	uitgescheden	door	het	Hoffa’s	vetweefsel	mede	verantwoordelijk	is	voor	
deze	 reactie.	Dit	betekent	dus	dat	 een	prostaglandine	 remmer,	 zoals	 celecoxib,	
mogelijk	gebruikt	zou	kunnen	worden	om	ontstaan	van	synoviale	fibrose	te	rem-
men.	
We	weten	nu	dat	het	Hoffa’s	vetweefsel	stoffen	uitscheidt	dat	het	kraakbeen	en	
synovium	beïnvloeden.	In	de	kliniek	zijn	de	resultaten	van	kraakbeenherstelopera-
ties	niet	optimaal,	want	er	ontstaat	een	soort	litteken	kraakbeen.	In Hoofdstuk 4 
hebben	wij	experimenten	uitgevoerd	om	te	kijken	of	het	Hoffa’s	vetweefsel	ook	
stoffen	uitscheidt	die	de	kraakbeenvormende	capaciteit	van	stamcellen	remmen.	
Wij	gebruikten	hetzelfde	soort	kweekmedium	welke	we	eerder	gebruikt	hebben	
voor	de	synoviale	fibrose	experimenten	in	Hoofdstuk 3.	Wij	zagen	dat	dit	kweek-
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medium	kraakbeenvormende	capaciteit	van	stamcellen	remde.	Verder	vonden	wij	
geen	verschil	in	het	remmende	effect	van	Hoffa’s	vetweefsel	tussen	obese	en	niet-
obese	donoren,	noch	tussen	artrotische	en	post-traumatische	donoren.	Dit	effect	
was	wel	Hoffa’s	vetweefsel	specifiek,	want	subcutane	vetweefsel	had	geen	effect	
op	de	stamcellen.	Tenslotte	toonden	we	aan	dat	pro-inflammatoire	macrofagen	in	
het	Hoffa’s	vetweefsel	bijdragen	aan	het	kraakbeenvorming	remmende	effect	van	
het	Hoffa’s	vetweefsel.		Dit	betekent	dus	dat	als	we	de	negatieve	effecten	van	het	
Hoffa’s	vetweefsel	willen	verminderen,	dat	we	een	medicijn	moeten	gebruiken	dat	
de	pro-inflammatoire	macrofagen	in	het	Hoffa’s	vetweefsel	beïnvloedt.	
In Hoofdstuk 5	probeerden	we	vervolgens	met	medicijnen	ontsteking	in	het	Hoffa’s	
vetweefsel	te	remmen.	We	gebruikten	celecoxib	en	triamcinolone	acetonide,	twee	
vaak	 gebruikte	 ontstekingsremmers,	 en	 pravastatine	 en	 fenofibraat,	 twee	 vaak	
gebruikte	cholesterol-	en	triglyceridegehalte	verlagers	met	ontstekingsremmende	
effecten.	We	kweekten	stukjes	Hoffa’s	vetweefsel	met	de	verschillende	medicijnen.	
We	vonden	dat	alleen	triamcinolone	acetonide	ontsteking	in	het	Hoffa’s	vetweefsel	
kon	verlagen.	Daarnaast	remde	het	ook	specifiek	de	pro-inflammatoire	macrofagen.	
Hierdoor	werd	het	Hoffa’s	vetweefsel	minder	negatief	voor	kraakbeenvormende	
capaciteit	van	de	stamcellen.	Verder	zagen	wij	ook	het	effect	van	Hoffa’s	vetweefsel	
op	synoviale	fibroblasten	veranderde.	Er	traden	namelijk	kraakbeenafbraak	pro-
cessen	op	synoviale	fibroblasten.	Het	lijkt	er	dus	op	dat	triamcinolone	acetonide	
gebruikt	kan	worden	om	specifiek	het	Hoffa’s	vetweefsel	te	moduleren	naar	een	
meer	voor	kraakbeenherstel	geschikte	staat.	
Het	meeste	 vetweefsel	 in	 het	 lichaam	bevindt	 zich	 onder	 de	 huid.	 Bij	 obesitas	
is	dit	onderhuidse	vetweefsel	ontstoken	en	de	ontstekingsfactoren	worden	sys-
temisch	uitgescheiden	en	bereiken	dan	via	de	bloedbaan	de	knie.	Hierdoor	kan	
kraakbeenschade	en	uiteindelijk	artrose	ontstaan.	Daarnaast	is	dit	ontstoken	mi-
lieu	mogelijk	minder	geschikt	voor	kraakbeenhersteloperaties.	Naast	ontsteking	
speelt	ook	metabole	ontregeling	een	rol	bij	obesitas	en	het	ontstaan	van	artrose.	
Om	de	complexe	verschillende	veranderingen	in	obesitas	te	onderzoeken,	is	het	
noodzakelijk	dierproeven	uit	te	voeren.	In	Hoofdstuk 6	gebruikten	wij	de	STR/Ort	
muizenstam,	die	spontaan	obesitas	en	metabole-	en	inflammatoire	veranderingen	
ontwikkelt.	Deze	muizen	kregen	gedurende	een	half	jaar	dagelijks	simvastatine	of	
fenofibraat	of	een	combinatie	hiervan.	Dit	zijn	twee	vaak	gebruikte	cholesterol-	en	
triglyceridegehalte	verlagers	met	ontstekingsremmende	effecten.	Na	een	half	jaar	
konden	we	 geen	 effect	 op	 kraakbeenschade	 vinden.	 Fenofibraat	 voorkwam	wel	
obesitas,	verlaagde	systemische	ontsteking	en	botsclerose,	maar	kon	kraakbeen-
schade	niet	voorkomen.	Tenslotte	waren	metabole	inflammatoire	veranderingen	
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in	de	muizen	niet	geassocieerd	met	het	ontstaan	van	kraakbeenschade.	Wij	con-
cludeerden	uit	deze	muizenstudie	dat	obesitas	en	obesitas	gerelateerde	metabole	
en	inflammatoire	veranderingen	niet	direct	de	oorzaak	zijn	van	kraakbeenschade	
in	deze	muizen.	Voor	de	patiënt	 suggereert	dit	 dat	 obesitas	niet	 altijd	 leidt	 tot	
kraakbeenschade.	
Als	een	obese	patiënt	eenmaal	wel	kraakbeenschade	heeft,	is	het	noodzakelijk	een	
kraakbeenhersteloperatie	uit	te	voeren	om	de	progressie	tot	artrose	te	voorkomen.	
Op	 dit	moment	worden	 obese	 patiënten	 in	 principe	 niet	 geopereerd	 omdat	 de	
klinische	resultaten	minder	zijn	bij	deze	patiënten.	Echter	is	het	nog	niet	duidelijk	
of	daadwerkelijk	de	kwaliteit	van	herstelde	kraakbeen	beïnvloed	wordt	door	obe-
sitas	en	hoe	dit	gebeurt.	Wij	hebben	geprobeerd	deze	vraag	te	beantwoorden	in	
Hoofdstuk 7.	In	dit	hoofdstuk	gebruikten	wij	DBA/1	muizen,	waarvan		bekend	is	
dat	ze	kraakbeenschade	kunnen	herstellen.	Wij	hebben	deze	muizen	een	hoog	vet	
dieet	gevoerd	waar	60%	van	de	energie	uit	vet	komt.	Daarnaast	maakten	we	een	
kraakbeendefect	in	hun	knie.	Deze	muizen	werden	dikker,	maar	tegen	de	verwacht-
ing	in,	herstelde	de	groep	die	een	hoog	vet	dieet	kregen	beter	dan	de	muizen	die	
een	controle	dieet	kregen.	Daarnaast	ontwikkelde	de	groep	die	een	hoog	vet	dieet	
kregen	ook	geen	artrose	en	hadden	de	muizen	geen	metabole	of	 inflammatoire	
veranderingen	op	de	lange	termijn.	Wij	concludeerden	naar	aanleiding	van	deze	
resultaten	dat	resistentie	tegen	hoog	vet	dieet	geïnduceerde	metabole	en	inflam-
matoire	veranderingen	mogelijk	gelinkt	is	aan	beter	kraakbeenherstel.	Wij	weten	
niet	precies	welke	mechanismes	hierin	een	rol	spelen,	daarvoor	is	meer	onderzoek	
nodig.	
Concluderend	 heb	 ik	 met	 het	 onderzoek	 beschreven	 in	 dit	 proefschrift	 	 aan-
getoond	dat	het	Hoffa’s	vetweefsel	niet	hetzelfde	 is	als	onderhuidse	vetweefsel.	
Het	Hoffa’s	vetweefsel	van	patiënten	met	artrose	of	knieschade	scheidt	factoren	
uit	die	het	kniegewricht	en	kraakbeenherstel	kunnen	beïnvloeden.	In	de	toekomst	
is	 het	 mogelijk	 met	 medicijnen	 het	 Hoffa’s	 vetweefsel	 te	 moduleren	 om	 zo	 de	
gewrichtsomgeving	 te	 optimaliseren	 voor	 kraakbeenherstel.	 Verder	 hebben	wij	
aanwijzingen	gevonden	dat	obesitas	niet	altijd	leidt	tot	artrose	en	niet	per	definitie	
negatief	is	voor	kraakbeenherstel.	Om	beter	te	begrijpen	waarom	dit	verschillend	
is	tussen	obese	patiënten	zijn	er	meer	onderzoeken	nodig.	Wellicht	kunnen	wij	in	
de	toekomst	hierdoor	ook	nieuwe	therapieën	vinden	om	artrose	te	verminderen	
en	kraakbeenherstel	te	verbeteren.
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中文简介
盖软骨作为减震器，可以使膝盖平滑无痛的运动。软骨可能会受损，一旦受损就不
能恢复，最终可能导致膝关节骨性关节炎。膝关节骨关节炎不能治愈，但通过治疗
可以缓解其症状。在骨性关节炎末期，需要施行关节置换手术更换整个关节。
软骨损伤可以通过软骨修复手术来治疗。但是，炎症会影响手术的效果。在肥胖人
群的脂肪组织多于常人，大多数脂肪组织位于皮下，而且会发炎。在膝盖内部有不
小的一片脂肪组织，称为髌下脂肪垫或霍法氏脂肪垫。本论文的研究表明，这种脂
肪垫与皮下脂肪不同。霍法氏脂肪垫分泌因子可能对膝关节和软骨的修复具有负面
影响。这可能是PGF2α 因子的分泌和促炎性巨噬细胞的存在引起的。添加曲安奈德可
以部分抵消这种负面作用。这意味着将来可以使用药物来调节霍法氏脂肪垫，从而
改善膝关节软骨修复的环境。
除了研究霍法氏脂肪垫引起的炎症之外，本论文还研究了额外关节脂肪组织炎症对
关节疾病和软骨修复的影响。通过小鼠活体实验发现，肥胖和肥胖相关的代谢和炎
症变化并不总是导致软骨损伤，也不总是对软骨修复具有负面作用。研究实验提供
的证据表明，肥胖相关的全身效应对退行性关节疾病和软骨修复影响具有变化性。
关于肥胖，脂肪组织和软骨修复之间的关系的未来研究可以侧重于这种变化性以揭
示新的治疗靶点
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DANKWOORD
Er	wordt	altijd	gevraagd	of	je	iets	opnieuw	had	willen	doen	als	je	wederom	voor	
dezelfde	keuze	staat.		Mijn	antwoord	op	de	vraag	of	ik	opnieuw	voor	een	promo-
tietraject	zou	hebben	gekozen,	is	volmondig	“JA!”.	De	vier	jaren	in	het	lab	op	de	
16e	zijn	voorbij	gevlogen.	Dit	proefschrift	was	nooit	tot	stand	gekomen	zonder	de	
steun	van	anderen.	Hierbij	wil	ik	in	het	bijzonder	een	aantal	personen	bedanken.
Allereerst	mijn	eerste	promotor	prof.dr.	Van	Osch.	Beste	Gerjo,	al	in	het	voorjaar	
van	2010	liep	ik	bij	je	naar	binnen	om	te	komen	praten	over	mijn	keuze	onderzoek.	
Ik	had	nauwelijks	een	idee	wat	fundamenteel	wetenschappelijk	onderzoek	inhield,	
noch	wat	er	te	doen	was	op	het	 lab.	Na	een	halfjaar	 intensieve	begeleiding	van	
jou	en	Yvonne,	was	ik	heel	blij	dat	je	mij	de	kans	bood	om	een	promotietraject	te	
starten.	Je	was	altijd	heel	laagdrempelig	te	bereiken	voor	overleg,	hoe	druk	je	het	
ook	had.	Daarnaast	was	er	nog	iets	waar	je	ook	altijd	tijd	voor	vrij	maakte:	jouw	
goudvissen.	Tijdens	 je	afwezigheid	werden	complete	schema’s	opgesteld	om	te	
zorgen	dat	ze	niet	overvoerd	werden.	Ik	vond	het	leuk	dat	je	onze	goudvis	Sep	(je	
noemde	hem	mini-Wu)	wilde	adopteren.	Helaas	heeft	hij	de	finish	van	dit	boek	niet	
gehaald.	Gerjo,	ik	ben	blij	en	dankbaar	jou	als	promotor	te	hebben.	
Daarnaast	mijn	tweede	promotor,	prof.dr.	Verhaar.	Beste	professor	Verhaar,	dank	
u	dat	u	mij	de	kans	gegeven	hebt	om	promotie	onderzoek	te	doen	op	de	afdeling	
orthopedie.	Met	uw	uitgebreide	kennis	uit	de	kliniek,	had	u	altijd	kritische	vragen	
over	mijn	onderzoek.	U	heeft	mij	geleerd	én	uitgedaagd	basaal	wetenschappelijk	
onderzoek	zo	klinisch	relevant	mogelijk	te	maken.	Ik	kijk	er	naar	uit	om	meer	van	
u	te	leren	in	de	kliniek.
 
Dr.	 Bastiaansen-Jenniskens,	mijn	 co-promotor	 Yvonne.	 Door	 de	 zeer	 intensieve	
begeleiding	heb	ik	veel	van	de	fundamentele	technische	zaken	van	het	lab	van	jou	
geleerd.	Veel	van	jouw	werk	vormde	de	basis	van	dit	boek.	Zelfs	via	de	WhatsApp	
konden	wij	het	vaak	hebben	over	verse	data.	Ook	buiten	het	werk	heb	ik	veel	lol	
met	je	gehad	met	de	door	jou	geliefde	slechte	House	muziek.	Na	al	het	intensief	
samenwerken	ben	ik	blij	dat	ik	niet	jouw	voorkeur	voor	roze	heb	overgenomen	en	
dat	jij	niet	Aziaat	bent	geworden.	
Beste	prof.	dr.	Hazes,	prof.dr.	Bulstra	en	dr.	Emans,	leden	van	de	kleine	commissie.	
Hartelijk	 dank	 voor	 het	 kritisch	 lezen	 en	 beoordelen	 van	 dit	 proefschrift.	 Dear	
prof.dr.	Dell’Accio,	thank	you	for	taking	time	to	visit	us	from	the	UK.	I	thank	you	for	
teaching	me	the	cartilage	defect	model	and	for	your	input	and	sharing	your	view	
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on	cartilage	repair.	Prof.	dr.	Van	Saase,	prof.dr.	Kleinrensink	en	dr.	Van	Lent,	dank	
voor	uw	bereidheid	om	plaats	te	nemen	in	de	grote	commissie.	
Dr.	Clockaerts,	 beste	 Stefan,	 jouw	werk	 vormde	 samen	met	dat	 van	Yvonne	de	
basis	voor	mijn	proefschrift.	Dank	voor	je	voorwerk	zodat	ik	direct	kon	instromen.	
Wie	kon	bedenken	dat	er	nog	zoveel	onderzoek	uitgevoerd	zou	worden	over	dat	
ene	stukje	vet	in	de	knie?	De	filosofeersessies	tijdens	de	ICRS	congressen	waren	
zeer	inspirerend	en	hopelijk	kunnen	we	in	de	toekomst	nog	iets	samen	opstarten.	
Daarnaast	wil	ik	de	andere	senior	onderzoekers	en	stafleden	van	de	afdeling	ortho-
pedie	graag	bedanken.	Jullie	waren	altijd	bereid	kritisch	naar	mijn	onderzoek	te	
kijken	en	actief	weefsel	te	verzamelen.	De	volgende	personen	wil	ik	hierbij	speciaal	
benoemen.	Beste	dr.	Bos,	vanaf	het	begin	hebben	we	vaak	met	Gerjo	gebrainstormd	
over	mijn	promotie	onderzoek.	Dank	voor	je	ideeën	hierbij.	Max,	trouwe	Ajacied,	
dank	voor	je	kritische	blik	op	mijn	manier	van	presenteren.	Erwin,	statistiek	blijft	
bijzonder.	Ik	waardeer	heel	erg	je	visie	hierin.	
Graag	wil	ik	alle	co-auteurs	bedanken	voor	hun	expertise	en	inzet,	waarbij	ik	de	
volgende	speciaal	wil	benoemen.	Lobke	Gierman	en	Anne-Marie	Zuurmond,	jullie	
waren	mijn	grote	TNO-hulplijnen.	Jullie	expertise	 in	high-fat-diet	heeft	onverwa-
chte	inzichten	opgeleverd.	Ik	kijk	nooit	meer	hetzelfde	naar	dikke	muizen.	Sander	
Botter,	bedankt	voor	het	delen	van	je	expertise	in	micro-CT	en	subchondraal	bot	
bij	vroeg	artrose.	Dear	Niamh,	talking	about	research,	macrophages	and	gingers	
came	‘hand	in	hand’	with	you.	Good	to	see	you	in	Holland	again!	Resti,	you	were	so	
organized	and	precise	in	your	work.	Your	Master	project	made	chapter	4	possible.	
Good	luck	in	Sweden	with	finishing	your	own	PhD.	Mathijs,	ik	heb	nooit	begrepen	
waar	je	alle	tijd	vandaan	haalde	om	alles	tegelijk	te	doen,	maar	het	is	je	allemaal	
gelukt.	We	spreken	elkaar	nog	 in	de	kliniek.	Dear	 John,	 fellow	Hoffa	enthusiast!	
Maybe	in	the	future	we	can	really	start	a	fan	club?	Thank	you	for	your	contribu-
tion!	Serdar,	thanks	for	culturing	the	Hoffa	and	performing	the	FACS	analysis	and	
good	luck	with	finishing	your	own	PhD!
Het	‘analistentrio’	Nicole,	Wendy	en	Janneke.	Jullie	zijn	de	vaste	krachten	van	het	
lab.	Altijd	ontspannend	even	bij	 te	praten	 in	 jullie	kantoor/kamer/hok.	Janneke,	
bedankt	voor	de	gezellige	momenten	in	de	ML2	tijdens	het	vele	verversen.	Wendy,	
jij	hebt	dit	groentje	veel	begeleid	tijdens	het	pipetteren.	Aan	het	eind	kon	ik	het	
best	goed,	al	zeg	ik	het	zelf.	Nicole!	Het	is	jammer	dat	je	niet	in	het	histologiehok	
kunt	snijden,	terwijl	je	aan	het	internetshoppen	bent	bij	de	Bijenkorf,	zonder	de	
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cake	van	de	week	te	missen,	voor	de	paraffinemachine.	Dank	voor	het	snijden	van	
al	die	knietjes	en	uitvoeren	van	vele	kleuringen.	
Sandra,	altijd	vrolijk.	Zonder	jou	was	het	qua	formulieren	niet	goed	gekomen	bij	
mij.	Ik	ben	dankbaar	dat	jij	mij	via	de	mail	structuur	hebt	gegeven	aan	de	afgelopen	
periode.	
The	foreign	seniors	of	the	lab.	Roberto,	I	was	there	when	you	did	your	first	mara-
thon	and	one	day	you,	Maarten	and	I	will	do	another	one	together!	Keep	up	the	
good	work	and	don’t	forget	to	eat	less	when	not	running.	Eric,	thank	you	for	your	
wisdom	about	FACS,	bone,	wine	and	cured	ham.	Kavitha,	grateful	for	your	advice	
in	the	last	months	of	my	time	in	the	lab.	
Aan	alle	collega	promovendi	op	de	16e:	Callie,	Johannes,	Marloes,	Nienke,	Mieke,	
Johan,	Jasper,	Michiel,	Anna,	Panithi,	Rintje,	Marjan,	Mairéad,	Marianne,	Lizette,	
Caoimhe,	 Shorouk,	 Simone,	 Sohrab	 en	 Laurie.	 Bedankt	 voor	 de	 samenwerking,	
koffie	drinken,	lab	days,	cake	van	de	week,	cursussen,	borrels,	inpakken	van	mijn	
bureau	 in	aluminium	 folie,	 selfies,	collages,	congressen	 in	Amerika	en	 leerzame	
tijd.	De	klinische	collega’s	ook	bedankt	voor	de	gezelligheid.	
Collega’s	van	de	chirurgie	in	Delft,	gedurende	de	vooropleiding	ben	ik	een	échte	
dokter	geworden.	Het	was	een	warm	bad	om	in	te	starten.	Ik	heb	met	plezier	met	
jullie	gewerkt,	inclusief	de	voetenpoli	en	proctopok.	Dank	voor	de	zeer	leerzame	
tijd	en	de	skireis.	
Team	Whiskey,	mijn	studievrienden,	waarvan	een	kleine	delegatie	uiteindelijk	ook	
in	de	toren	gepromoveerd	is	of	gaat	promoveren.	Ik	hoop	dat	we	onze	vriendschap	
zullen	blijven	voortzetten	met	regelmatig	etentjes,	reizen,	festivals	en	fietsen.	De	
SV-mannen	en	oud-CLD’ers	van	de	KEB-groep:	jullie	vormden	een	belangrijke	bron	
van	afleiding	tussen	het	schrijven	en	pipetteren	door.	Niek,	denkende	aan	het	oude	
Sintinel	tijdperk,	wil	ik	je	hierbij	speciaal	danken	voor	de	mooie	omslag.	
Chris	en	Maarten:	de	een	kon	zijn	benen	 in	zijn	nek	 leggen,	de	ander	had	haar	
tot	zijn	schouders	en	ik	had	iets	meer	weke	delen.	Vroeger	stonden	we	met	veel	
bier	bij	Goldfish	vooraan,	tegenwoordig	gewoon	rustig	met	een	wijntje	aan	tafel.	
Maarten,	met	jou	ben	ik	in	2011	tegelijk	met	dat	pipetteren	begonnen,	de	start	van	
een	geweldige	periode.	Een	muur	was	niet	dik	genoeg	om	ons	te	scheiden.	ik	ben	
blij	dat	we	ook	de	volgende	stap	van	onze	carrière	tot	orthopedisch	chirurg	samen	
kunnen	volgen.	Bedankt	dat	je	mijn	paranimf	wil	zijn.	
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Mijn	schoonzussen	Lisa	en	Malou.	Lisa,	altijd	aan	het	lachen	en	geïnteresseerd	in	
wat	ik	aan	het	doen	ben.	Onze	discussies	zijn	soms	fel,	maar	dat	maakt	mij	ook	
weer	scherp.	Jij	en	Joost	hebben	een	prachtig	dochter,	Evi.	Ik	ben	blij	dat	ik	voor	
het	eerst	oom	geworden	ben!	Malou,	de	kleine	sportieveling.	Je	wordt	onderschat	
door	je	lengte,	maar	zwemmend	in	het	water,	rennend	op	het	land	en	rijdend	op	de	
fiets,	ben	je	super	snel.	Misschien	zelfs	iets	sneller	dan	Michiel?	Dat	promoveren	
gaat	jou	natuurlijk	makkelijk	lukken!	
Lieve	 schoonvader	 Jos,	 op	 geneeskundig	 vlak	 ben	 je	misschien	 een	 leek,	maar	
desondanks	vind	ik	dat	je	toch	veel	van	het	medische	af	weet.	Misschien	ook	wel	
doordat	we	aan	tafel	alleen	maar	hierover	kunnen	praten.	Om	dit	goed	te	maken	
zijn	er	wel	twee	in	je	geliefde	stad	gepromoveerd,	echter	de	derde	moet	je	helaas	
aan	de	concurrent	over	laten.	Je	bent	een	fijn	en	zacht	persoon	en	altijd	welkom	
bij	ons.	Lieve	schoonmoeder	José,	je	was	altijd	geïnteresseerd	in	wat	ik	deed	en	
vroeg	mij	de	oren	van	het	lijf.	Door	je	betrokkenheid	voelde	ik	me	al	snel	thuis	bij	
jullie.	Ik	zal	je	blijven	herinneren	als	een	liefdevol	persoon.
Mijn	 lieve	ouders,	omdat	Chinees	binnen	ons	gezin	de	voertaal	 is,	zal	 ik	verder	
gaan	 in	 het	 Chinees.	我亲爱的爸妈，谢谢你们让我成长在这么温暖又充满爱的家庭
里。你们俩一直希望我能够生活幸福事业顺利。妈，你经常说作为一个中国父母，
孩子是最重要的。一直到现在，无论我做什么你们都无条件地支持和帮助我。爸，
我现在跟你一样也是博士了，能够引用你的论文并且由你来当我的paranimf，我十
分高兴也非常很骄傲。 除了你们，我也想用这个机会感谢我的全部家人和其他好
友。谢谢你们一直以来对我的照顾与关心，以及对我完成博士论文的支持与鼓励。
Mijn	allerliefste	Myrthe.	Jij	bent	de	meest	veerkrachtige	en	sterkste	persoon	die	
ik	ken.	Na	alles	wat	de	afgelopen	jaren	gebeurd	is	en	hoe	gestrest	en	chagrijnig	ik	
ook	was,	jij	bleef	altijd	super	lief	en	geduldig.	Als	stel	zijn	wij	soms	een	complete	
chaos,	maar	meestal	voelen	wij	elkaar	heel	goed	aan.	Wat	we	ook	samen	doen,	de	
tijd	vliegt	veel	te	snel	voorbij.	Ik	ben	heel	gelukkig	dat	jij	in	mijn	leven	bent	en	ik	
weet	dat	wij	er	altijd	voor	elkaar	zullen	zijn.	Ik	hou	van	je.
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